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ABSTRACT

CHARACTERIZATION AND USE OF FOLATE RECEPTOR ISOFORMS FOR
TARGETING OF EPITHELIAL AND MYELOID CELLS
by
Sreya Biswas
The University of Wisconsin-Milwaukee, 2016
Under the Supervision of Professor Douglas A. Steeber

Folate receptor (FR) is a GPI-anchored glycoprotein with high binding affinity for folic acid. FR
has two membrane-associated isoforms, α and β, that are overexpressed on epithelial and
myeloid tumors, respectively. Normal cells may also exhibit FR expression at very low levels but
interestingly, FR-α on normal cells is restricted to the apical surface i.e., away from the blood
stream. This differential expression and orientation of the FR-α isoform on tumor cells has been
exploited to selectively target and deliver conjugates (e.g., drugs, nanoparticles, liposomes) to
tumor cells without harming neighboring healthy cells. However, the functions and use of FR-β
as a potential target have not been explored, and its functions on myeloid cells remain largely
unknown. Therefore, we investigated the functions of FR-β to determine its potential as a target
in myeloid malignancies using a human myelomonocytic leukemia cell line, U937. FR-α studies
were conducted using a murine epithelial breast carcinoma cell line, 4T1, and tumors harvested
from 4T1 tumor-bearing mice. The isoforms were found overexpressed on tumor cells and
tissues, both in vitro and in vivo, with no expression observed on corresponding normal cells.
Studies conducted using folic acid-fluorochrome conjugates to determine intracellular receptor
fate indicated that FR-β was not internalized into cells unlike FR-α. However, both isoforms
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exhibited strong binding to folic acid conjugates (e.g., fluorochromes, nanoparticles) thus
indicating that they could be selectively targeted using folic acid-dependent methods.
We also determined the potential of a novel histone deacetylase (HDAC) inhibitor (HDACi)
as an anti-cancer agent that could be used along with folic acid for achieving better selectivity in
targeting tumor cells. Preliminary studies showed that Compound 5 (Cpd5) is stable with strong
anti-proliferative activities against human tumor cells. Cpd5 was also able to reduce the rate of
4T1 tumor growth in mice without inducing systemic toxicity in the animals. In addition, Cpd5
exhibited desirable pharmacokinetic properties and showed direct effects on acetylation levels of
histone proteins. These studies not only provide insights into the functional differences
associated with FR-α and FR-β isoforms, but also highlight the potential of future targeting
strategies utilizing these to target both epithelial and myeloid malignancies with improved
selectivity.
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CHAPTER 1
GENERAL INTRODUCTION
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I. Introduction
Immunotherapy is mainly of two kinds, active and passive with both having a potential
role in cancer therapy. Passive immunotherapy involves passive diffusion-based or
-derived therapies while active therapy is dependent on targeting tumor-associated
antigens (TAA) with specific characteristics1. The effectiveness of active therapeutic
strategies is highly dependent on the efficiency of TAAs to stimulate the effector arm of
the immune response that can overcome the immunosuppression generated during cancer
progression, but without generating toxicity1. There has been a great deal of research
oriented to determining such effective therapies with a focus on identifying the most
suitable TAAs to target. In order to be a suitable TAA, the molecule needs to have a
relatively high specificity and distinct overexpression or hyperactivity in the targeted
cancer cells. Proteins, gene-therapy vectors and liposome-encapsulated drugs have shown
promising effects in cancer therapy as compared to traditional chemotherapeutic agents
due to their high specificity and prolonged delivery2–5. On the contrary, high molecular
weight agents such as macromolecular drugs encounter significant permeability barriers
that limit potential therapies. Hence, use of ligand-specific therapies can be a potential
alternative to overcome such limitations. This approach however, has been applied
mostly to epithelial tumors and has not been examined for its effectiveness for myeloid
tumors. Therefore, there remains a significant need to investigate the prospects of using a
ligand-specific approach in targeting epithelial and myeloid cells.
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II. Folate receptor (FR)
The folate receptor (FR) is also known as the folate binding protein. It is a single-chain
cell surface glycoprotein having a high affinity for folic acid (FA) with a dissociation
constant (KD) < 10-9M and its circulating form, 5-methyltetrahydrofolate (5-mTHF). FR
is a glycophosphatidylinositol (GPI)-anchored glycopolyleptide with a KD in the
subnanomolar range6. The folate receptor is expressed in a limited number of normal
tissues but overexpressed in several malignancies7–10. The FR transports FA as well as the
derivatives of folate by a non-classical endocytic mechanism11. For most normal cells
that lack FR expression, other folate carriers mediate folate uptake12. Among them, the
reduced folate carrier (RFC), usually expressed ubiquitously in normal adult tissues, is
unable to bind to folic acid but can efficiently bind to folate derivatives such 5-mTHF
and transport them efficiently into cells. The transport process is quite rapid and
sufficient to fulfill the cellular stores of the co-enzyme13. FR is predominantly expressed
on the apical surface of polarized epithelial cells where it never encounters circulating
folate6,14. In addition, FR expressed in mature hematopoietic stem cells is unable to bind
folate. Importantly, the FR is capable of transporting or binding to a wide variety of
conjugates of FA, anti-folate drugs and other immunological agents1,2. All these factors
have initiated intense interest in the field of therapeutics and tumor therapy to selectively
target FR in cancer15. Human FR is encoded by a family of genes whose homologous
products are FR-α, -β and -γ9,11–13,15,16. A fourth isoform named FR-δ has been recently
identified, but neither its expression nor its function as a folate binder has been
established17. Based on the structural similarity of the encoded proteins, FR genes appear
to belong to a superfamily that includes the riboflavin protein18 and a putative carotenoid
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or flavonoid binding retinal protein called retbindin19. In addition, based on the National
Center for Biotechnology Information genomic database, this family also appears to have
accompanied the evolution of vertebrates with close homologs in fish, amphibians, birds
and mammals.
A. FR-α
FR-α is the most widely expressed FR isoform in normal adult tissues, located at the
apical surface of the epithelium where it does not come in contact with blood vessels and
thus does not interact with circulating folate20,21,22. In contrast, tumor cells lose
polarization of FR-α and thus are in contact with circulating folate. This is an advantage
in the case of drug delivery with folate-conjugates, which can be selectively used to treat
tumor cells, leaving the normal healthy cells unharmed23 (Fig. 1). FR-α is a membraneassociated form of the FR and is capable of transporting folate into the cells24. FR-α is
predominantly expressed on epithelial cells and many of their malignant derivatives14
such as proximal tubules of kidney and renal cell carcinoma, choroid plexus and its
carcinoma, ovarian carcinoma and breast carcinoma cells10,25,26. In general, FR-targeted
therapeutics have been focused more on ovarian27 and endometrial cancers28 as these
more frequently overexpress FR-α in a consistent manner. FR-α expression is reported to
vary with the stage of malignancies, and is found to be down regulated in mucinous and
cervical adenocarcinomas but expressed de novo in adenocarcinoma of the uterine
endometrium28–30. FR-α is consistently expressed in non-mucinous adenocarcinomas of
the ovary, uterine adenocarcinoma, testicular choriocarcinoma, ependymal brain tumors
and non-functioning pituitary adenoma, frequently in malignant pleural mesothelioma
and less frequently in breast, colon and renal carcinomas28–31. There is also variability in
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the expression levels of this receptor sub-type among tumors obtained from different
patients as well as within the same tumor30. It is evident from numerous reports that there
is a quantitative increase in FR-α expression associated with foci of poor differentiation
as well as the more poorly differentiated tumors32. This observation is in contrast to an
increase in FR-α associated with differentiation in an epithelial squamous carcinoma cell
line, which suggests there might be systemic as well as cellular effectors of FR regulation
in cancers33.
FR-α has a globular structure with four long α-helices (α1, α2, α3, α6), two short αhelices (α4, α5), four short β-strands (β1- β4) and many loop regions34. The presence of
eight disulfide bonds (formed by 16 conserved cysteine residues) stabilizes the tertiary
structure of this isoform13. FR-α also has three N-glycosylation sites12,18,35, which
contribute to the receptor’s ability to bind the oxidized form of folate, folic acid, with
high affinity (KD ranging from 0.1- 1 nM)35–37. On the contrary, FR-α exhibits  10 times
lower affinity for the reduced forms of folate such as methotrexate (KD: 1-10 nM) and 5mTHF (KD: 1-10 μM)38–41. Thus, the high selectivity of these transport mechanisms is
dependent on the low affinity of FA for RFC, and its high affinity for FR-α6,42.
B. FR-β
FR-β is mainly found in cells of myelomonocytic lineage with increased expression
during the maturation of neutrophils43; however, in normal tissues it is restricted only to
the placenta and hematopoietic stem cells7,15,44,45. FR-β is co-expressed with the myeloid
markers CD14, CD33 and CD11b markers but not with lymphocyte markers CD3 (T
cells) and CD19 (B cells)46. FR-β is also consistently expressed in chronic myeloid
leukemia (CML), while in acute myeloid leukemia (AML) 70% of the AMLs are FR-β
5

positive and often co-express CD3410,47. FR-β expression is also reported to be increased
in activated monocytes and macrophages with a recent study showing its elevated
expression on synovial macrophages in Rheumatoid Arthritis (RA) patients48 and in a rat
arthritic model49. Since macrophages are a major contributor to the pathogenesis in RA,
FR-β could be exploited to target the synovial macrophages in RA patients50.
Interestingly, FR-β expressed on normal CD34+ progenitor cells in the bone marrow and
on mature neutrophils and monocytes is unable to bind folate while FR-β expressed on
CML, AML and on synovial macrophages is capable of binding folate46,47,51. This
difference in ligand binding between normal hematopoietic cells and pathogenic cells
appears to be related to certain post-translational modifications of the receptor and could
be beneficial by providing protection to normal cells from FR-targeted drugs and
therapies2,10,25. Also, FR-β has been reported to have much lower binding affinity (KD
ranging from 10-50 nM) to FA and other reduced forms of folate than FR-α38,52,53.
Importantly, this functional difference between the two receptor isoforms is attributed to
a few amino acid residue differences between the isoforms13,15,24,37,39. The functional
differences between the FR isoforms might be advantageous for selective tissue-targeting
and FR-mediated drug delivery.
C. FR-γ
FR-γ was detected by polymerase chain reaction analysis (PCR) and was found to be
secreted constitutively in normal and leukemic (CML, AML, CLL) hematopoietic tissues,
including bone marrow, spleen and thymus9,10,16,25. Since, FR-γ is almost undetectable in
serum and is not a membrane-bound receptor; few studies have been performed.
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However, this protein might be useful as a serum marker for myeloid and lymphoid
tumors9.
II. Transport of reduced folates
A. Reduced folate carrier (RFC)
The RFC is a cellular uptake system that transports folates to the cytoplasm of cells
using a bidirectional anion exchange mechanism 40,54. The transport kinetics and affinity
for oxidized and reduced forms of folates differ significantly between the FR and the
RFC systems48,53. The RFC is a 591 amino acid transporter with 12 transmembrane
domains55. It is widely expressed on cells and mediates the uptake of reduced folates such
as dihydrofolate, tetrahydrofolate and 5-mTHF with relatively high affinity at micromolar
concentrations (KM: 1-10 μM)42. However, it has relatively poor affinity for the oxidized
form of folate, folic acid (KM: 200-400 μM)24,40,41,56, and is unable to transport it across
the membrane. The potential binding capacity of the RFC is about one hundred times
greater than the amount of folate in serum57. Thus, the high selectivity of these
mechanisms resides in the low affinity of folic acid for the RFC, and the high affinity of
folic acid for the folate receptors58.
B. Regulation of FR expression
FR-α regulation by folate has important implications in transport-related anti-folate
drug resistance mechanisms and in developing strategies to increase FR-α expression in
malignant tissues for targeting/therapeutic purpose. However, FR-α does not bind and
carry reduced folates as efficiently as does the RFC53,59. Several studies have
demonstrated that varying the concentration of either intracellular or extracellular folate
7

is able to modulate the expression of FR-α in a variety of cells58,60,61. For example, in
cervical carcinoma cells, folate-dependent regulation of FR-α expression was found to
occur at the transcriptional level while in other cases, expression was reported to be
regulated by FR-α mRNA levels62. In cultured chinese hamster lung fibroblasts, FR-α
gene amplification was observed in response to severe folate restriction61. Interestingly,
some FR-α negative tumors have been found to start expressing FR-α following treatment
with anti-folate chemotherapeutic drugs such as methotrexate, likely to facilitate folate
uptake to support cell proliferation. These tumors would now be susceptible to FRtargeting strategies which is important since many tumors develop drug resistance due to
defective transport of the drugs into the cell63. Hence, regulation of FR expression in
response to folate or a combination of folates and anti-folates, is a potential avenue for
developing novel FR-mediated therapies25,64–66.
III. Transport of oxidized folate
FA is the oxidized form of folate that exhibits high affinity for FR and is required by
cells in the biosynthesis of nucleotide bases. Hence, cell survival and proliferation are
dependent on a cell’s ability to acquire this vitamin67. As mentioned above, cellular
uptake of folate is facilitated by either the RFC or the FR. The RFC is selective in
facilitating transport of mainly reduced forms of folate while the FR has the ability to
transport FA as well as folic acid-linked cargos of various kinds (e.g., chemotherapeutics,
imaging agents, proteins, liposomes and nanoparticles)6,68–70. FA is also known as
pteroylglutamate and is non-immunogenic in nature. It is small (441 Da) and stable over
a broad range of temperatures and pH. It is also inexpensive and retains its ability to bind
to the FR after conjugation with drugs or diagnostic markers71–74. Cells expressing FR-α,
8

thus bind FA with high affinity and transport it by endocytosis. Although the literature
suggests many possible mechanisms associated with FR-α-mediated endocytosis, the
process has yet to be fully elucidated.
A. Receptor-mediated endocytosis
Receptor-mediated endocytosis is also known as clathrin-dependent endocytosis and
involves binding of a ligand and activation of a receptor-mediated internalization
pathway (Fig 2). Initially, internalization of FA conjugates in tumor cells was considered
to proceed in a similar manner through the binding of the folate-conjugate to the cellsurface FRs75,60,76. After binding, membrane invagination would occur followed by
internalization of the conjugate to form an endocytic vesicle. Acidification of the
endosomal compartment occurs at pH 5-6, which results in the release of some of the
folate conjugates from the receptor77,78. The acidic endosome is then transported to a
recycling center, which allows separation of the membrane-bound FR-α from the released
conjugates74,79. Released folate conjugates are reported to escape the endosome through
an unknown mechanism resulting in their release into the cytoplasm74. The dissociated
receptors recycle back to the plasma membrane surface allowing for delivery of
additional folate-conjugates into the cell75.
B. Internalization via non-clathrin coated pathways
The exact mechanism by which FR-α transports FA into cells remains unresolved.
There have been conflicting reports describing the internalization pathway and trafficking
of FR-α2,60,80 and some studies have suggested that receptor internalization is associated
with non-clathrin-coated pathways81. This is a distinct phenomenon associated with most
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GPI-anchored proteins where the GPI anchor likely plays a role in mediating receptor
clustering in association with flask-shaped membrane structures, called caveolae82,83. It
was proposed that FR was internalized by the pinching off of the membrane, forming
small pockets of caveolae followed by formation of small vesicles called caveosomes that
are distinct from endosomes84. Polymerization of a protein called caveolin is thought to
trigger the formation of caveosomes; however, the mechanisms are still under
investigation40,60,85. Recent studies have proposed that the receptors are organized by the
GPI anchor into “lipid rafts” or receptor-rich complexes on the cell membrane60,86,87.
These domains are rich in sphingolipids and cholesterol, and are anticipated to have a
role in facilitating FR internalization after binding with FA88–90. It has been suggested
that there are special protein kinase residues inside the rafts that generate signaling
pathways which further directs the sorting of lipid raft-mediated vesicles91,92. It is further
speculated that the receptors could internalize through their interactions with the lipid
rafts and eventually form caveosomes inside the cell; however, the exact mechanism for
this is still unknown. In parallel with lipid rafts, GPI-enriched early endosomal
compartments (GEECs) have also been proposed as a potential mechanism involved with
FR internalization93,94. According to this pathway, the receptors can also be endocytosed
into cells via clathrin-coated pathways but specifically are sorted into specialized
endosomal compartments that are different from those formed in receptor-mediated
endocytosis95. Regardless of the route of entry, physiologic FA clearly moves across the
plasma membrane into the cytoplasm via a specialized endocytic pathway mediated by
the FR.
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IV. Folate-targeted therapeutics
FR-α despite being expressed on a few normal cells and tissues, is mostly restricted to
the apical side of polarized epithelia. Hence, they are inaccessible to blood-borne folate
conjugates, which makes FR-α targeting a potential selective therapy96. Considering this,
many FR-α targeting studies have been initiated in recent years utilizing the high affinity
ligand, FA. A major application of folate targeting involves the specific delivery of drugs
to abnormal or pathologic tissues, which in their non-targeted form would show systemic
toxicity. Keeping this in mind, a variety of folate-linked molecules and complexes have
been designed to achieve selective delivery of therapeutics to the target cell, including
FR-positive cancer cells and activated macrophages25,74,79.
Delivery of therapeutic agents utilizing FA can occur via a ligand-activated
endocytosis pathway where drugs requiring intracellular release to induce cytotoxicity are
transported into the cytoplasm of targeted cancer cells by FR70,97,2. Some examples of
molecules that fall into this category are protein toxins98–100, drug-encapsulating
liposomes101–103, gene therapy vectors104,105 and many colloidal drug carriers106–108.
On the contrary, there are also several drugs that do not require intracellular release to
mediate their actions. Instead, they can induce cytotoxic effects at the surface of a target
cell. FR then acts as a tumor marker that functions to concentrate the drug on that specific
cell2. Examples of this class of molecules include pro-drug activating enzymes109 and
immunotherapeutic agents that can stimulate or redirect the immune system of the host to
the cancer cell110,111. The most important part of such targeting is based on the fact that
FR is continuously recycled back to the cell surface, thus enabling both types of targeting
strategies to be exploited.
11

A. Protein toxins
Folate-targeted protein toxins have been explored as a tumor-selective cytotoxic agent
since the 1990s. Pseudomonas exotoxin and momordin are protein synthesis
inhibitors98,99 that were tested in vitro as protein toxins for targeting purposes. Folatemomordin (IC50 1 nM) was shown to selectively kill malignant cells when cocultured
with nontransformed cells112. Although both nontargeted toxins inhibited protein
synthesis in cell-free systems with equal potency, folate-Pseudomonas exotoxin was
found to exhibit higher cytotoxicity (inhibitory concentration, IC50 < 10 pM) than folatemomordin74. The difference was due to the fact that Pseudomonas exotoxin has a
translocation domain that allows its escape from intracellular endosomal vesicles whereas
momordin does not113. This led to an understanding that escape of folate conjugates from
their endosomal compartments is an important factor that can affect therapeutic
efficiency and thus needs to be taken into account when designing conjugates or drugs for
delivery into cells74.
Another form of folate-mediated protein targeting is the delivery of enzymes to cancer
cells for pro-drug therapy109. This is an enzyme-based method where an enzyme that
converts an inactive prodrug to an active therapeutic agent is targeted to the cancer cell
with folate114. When the prodrug is administered systemically, it will not have any
activity until it encounters the enzyme. In this way the enzyme-containing cancer cells
will be killed while the normal cells without the enzyme will be unaffected115. However,
to date little has been reported on the efficacy of protein-folate conjugates in live animals.
In addition, repeated administration of a foreign protein can elicit an immune response,
thus inhibiting the therapy. The size of the protein also needs to be considered since large
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proteins may penetrate solid tissues less efficiently than smaller ones. Therefore, size of
the folate conjugate is a major obstacle in treating solid tumors.
B. Small molecular weight chemotherapeutics
FA-conjugated therapeutic agents can serve as alternatives to FA-targeted protein
toxins. Although they are less potent than protein toxins, their small size helps in better
tissue penetration and their non-immunogenic nature enables multiple dosing regimens.
So far, most folate-drug conjugates have been developed as anti-cancer agents116–119. For
example, folate-maytansinoid and folate-mitomycin C (EC72) have shown high
cytotoxicity and selectivity for FR-positive cells116,120,121. In addition, repeated
administration of folate-mitomycin C in mice was successful without any signs of
toxicity in the animals120. However, certain factors such as the hydrophobic nature of
some therapeutic agents can limit these approaches as they show less tumor specificity
than water-soluble ones122. Thus, it is necessary to build a water-soluble linker between
folate and the therapeutic cargo. Second, it is important to ensure that the affinity of
folate for its receptor is retained even after conjugating the therapeutic cargo 74. This can
be achieved by preventing intramolecular interactions between folate and the tethered
drug. Third, it is important for drugs to be released into the cell in unmodified form to
maintain their activity. This can be assured by inserting a cleavable bond between the
drug and the molecule20. Several linkers such as disulfide bonds, acid-sensitive linkers
and enzymatically cleavable bonds have been tested and approved123,124. Hence, there are
many approaches that can be investigated to improve the potential of folate-conjugated
chemotherapeutics including the novel use of nanoparticles.
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C. Nanoparticles
Targeted nanoparticle delivery of therapeutic molecules has the potential to provide
safer and more effective therapies for cancer treatment125. Current research is focused
towards understanding the parameters that influence targeted nanoparticle behavior for
easy development of nanoparticle-based therapeutics and imaging agents. Nanoparticles
have specific properties that enable their use in cancer treatment. Their high surface-tovolume ratio makes them perfect for functionalization and conjugation with therapeutic
agents. Their size and malleable nature allows their use in both active and passive
targeting systems with higher tumor specificity than other methods126,127.
Passive targeting takes advantage of two major differences between tumor tissue and
healthy tissue, including a leaky vasculature and an acidic tumor microenvironment128.
Rapid growth of tumor cells requires rapid vascularization, leading to an abnormal
vasculature that is more permeable than that of normal tissues. This increase in
permeability makes cancerous tissues easily accessible to therapeutic drugs. In
combination with the lack of lymphatics in the tumor bed, this allows for increased
accumulation of the drug within the tumor resulting in an enhanced permeability and
retention (EPR) effect129. This is applicable to all nanoparticle-based therapies and
enables them to penetrate into the tumor vasculature with much higher retention times
than normal tissues130,131. In addition to a leaky vasculature and lack of lymphatics, the
tumor microenvironment also aids passive targeting through an acidic cytosol within the
tumors, which potentially can be exploited by the use of pH-sensitive drug conjugates132.
These are designed to be broken down after entering the tumor cells resulting in the
release of the drug into the cytoplasm133,134.
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Similarly, nanoparticles can also be used in active targeting of cancer cells. In this case, a
nanoparticle is directly conjugated with a targeting moiety, thus allowing selective
accumulation of the drug into target cells and tissues that are associated with tumorspecific molecules128,134. Several classes of molecular targets for active targeting have
been proposed including cell-surface carbohydrates (carbohydrate targeting), cellular
antigens (antibody targeting) and cell-surface receptors (receptor targeting)100,135,136,126.
Carbohydrates are targeted by directing nanoparticle-mediated treatments to tumor cells
by attaching lectins that bind to cell-surface carbohydrates137. Antibody targeting utilizes
overexpressed antigens on the tumor cell surface138,139. Receptor targeting makes use of a
ligand that can bind to specific receptors expressed on the tumor cell surface140,141. The
ligand is often conjugated to drugs and then allowed to internalize via receptor-mediated
endocytosis, resulting in the release of the drug into the cell97,107,142.
A variety of nanoparticle materials are currently being used and tested for use in drug
targeting. Polymeric nanoparticles have drugs conjugated to the side-chain of the linear
polymer through a linker that has a cleavable bond126,130. The drug is activated as soon as
the linker is cleaved after entering the tumor tissue. Micelles have a nano-sized core shell
structure with a hydrophobic core region that serves as a reservoir for drugs143,144. The
outer hydrophilic shell helps stabilize the core and makes it amenable to intravenous
administration. Dendrimers are synthetic polymeric macromolecules with multiple highly
branched chains emerging from the core region with multiple sites for drug
attachment145,146.
Other methods make use of liposomes, viral nanoparticles or carbon nanotubes
(CNTs)74,101,147. Liposomes are spherical structures that are composed of an outer lipid
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bilayer surrounding a central aqueous space148. Once a liposome enters a cell, it is
important for it to unload its cargo into the cell. However, the stable nature of liposomes
can prevent the encapsulated drug from being released efficiently149,150. Hence, studies
are ongoing to synthesize liposomes with pH-sensitive lipids and peptides to accelerate
drug release into cells80,151,152. These can help liposomes maintain stability in the
circulation but enable them to release their cargo into the cytosol of cells.
Viral nanoparticles, derived from a variety of viruses including the cowpea mosaic
virus, canine parvovirus and bacteriophages, have recently been shown to be useful for
active targeting in combination with CNTs153,154. CNTs can also be conjugated to several
active molecules such as nucleic acids, peptides, proteins and other therapeutic
compounds, and functionalized for cancer treatment155–158. Recent studies have indicated
that CNTs can also serve as ideal targeted imaging agents that can produce strong
magnetic resonance imaging contrast, which can be beneficial in detecting circulating
tumor cells in peripheral blood159–161.
Inorganic nanoparticles are primarily metal-based and have been extensively studied
for imaging. They are easily functionalized, non-toxic and non-immunogenic162,163.
Several types of nanoparticles can convert energy into heat at levels up to 70°C164–166.
Iron oxide nanoparticles coated with aminosilane are in clinical phase II trials in
Germany for brain and prostate cancer therapy using hyperthermia167,168. The phase I trial
results indicated that tumor cells could be locally killed by magnetic oxide
nanoparticles168,169. The small nanoparticles (20 nm) reportedly penetrated the tumor and
generated heat when exposed to magnetic fields (50kZ and 100kZ). This allowed
treatment within a circular area of 20 cm of diameter without any signs of toxicity in the
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patients170. Several formulations are still in the discovery stage using drugs such as
paclitaxel, doxorubicin or interleukin (IL)-12171–176.
Compared to polymeric micelles and liposomes, gold nanoparticles are much smaller
making them more desirable for passive targeting via the EPR effect129,177. Gold
nanoparticles have also been used for hyperthermia treatment of tumors. Gold
nanoparticles absorb strongly in the near-infrared wavelengths, and release this energy in
the form of heat, which has been shown to induce antitumor efficacy in tumor cells. In
addition, this has also been combined with traditional chemotherapy to enhance its
effects178.

However, a major limitation associated with it is non-specific tissue

damage179. Alternatively, the issue of nonspecific tissue damage could be addressed by an
approach that could generate highly localized heating. This could be accomplished by the
active targeting of nanoparticles composed of magnetic iron oxide, such as magnetite,
and subsequent exposure to an oscillating magnetic field (OMF). Heating in the region of
the membrane-bound nanoparticles would then cause cell damage and, potentially, cell
death. Although light- and temperature-based targeting strategies like this may reduce
toxicity, they can also cause damage to adjacent tissues due to non-specific
accumulation178.
V. Immunosuppression in Cancer
Preclinical studies of cancer immunotherapies have shown considerable promise;
however, their potential is often not realized in vivo. This is mostly due to infiltration by
immature population of myeloid cells that are associated with undesirable clinical
outcomes180. Tumor-induced immunosuppression is a key factor that allows tumors to
escape the immune-mediated destruction initiated in the host181. Despite a still incomplete
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understanding of tumor immunology, current approaches to immunotherapy focus on
enhancing the capability of surveillance by the host’s immune system182–184. With this
strategy, abnormal or cancerous cells can be eliminated and cancer progression can be
inhibited. However, several cellular interactions and feedback loops within the immune
system tend to limit clinical applications and immunotherapeutic approaches. Studies
have demonstrated that the immune responses generated during malignant conditions are
often inhibited by different subsets of tumor-infiltrating myeloid cells, among which
myeloid-derived suppressor cells (MDSCs) have been of special interest185,186. Due to
their critical role in cancer progression, MDSCs have been extensively studied in many
human cancers and in experimental models with human xenografts187,188. MDSCs
primarily inhibit T cell activity against tumor antigens, thereby reducing the effectiveness
of therapeutic approaches188,189. For example, a patient’s T cells can be modified to
express novel receptors on their surface called chimeric antigen receptors (CARs) that
recognize a specific protein or antigen on tumor cells190. These engineered CAR T cells
are infused back into patients, where they multiply and then recognize and kill the tumor
cells. CAR T cells have been successfully used for the treatment of hematologic
malignancies191, but their use in solid tumors has been completely unsuccessful as
MDSCs tend to inhibit these CAR T cells. Therefore, targeting and eliminating
suppressor cells is expected to emerge as a successful immunotherapeutic strategy. A
better understanding of the local tumor microenvironment and the mechanisms resulting
in expansion of suppressor cells will provide more opportunities for novel treatments
directed to target these undesirable populations of cells, thus improving the anti-tumor
immune response in the host.
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VI. Myeloid-derived suppressor cells (MDSCs)
A. Generation and activation
MDSCs are a heterogeneous population of immature myeloid cells that are expanded
in various pathologic conditions including cancer192,193. MDSCs function to inhibit the
immune response in the host, thus inhibiting immunotherapy188,194,180,195. MDSCs are
characterized as a morphologic mixture of granulocytes and monocytes including
myeloid

progenitor

cells,

macrophages,

and

immature

granulocytes

and

macrophages197,202, that lack the expression of cell-surface markers associated with the
fully differentiated forms of such cells197. MDSCs are generated in the bone marrow in
response to several cancer-derived factors, such as granulocyte colony stimulating factor
(G-CSF)188,198, granulocyte-monocyte colony stimulating factor (GM-CSF)199, stem cell
factor (SCF)200, IL-6201, IL-1β202, prostaglandin E2 (PGE2)203,204, vascular endothelial
growth factor (VEGF), and tumor necrosis factor-α (TNF-α)199,205,206. Most of these
factors affect myelopoiesis and tumor progression via the signal transducer and activator
of transcription (STAT) 3 signaling pathway207–209. Activated STAT3 is suggested to
increase the survival and proliferation of immature myeloid cells via upregulation of
factors such as B-cell lymphoma (BCL)-XL, cyclin-D, c-Myc and survivn183,210,211.
Further activation of MDSCs is reportedly driven by factors such as toll-like receptor
(TLR) ligands, IL-4, IL-13 and transforming growth factor-β (TGF-β), which trigger
signaling via STAT1, STAT6 and nuclear factor-kappa B (NF-kB)212–214. This results in
an increased expression of enzymes such as arginase-1 and inducible nitric oxide
synthase (iNOS) that are involved in MDSC-mediated immunosuppression215–217.
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B. Subsets of murine and human MDSCs
In mice, MDSCs are characterized by the co-expression of the myeloid lineage
differentiation antigens CD11b and Gr-1197,218,219. In healthy mice, cells with this
phenotype constitute about 20-30% of cells in the bone marrow and 2-4 % in the spleen;
however, in tumor-bearing mice these percentages increase significantly218. Anti-Gr-1
antibodies can bind to two distinct epitopes, Ly-6G and Ly-6C, thus making it possible to
further discriminate subsets of MDSCs using antibodies that can specifically target these
antigens. Specifically, Ly-6G is primarily expressed by granulocytes while Ly-6C is
expressed by monocytes180,197. Therefore, polymorphonuclear (PMN)-MDSCs have a
CD11b+Ly-6G+Ly-6Clow phenotype while the monocytic (MO)-MDSCs have a
CD11b+Ly-6G-Ly-6C+ phenotype220,221.
In humans, MDSCs have a CD14-CD11b+CD33+CD15+ phenotype187,213,222. They lack
expression of markers of mature myeloid and lymphoid cells and also lack expression of
the major histocompatibity complex (MHC) class II molecule HLA-DR220,223. About
0.5% of peripheral blood mononuclear cells (PBMC) are comprised of this population in
healthy individuals, but in cancer patients this increases to about 10%224–226. Recent
studies have also indicated that there is a significant diversity in the MDSC subsets in
different human cancers218,221,227. However, it remains unknown if this diversity arises
due to different mechanisms by which the MDSCs are expanded in different cancers.
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C. Mechanisms of MDSC-mediated immunosuppression
T-cell proliferation is affected by several factors that include cytokines, growth factors
and amino acids228. These factors are altered under pathologic conditions often due to the
increased

expansion

of

suppressor

cells.

Specifically,

MDSC-mediated

immunosuppression is reported to be primarily regulated by two enzymes: Arginase-1
(ARG1) and iNOS194,229.
ARG1 metabolizes L-arginine to L-ornithine and urea, and is induced in myeloid cells
by anti-inflammatory cytokines such as IL-10, IL-4, IL-13230,231 as well as TGF-β232,233
and GM-CSF234, and its expression is largely regulated by STAT6 activity235. iNOS
coverts L-arginine to L-citrulline and nitric oxide (NO) and can be induced by proinflammatory cytokines such as interferon (IFN)-, IL-1, IFN-α, IFN-β and TNF-α via the
STAT1 signaling pathway214,228,234,236,237. Hence, the expression of these two enzymes is
differentially regulated. Furthermore, inhibition of ARG1 results in an increase in iNOS
function, while upregulation of ARG1 depletes L-arginine, thus leading to a decrease in
iNOS translation and NO production217,238.
L-arginine depletion is reported to suppress T cell function by two distinct
mechanisms: first, by inducing loss of CD3ζ chain expression239, which is an important
co-factor associated with T cell receptor (TCR) function; and second by preventing upregulation of cell cycle regulators such as cyclin D3 and cyclin-dependent kinase 4
(CDK4) which results in arrest of T cells in the G0/G1 phase of the cell cycle240. Lack of
L-arginine also interferes with IL-2 receptor signaling in T cells by inhibiting the
upregulation of the tyrosine kinase Janus kinase (Jak)-3 necessary for STAT5-dependent
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transcription in response to IL-2241–243. IL-2 signaling is also inhibited by exposure to
NO, which induces T cell apoptosis244–247.
Reactive oxygen species (ROS) production has emerged as a key mechanism of
MDSC-mediated immunosuppression248. Hyper-production of ROS is observed to be a
key feature exhibited by MDSCs in both tumor models and cancer patients249–253. This
elevated level of ROS is accounted for by an increase in NADPH oxidase 2 (NOX2)
activity250. In addition, L-arginine depletion in the tumor environment triggers superoxide
generation from iNOS, which then reacts with water to generate hydrogen peroxide254–257.
ROS are implicated in the inhibition of specific CD8+ T cell responses in tumor-bearing
mice and are also suggested to have a direct role in inhibiting T cell responses by
increasing the expression of the anti-apoptotic protein Bcl-2 expression250,252,254,258,259. In
addition, peroxynitrite, a highly reactive cell-permeable molecule, inhibits T cell function
by nitration and nitrosylation of cysteine, methionine, tryptophan and tyrosine in multiple
protein targets260–264. MDSCs are efficient producers of peroxynitrite and their increased
levels are associated with tumor progression189,264,265. Direct contact between T cells and
MDSCs allows MDSCs to induce nitration of tyrosine residues in the TCR and CD8 coreceptors, thereby impairing T cell interactions with the MHC and inhibiting T cell
cytotoxic responses260,266–268.
MDSCs also exert their suppressive functions through the immunoregulatory cytokine
TGF-β, which is regulated in MDSCs by IL-13 and CD4+CD1d- restricted T cells269,270.
Blocking IL-13 or TGF-β is shown to inhibit tumor progression in murine transplanted
tumor models271–273. MDSCs can also systemically downregulate L-selectin (CD62L) on
T cells in tumor-bearing mice, which eventually impairs naïve CD4+ and CD8+ T cell
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homing to lymph nodes204,267,274. Thus, T cells lose their ability to become activated by
tumor antigens275. In addition, MDSCs indirectly suppress anti-tumor responses by
inducing differentiation of other immunosuppressive populations such as regulatory T
cells (Treg)276–278. They can activate both clonal expansion of existing Treg cells and the
conversion of naïve CD4+ T cells into Treg cells via various mechanisms, including
secretion of IL-10 and TGF-β as well as ARG1 functions204,279,280. Furthermore, a recent
study reported the importance of the CD40 co-stimulatory molecule on MDSCs to induce
tumor-specific Treg expansion in a mouse colon cancer model281.
In addition to T cell suppression, MDSCs restrict innate immune responses via their
interactions with macrophages and natural killer (NK) cells to impair anti-tumor
immunity. MDSCs inhibit expression of the NKG2D receptor on NK cells, thus
impairing NK cell activity282. They also downregulate IL-12 production by macrophages,
thus skewing tumor immunity283. Apart from immunosuppression, MDSCs support tumor
growth by augmenting blood vessel development and enhancing tumor cell invasion and
metastasis, a process called angiogenesis284–286. Matrix metalloproteinase (MMP) 9 is
considered to be a critical factor in angiogenesis as it promotes degradation of the
extracellular matrix along with an increase in the pro-angiogenic signal, VEGF287. In
addition to MMP9, various other MMPs such as MMP14, MMP13 and MMP2 that are
reportedly present in high levels in the tumor microenvironment, are reported to facilitate
tumor progression and metastasis and escalate MDSC-mediated immunosuppression287–
289

.
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VII. Epigenetic regulation and cancer therapy
Cancer is a complex process that is influenced by multiple factors and progresses in
multiple steps. Progression of tumor growth is facilitated by tumor cells that manage to
escape the host’s immune surveillance thus restricting immunotherapy. As mentioned
above, the presence of immunosuppressive factors such as MDSCs and Treg cells play a
major role in inhibiting cancer treatments. In addition to tumor-suppressive factors,
genetic abnormality of cancer-related genes and epigenetic regulation are major factors
associated

with

cancer290,291.

Epigenetic

regulation

involves

modification

of

deoxyribonucleic acid (DNA) and/or histones that alters gene expression. Modifications
such as DNA methylation, acetylation, deacetylation, and ubiquitination of specific
amino acid residues of the histones can all affect transcriptional regulation of genes that
are involved with cell cycle progression, proliferation and apoptosis292,293.
A. Histone-modifying enzymes as key regulators in gene expression
Histones are one of the most evolutionary conserved and most abundant proteins found
in the nucleosome of eukaryotic cells294. There are five classes of histones (H1, H2A,
H2B, H3 and H4) organized into core histones (H2A, H2B, H3 and H4) and linker
histones (H1) that are assembled in an octameric core with 146-147 bp of
deoxyribonucleic acid (DNA) wrapped around it295,296. The core histone N-terminal
domains are rich in positively charged amino acid residues that actively interact with the
DNA. This interaction is largely regulated by the modification of lysine residues295.
Among several modifications, histone acetylation is one of the most crucial events
associated with the transcriptional response of the cell297–299. Acetylated histones are
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reported to be associated with transcriptionally active chromatin while deacetylated
histones are associated with inactive chromatin299–301.
Under normal conditions, chromatin acetylation is regulated by the balance between
two key enzymes: the histone acetyltransferases (HATs) and histone deacetylases
(HDACs)299,300. The HATs transfer acetyl groups from acetyl coenzyme A onto
conserved lysine residues within the histones, neutralizing their positive charge and
thereby inhibiting interactions with the negatively charged DNA backbone. This leads to
an active chromatin structure that enables the binding of several transcription factors for
active gene transcription298,302,303. On the contrary, the HDACs catalyze the establishment
of positive charges in the amino terminal tails of the core histones by removing acetyl
groups. This strengthens the interactions between the histones and the DNA backbone,
blocking the binding sites on promoters, thus inhibiting transcription304,305. Hence, this
subtle balance between the HATs and HDACs is required to maintain normal cellular
functions306,307. Perturbation of this balance is considered to be a key factor in cancer
development308–310.
B. Histone deacetylases (HDACs)
In eukaryotes, HDACs are classified into four major classes based on their homology
to yeast HDACs311,312. The class I family is comprised of HDAC1, 2, 3 and 8, and is
related to the yeast HDAC reduced potassium dependency 3 protein that is ubiquitously
expressed and characterized by a nuclear localization signal (NLS) that primarily
confines them in the nucleus of the cell313. Class II HDACs are comprised of HDAC4, 5,
6, 7, 9 and 10, and are homologous to histone deacetylase Hos3 (also known as HDA1) in
yeast314. They are primarily located in the cytoplasm but also have the ability to shuttle
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between the nucleus and cytoplasm due to the presence of a NLS315,316. Class I and II
HDACs are evolutionarily related and have a catalytic domain that assists in the removal
of acetyl groups via a Zn+ ion317.
HDAC1 and HDAC2 are reported to be inactive deacetylases that require the
involvement of multi-protein complexes such as Sin3 (switch independent 3), NuRD
(nucleosome remodeling histone deacetylase) and Co-REST (co-repressor to RE1
silencing transcription factor) to mediate deacetylase activity and DNA binding318,319.
HDAC3 is slightly different from HDAC1 and 2 as it contains a nuclear export signal
(NES) as well as a NLS, thus enabling it to shuttle between the nucleus and the
cytoplasm. In addition, it is implicated in other multi-protein complexes with corepressors N-CoR (nuclear receptor co-repressor) and SMRT (silencing mediator for
retinoic acid and thyroid hormone receptor)320. HDAC8 is the newest member of the
Class I family and is yet to be isolated as part of a multi-unit HDAC complex311.
Class II HDACs are classified into two subsets: Class IIa, which is composed of
HDAC4, 5, 7 and 9; and Class IIb, made up of HDAC6 and 10321,322. These HDACs
exhibit specific tissue expression patterns. Specifically, HDAC4, 5 and 9 are mainly
expressed in the heart, skeletal muscles and brain tissues, while HDAC7 is expressed in
the heart and lungs. HDAC6 is mostly found in the testis while HDAC10 is found in the
liver, spleen and kidney. The Class IIb subset is characterized by the presence of a single
C-terminal catalytic domain, an NES, an NLS and an N-terminal region comprising
multi-protein binding domains314,315,323. Class IIa HDACs are reported to interact directly
with transcription factors such as MEF2 (monocyte enhancer factor 2), BCL-6 and PLZF
(promyelocytic leukemia zinc finger) and are also found to be associated with nuclear co26

repressors such as N-CoR and SMRT320,322,324. Class IIb HDACs are characterized by the
presence of two HDAC domains. HDAC6 contains two functional catalytic domains
while HDAC10 contains a single functional domain, the second one being a vestigial
domain325,326. In addition to this, a major difference between HDAC6 and the rest of the
Class I and II HDACs is that HDAC6 is primarily located in the cytoplasm with the
microtubule network and is associated with the deacetylation of α-tubulin326. On the
contrary, HDAC10 mainly resides in the nucleus and interacts with HDAC3 and
SMRT320.
The class III family of HDACs (Sirtuins) is homologous to SirT2 in yeast. This family
has seven members and is reported to be conserved in organisms ranging from bacteria to
humans327. However, they are different from the Class I and II family as they utilize
NAD as a co-factor instead of a Zn+2 ion328.
A new member protein, HDAC11, was identified but remained unclassified for quite a
long time. However, it is now suggested that HDAC11 is located in both the nucleus and
cytoplasm and belongs to the Class IV family of HDACs. It has a conserved domain in
the catalytic region and is reported to share features with both the class I and II family of
HDACs329.
C. Role of HDACs in cancer
It is well established that the acetylation state of histones has a significant impact on
the biological activity of a cell. Any imbalance in the levels of acetylation can induce
abnormal outgrowth and cell death, leading to neoplasmic transformations309. HDACs are
reported to be overexpressed in several tumor lines and tissues and can affect global
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transcriptional profiles330. However, recent studies have reported that the primary
substrates of HDACs do not just include histone proteins but also several non-histone
proteins such as tumor suppressor genes that include p53, p21, NF-kB and RUNX3331,332.
These tumor suppressor genes are reported to be repressed while the tumor activator
genes, such as hypoxia-inducible factor-1 (HIF-1), VEGF and heat shock protein 90 are
up-regulated333,334. In addition, these tumor activator genes are also overexpressed under
conditions of hypoxia and hypoglycemia335. Hypoxia is one of the key factors that
induces angiogenesis, which is the process of formation of new blood vessels by
endothelial cells. This plays a major role in the spread of cancer cells in blood, and
peripheral organs and tissues336. Hence, inhibition of HDAC activity has emerged as a
potential strategy for cancer therapy. Inhibition of HDACs by HDAC-specific inhibitors
has gained much attention in recent years, and studies have shown that these inhibitors
induced changes at both the molecular and cellular level. Changes reported include
acetylation levels of histones, gene expression, and morphology and proliferation of
cells296.
D. Histone deacetylase inhibitors (HDACi)
Histone deacetylase inhibitors (HDACi) are small molecule inhibitors that block the
activity of HDACs thus increasing acetylation levels in cancer cells337–339. They have the
ability to affect epigenetic regulation of histones by shifting the balance between HAT
and HDAC enzyme activity by inducing hyperacetylation of histones340,341. However,
many of the mechanisms associated with HDAC-mediated activity are still unknown
although there are reports of multiple pathways that could be involved in this
process338,342–344.
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Association of HDACs with carcinogenesis has increased interest in the use of these
inhibitors as potential anti-tumor agents337,345–349. HDAC inhibitors are reported to
mediate activity in tumor cells by triggering cell cycle arrest in the G1 and/or G2 phase,
and by inducing apoptosis and differentiation in cultured cells343,350–352. HDACi have
shown strong growth-inhibitory activities in almost all transformed cell lines arising from
hematologic and epithelial tumors while normal cells remain relatively resistant to
HDACi-induced cell death351,353–355. HDACi can lead to accumulation of acetylated
histones and even non-histone proteins that are associated with cell proliferation,
differentiation, cell migration and apoptosis331,356. HDACi can trigger these events by
activating intrinsic apoptotic pathways, extrinsic apoptotic pathways357,358, mitotic
failure359, autophagy360,361 and ROS-facilitated death362,363. In addition, these inhibitors
are also reported to induce anti-angiogenic effects by suppressing HIF-1α and VEGF
levels364–367. However, generation of these effects is reported to be dependent on the state
of the cell such as the type of molecular changes the cell has or is likely to undergo345,368.
In addition, the type of HDACi, the concentration used and even the time of exposure are
also expected to have added effects on the fate of the cell369. The effectiveness of the
HDACi in binding to the HDAC enzyme pocket can also play an important role in
determining their activity370,371. Tighter binding would slow the release process of the
inhibitor from the pocket, thus leading to a more lasting inhibition. This can also lead to
higher toxicity and other adverse effects on the cells or tumor models.
HDAC inhibitors are usually classified on the basis of their chemical structure and
include hydroxamates, cyclic peptides, aliphatic acids and benzamides290. In addition,
they can also be classified based on their selectivity to HDACs. There are over 500
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clinical trials ongoing with HDACi as monotherapy or in combination with other agents
such as retinoids, paclitaxel (Taxol), radiation, etc., in patients with hematologic
malignancies and solid tumors including breast, pancreas, leukemias, lymphoma and
multiple lymphoma338,346,368. Although these inhibitors differ in structure, potency and
HDAC enzyme selectivity, they are reported to primarily target Class I and II HDACs
with almost no effect on Class III. However, most of the downstream effects associated
with these inhibitors are still under investigation as it is suggested that those are highly
dependent not only on the type of the inhibitor but also on the cells that are being
targeted.
Trichostatin-A (TSA) is a natural hydroxamate and was one of the first discovered
compounds to show HDAC inhibition372. Since then, several hydroxamic acids have been
identified including suberoylanilide hydroxamic acid (SAHA), also commercially known
as Vorinostat, which was the first one to be approved by the FDA for the treatment of
cutaneous T-cell lymphoma (CTCL)373,374. Clinical trials using SAHA showed significant
anti-cancer activity at all given doses and it was also well tolerated by patients. PCI24781 is a phenyl hydroxamic acid that has been evaluated alone as well as with ionizing
radiation and other DNA-damage agents in pre-clinical studies. A phase I clinical trial in
advanced solid tumor patients indicated that intravenous or oral doses of PCI-24781 were
well tolerated. ITF2357 is a synthetic HDACi containing a hydroxamic acid group linked
to an aromatic ring. Reports indicated that this compound induced pro-inflammatory
cytokines and cytotoxicity both in vitro and in vivo in patients with malignant
tumors375,376. Panobinostat (LBH-589) is a novel hydroxamate analog HDACi that is
reported to induce acetylation of H3 and H4. In addition, it also increases p21 levels,
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disrupts chaperone functions, induces cell cycle arrest and triggers apoptosis in K562
cells and acute leukemia (MV4-11) cells377,378. The first clinical trial of Panobinostat was
conducted in patients with hematologic malignancies, and preliminary data suggested it
was well tolerated in the patients379. It is also reported to have a longer half-life than
SAHA and is currently in clinical trials for CTCL380.
Romidepsin (FK228, FR901228) is a bicyclic peptide that was naturally isolated from
Chromobacterium violaceum381,382. It has shown strong anti-proliferative activities
against tumor cell lines and good efficacy against human tumor xenografts. Several
clinical trials were conducted in patients with various malignant conditions including
renal cancer, lung cancer, CLL and AML. FK228 received FDA approval in November
2009 for the treatment of CTCL383.
For further development of more potent and specific HDAC specific inhibitors, X-ray
crystal structure analysis was performed to decode the molecular action of HDACs.
Initial studies involved X-ray crystallography of the catalytic domain of an HDAC from a
hyperthermophillic bacterium, Aquifex aeolicus, to determine structure-function
relationship of the HDAC384. Results showed that the HDAC catalytic domain consisted
of a tubular pocket, a zinc-binding site, and two asparagine-histidine charge-relay
systems290,296. Structure-activity relationship determination showed that inhibitors such as
TSA and SAHA were able to block the HDAC activity through chelation of the zinc ion
using a polar moiety such as hydroxamic acid or benzamide groups385–388.
Results from preliminary studies have encouraged further development of more HDAC
inhibitors for use in cancer therapy. However, the quest for class-specific inhibitors that
would provide selective targeting is still ongoing. Many clinical trials for HDAC
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inhibitors that can target both hematologic and solid malignancies are also in progress.
Currently, HDAC inhibitors are considered to be one of the most promising targets for
the development of anti-cancer drugs. However, the mechanism by which they are
recruited to the HDAC pocket and mediate corresponding cellular activities is still
unknown. A better understanding of the nature of the molecular basis of the selectivity of
the HDAC inhibitors will enable the development of more effective and specific agents to
treat cancer.
VIII. Study Rationale:
Folate receptor is overexpressed in almost all cancers including epithelial (breast, lung,
cervical, prostate, renal, colon) and myeloid (leukemias) malignancies25,26. However,
only 4-6% of normal cells are reported to express FR, and those that do, express FR only
on their apical surface and thus away from the bloodstream6,14. This distinct expression
profile enables opportunities for selective targeting of FR in tumor cells using
therapeutics such as drugs and nanoparticles. In addition, a major difference between FR
isoforms is that FR-α is expressed only on epithelial cells while FR-β has only been
reported in myeloid cells7,17,46,390. However, a common feature applicable to both
isoforms is that they both exhibit high affinity for FA35,75. Previous studies have focused
on understanding and targeting the FR-α isoform while the functions and role of FR-β
remain unknown. Another important aspect of studying the FR-β isoform is that it is
reported to be expressed on some immunosuppressive cell populations such as MDSCs.
These cells dramatically expand in number during pathogenesis and cancer where they
inhibit T cell activity thereby suppressing the immune responses in the host180,195. Hence,
targeting FR-β to selectively eliminate MDSCs could be a potential immunotherapeutic
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strategy for cancer patients. Therefore, the overall goal of the first part of this study was
to compare FR-α and FR-β activity and determine the potential of FA-mediated
therapeutic approaches to target these receptors in malignant epithelial and myeloid cells.
FR-α studies were performed on a murine epithelial breast cancer line, 4T1, which
serves as a model of stage IV human breast cancer. The FR-β studies were conducted on
U937 cells, which is a human myelo-monocytic leukemia cell line. FR-α is reported to be
internalized by tumor cells while FR-β is considered partially inactive44,45. However, this
can vary across tumor lines. Hence, it was important to determine the receptor expression
and localization on the model cell lines, 4T1 and U937. It was also necessary to track
both receptors intracellularly, compare their activities and define their functions. This
was achieved by utilizing the high-affinity ligand, FA. Folic acid was conjugated to
fluorochromes (fluorescein isothiocyanate, FITC; and tetramethylrhodamine, TRITC) to
enable tracking of receptors using flow cytometry and fluorescence microscopy.
Previous reports suggest that FRs can be internalized by receptor-mediated
endocytosis60,76; however, more recent studies have proposed that special lipid-rich
membrane deposits, also known as “lipid rafts”, are associated with the internalization of
most GPI-linked proteins including FRs. Lipid rafts are small microdomains on the
membrane that are formed from deposits of cholesterol and sphingolipids87,90. Therefore,
the role of cholesterol on FR-α and FR-β receptor activity was investigated. In addition,
comparisons were made with well-established markers of internalization, transferrin and
dextran. Transferrin receptor is internalized via receptor-mediated endocytosis to
transport iron into the cells while dextran is commonly used to define the process of
pinocytosis or “cell-drinking”69,105.
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With the help of the above experiments, we can gain a better understanding of the
activity of FR-β and accordingly develop therapeutics to target both isoforms. For
example, if FR-β did not show internalization, therapeutic strategies to deliver cargo
(e.g., drugs) into the cells will not work. This would require developing a method that can
mediate cell-surface selective killing of the FR-β-expressing cells. Therefore, a
preliminary study was initiated to determine if gold nanoparticles could be selectively
targeted to FR-expressing cells. If successful, this would serve as a model system to
develop FA-conjugated gold-coated magnetite nanoparticles that can be used to target
and destroy FR-expressing cells following exposure to an oscillating magnetic field.
Application of an oscillating magnetic field generates localized heat around the
nanoparticles causing membrane damage and cell death without causing damage to the
neighboring healthy cells.
Most anti-cancer therapy is dependent on the concepts of active and passive targeting.
The active form of targeting utilizes a specific molecule or protein expressed by the
tumor cells (e.g., folate receptor) as described above, which is then targeted via linking
the appropriate ligand or antibody to drugs, nanoparticles or other therapeutic
molecules2,136. On the other hand, passive targeting utilizes the leaky vasculature of blood
vessels and tissue matrix in a tumor environment, also known as the EPR effect. This
enables drugs or any carrier molecules to easily diffuse into the tissue71. Hence, exploring
the prospects of passive targeting in parallel with actively targeting the folate receptor
can help determine the effectiveness of both methods in the field of cancer therapy. The
use of HDACi has gained intense interest in recent years as biologically active molecules
that can target and manipulate cells at the gene level. These naturally derived or
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synthesized compounds can inhibit HDAC hyperactivity in tumor cells368. It is already
known that many epithelial tumors, as well as hematologic malignancies, overexpress
HDACs that suppress transcription factors that are associated with normal cellular
activity315,330. HDACis such as SAHA and FK228 have made it through clinical trials and
are currently FDA approved for the treatment of cutaneous and cytotoxic T-cell
lymphoma. Despite this limited success, there is still a major need for new HDAC classspecific inhibitors. Hence, the synthesis of novel compounds with potent anti-cancer
activity as well as HDAC specificity, are required to address drug-associated toxicity and
other side-effects in patients. Therefore, a collaborative study was undertaken to
characterize a novel compound (Cpd5) having increased class I HDAC specificity. Initial
studies of metabolism, pharmacokinetics, histone acetylation, cytotoxicity against tumor
cell lines, in vivo tumor growth and systemic toxicity all showed promising results. It is
tempting to speculate that the increased specificity of Cpd 5 for class I HDACs resulted
in retaining the desirable HDACi effects while producing fewer side effects in the
animals. This project hopes to contribute significantly to the understanding of functional
differences in the folate receptor isoforms and provide insights into potential therapeutic
strategies that can be used to target malignant epithelial and myeloid cells with improved
selectivity.
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FIGURES AND LEGENDS

Figure 1. Differential expression of FR-α in normal and cancer cells facilitates selective
targeting.
FR-α receptor expression is restricted to the apical surface of normal epithelial cells and tissues.
This orientation keeps the receptors away from the basal surface and bloodstream thus making
the receptors inaccessible to FA-conjugates that are administered intravenously. Tumortransformed cells lose polarity and intercellular junctions resulting in expression of folate
receptors across the cell surface. This enables FA-conjugated drug or therapeutic molecules to
gain access to the receptors and selectively induce effects in these cells without harming the
neighboring healthy cells (adapted from Madduri Srinivasarao et al., Nature Reviews, Drug
Discovery392).
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Figure 2. Proposed receptor-mediated endocytosis of folic acid-conjugates in a tumor cell.
The folate-conjugate binds to FR expressed on the surface of a cell. The membrane forms an
invagination and internalizes the folate-conjugate via formation of an endocytic vesicle. As the
pH reduces to 4.5 to 6, the conjugates dissociate from the receptors due to a process called
endosomal acidification initiated by a proton gradient. The unbound receptors are then recycled
back to the surface for delivery of additional folate-conjugates to the cell. It has been reported
that only 15-25 % of the receptor-bound conjugates are actually released into the cell while the
rest of the bound receptors get recycled back to the surface75.
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CHAPTER 2
FOLATE RECEPTOR ISOFORMS α AND β HAVE DICTINCT EXPRESSION PROFILES
AND EXHIBIT DIFFERENTIAL ACTIVITY
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ABSTRACT
The folate receptor-α (FR-α) has been under extensive study for its potential use as a target in
cancer therapy. FR-α is expressed on a wide range of epithelial tissues but found only on the
apical surface of the polarized cells. However, during malignant transformation, the cell loses
polarity, which results in FR-α expression across the cell surface. Expression of FR-α in cancer
is well established and usually varies among tumors, showing high expression in serous ovarian
cancer and renal carcinoma versus low-to-moderate expression in breast, colorectal and lung
cancer. However, its high binding affinity for its physiologic ligand folic acid, has encouraged
tumor-targeting studies utilizing folic acid conjugates. The FR-β isoform is primarily found on
cells of myelo-monocytic lineage. A significant amount of FR-β is also expressed in normal
tissues such as placenta and hematopoietic cells. In addition, FR-β has been reported to be
expressed on myeloid-derived suppressor cells (MDSCs). MDSCs are of myeloid lineage and are
dramatically expanded during cancer where they act to inhibit T cell functions. Preliminary
studies on FR-β have indicated structural variability from FR-α suggesting possible functional
differences. Therefore, the expression profile and activity of FR-β were examined to determine
its potential use as a therapeutic target in parallel to FR-α. In this part of the study the expression
of FR-α and FR-β in both normal and tumor cell lines of epithelial and myeloid origin,
respectively were determined. Antibody-labeling studies using the 4T1 murine mammary
carcinoma epithelial cell line and the human myeloid myelomonocytic leukemia cell line, U937,
showed restricted expression of FR-α and the FR-β, respectively. Thus, 4T1 and U937 cells were
appropriate models to examine these receptors individually. Qualitative analyses showed that
FR-α receptors exhibited a strong punctate staining pattern on the 4T1 cell membrane, while FRβ on U937 cells was mostly polarized to one end of the cell membrane. Next, the effect of free
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folic acid on FR internalization and recycling was investigated. Both isoforms showed strong
binding to folic acid; however, FR-β exhibited lower binding affinity than FR-α. FR-α receptors
efficiently internalized into 4T1 cells after exposure to folic acid and showed evidence of
recycling and/or re-expression. On the contrary, FR-β on U937 cells lacked the ability to
internalize. These findings suggest: 1) FR-α and FR-β have distinct cell surface localization; 2)
both receptors exhibit differential activity but strong binding to folic acid; and 3) both receptors
can be potentially targeted by folic acid-dependent strategies.
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INTRODUCTION
The high-affinity folate receptor (FR) was originally reported in membrane fractions of
placenta, choroid plexus, proximal kidney tubules, and KB epidermoid carcinoma cells 7,8. The
complete and partial amino acid sequences of FR-α were derived from bovine and human milk,
respectively18. The cDNA of FR-α was isolated from KB cells, CaCo-2 cells, and the
placenta,42,393 while that of FR-β was cloned from placenta9,46. Mouse homologues for FR-α and
FR-β have also been identified17. FR-α and FR-β are reported to only share 71-73% amino acid
sequence similarity37,39. The predicted amino acid sequences from the cDNAs contained amino
terminal signal sequences of 25 residues for FR-α and 19 residues for FR-β alongside 16
conserved cysteine residues. Mutagenesis studies have also indicated that the number of Nglycosylation sites for the two isoforms are different, with FR-α having three sites while FR-β
only has two. These N-glycosylation sites are thought to mainly contribute to cell surface
expression of FR, without having any effect on the ligand-binding efficiencies of the
receptors13,36. Membrane-bound FR-α and FR-β are both able to bind folic acid with high affinity
(KD < 1 nM), but bind reduced forms of folate such as 5-methyltetrahydrofolate (5-mTHF) with a
much lower affinity. However, FR-β still exhibits >50-fold lower affinity for folates than FR-α37.
These ligand specificities were attributed to amino acid sequence divergence that involved Leu49 in FR-β, and Ala-49, Val-104 and Glu-166 in FR-α36,39. These structural differences showed
direct correlation with binding affinity thus suggesting possible major functional differences, and
hence required further investigation.
FR expression exhibits a distinct tissue and tumor specificity. mRNA and protein expression
patterns of the respective FR isoforms have been well studied using non-quantitative
immunohistochemical methods as well as quantitative methods including northern blots, radio41

immunoassays, flow cytometry and PCR7,29. Results from various studies have indicated that the
functionality of FR in normal and malignant tissues correlates with their ability to bind either 3Hlabeled or fluorochrome-conjugated folate. Importantly, the mRNA results also showed that FR
expression in cell lines did not reflect the expression profiles in vivo75.
Previous studies have shown that FR-α on normal cells is present on the germinal epithelium
of the ovary, fallopian tubes, uterus and placenta7,14,42. These receptors are typically expressed on
the apical surface of polarized epithelial cells which protects the normal tissues from FR-targeted
agents that are administered through the blood. Various studies have utilized mRNA microarray
techniques to test the expression of FR-α in malignant tissues; however, most of the attention in
developing FR-targeted therapies has focused on ovarian and endometrial cancers30,394. These
tumors have a consistent expression of FR-α throughout the stages of cancer progression, unlike
the adenocarcinomas. FR-α was reportedly downregulated in mucinous and cervical
adenocarcinoma and expressed de novo in uterine adenocarcinoma. Inconsistent FR-α expression
was also observed in breast, colon and renal carcinomas395; however, the folate binding ability of
the receptors was intact in both early and malignant stages of the cancer. Thus, the variable and
limited expression of FR-α in epithelial tumors limits the prospects of folate-targeted therapy to
only specific cancers. Expanding the targeting strategy to include the FR-β isoform would
increase the number of cancers that could be treated, such as leukemias.
The initial suggestion that FR-β was a myeloid marker was based on an early study that
showed elevated levels of membrane-bound FR-β in splenic tissues of patients with
myelogenous leukemia45. Flow cytometric data for peripheral blood leukocytes showed
consistent results with the observation that FR-β expression was mainly restricted to neutrophils.
Hence, co-expression of FR-β with CD19 and CD3 was not observed while FR-β co-expression
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with myeloid markers such as CD13 and CD11b was found46. In addition, lack of co-expression
of FR-β in CD34+ cells from normal bone marrow indicated that FR-β is not expressed during
early stages of normal bone marrow hematopoiesis. Interestingly, FR-β in normal cells are
unable to bind folate whereas various leukemia cells such as AML and CML, have high folate
binding ability36,47. This difference can offer a huge advantage in developing methods to
selectively target cells overexpressing this isoform. Therefore, additional studies examining FR-β
expression and folic acid binding characteristics are required to determine the prospects of
folate-conjugates to target leukemic cells.
To further characterize functional properties of FR-α and FR-β, an epithelial murine breast
carcinoma cell line, 4T1, and a human myelomonocytic leukemia cell line, U937, were chosen.
FR-α and FR-β expression patterns were analyzed for each cell line to determine distribution of
the receptors. In addition, FR expression was quantified on normal epithelial and normal myeloid
cells to determine whether FR expression was restricted to only carcinomas. Folic acid, the high
affinity ligand, was utilized to determine receptor activity. Binding and internalization by the
receptor isoforms were investigated and compared.
Consistent with previous studies, FR-α and FR-β were found limited to epithelial and myeloid
cell lines, respectively, and thus these two cell lines are appropriate models to further examine
these receptors. However, the isoforms demonstrated very different staining patterns on the
respective cells. Importantly, FR-α was found consistently overexpressed in tumors harvested
from 4T1 tumor-bearing mice showing that expression was maintained in vivo. In contrast,
normal epithelial cells isolated from the trachea of healthy mice did not exhibit FR-α expression.
Similarly, FR-β expression was significantly elevated on the U937 cell line while monocytes
isolated from normal human blood lacked expression of the isoform. FR-α in the 4T1 cells not
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only showed binding to folic acid, but also demonstrated rapid internalization within 5 minutes
of exposure to free folic acid. Results also showed that receptor recycling and re-expression
occurred 2 hours after folic acid binding. In contrast, the FR-β receptors on U937 cells also
showed binding to folic acid but did not show any signs of internalization. Taken together, these
findings indicate that the FR isoforms are functionally distinct from one another. Therefore,
despite the ability of both FR isoforms to bind folic acid, the differences observed in receptor
activity following binding will have to be taken into account when designing FR-targeting
strategies for epithelial and myeloid tumors.
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MATERIALS AND METHODS
Cell lines and reagents
The 4T1 murine mammary carcinoma epithelial cell line (ATCC CRL-2539) was purchased
from ATCC (Manassas, VA). The line was originally derived from a spontaneous mammary
tumor from a BALB/cfC3H mouse396. When transplanted ectopically into syngeneic BALB/c
mice, the 4T1 cell line generates a solid, highly metastatic tumor that spreads to nearby lymph
nodes, lungs, bones, brain, and liver, thus resembling stage IV metastatic breast cancer in
humans. The U937 human myelomonocytic leukemia (myeloid) cell line (ATCC CRL-1593.2)
was also purchased from ATCC and was originally derived from malignant cells obtained from
the pleural effusion of a patient with histiocytic lymphoma. The 4T1 cell line was cultured in
RPMI 1640 medium (Life Technologies, Grand Island, NY), supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Flowery Branch, GA), 100 U/ml penicillin, 100 μg/ml
streptomycin and 2mM L-Glutamine (all from ThermoFisher Scientific, Waltham, MA) and 55
μM 2-mercaptoethanol (Life Technologies, Grand Island, NY). The U937 cells were cultured
similarly as above except without 2-mercaptoethanol. At a confluency of 70% or less, the 4T1
cells were lifted with CellstripperTM (Mediatech Inc., Manassas, VA) according to the
manufacturer’s instructions. However, the U937 cell line, being non-adherent, was grown in
suspension. Cell counts and viability were determined using a hemacytometer following
appropriate dilution in trypan blue exclusion dye.
Antibodies used in flow cytometry, fluorescence and confocal microscopy, and
immunohistochemistry experiments included polyclonal rabbit anti-FR-β antibody (Thermo
Fisher Scientific, Waltham, MA); polyclonal rabbit anti-mouse/rat/human all isotype FR
antibody (Santa Cruz Biotechnology, Santa Cruz, CA); and Alexa Fluor® 647 conjugated anti-
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human CD14 antibody (BioLegend, San Diego, CA). The primary rabbit antibodies were
detected with a secondary Alexa Fluor® 647- or Alexa Fluor® 488-conjugated goat anti-rabbit
IgG antibody (Jackson Immunoresearch, West Grove, PA). Leukocytes were identified using an
allophycocyanin (APC)-conjugated anti-mouse CD45 antibody (eBioscience, San Diego, CA).
Folic acid (Thermo Fisher Scientific) was used to determine receptor binding kinetics in pulse
chase experiments. Folic acid powder was weighed and dissolved in 100% DMSO (250 mM)
and stored at 4°C for no longer than one month. Working concentrations were prepared by
diluting in phosphate-buffered saline (PBS) immediately before performing experiments.
Animals and tumor induction
BALB/c (wild type) mice were originally purchased from the Jackson Laboratories (Bar
Harbor, ME) and further housed and bred in a specific pathogen-free barrier facility in the animal
resource center at the University of Wisconsin-Milwaukee, and screened regularly for pathogens.
All procedures were approved by the Animal Care and Use Committee of the University of
Wisconsin-Milwaukee. For tumor induction, 1x104 4T1 cells in 50 µl supplement-free RPMI
1640 medium were injected subcutaneously into the mammary fat pad of 8-12 week old wild
type BALB/c female mice. Tumors were monitored by caliper measurements of the major (L,
length; mm) and minor (W, width; mm) axes and tumor volume (V, volume; mm 3) was
calculated by the formula: V= (L x W2) / 2.
FR-α and FR-β labeling on tumor cell lines
4T1 and U937 cells were cultured and suspended in RPMI 1640 medium at a concentration of
0.5x106 cells per 50 μl in 5 ml round-bottomed tubes. The cells were labeled with 50 μl of antiall isotype FR antibody that recognizes both FR-α and FR-β isoforms or an antibody specific to
FR-β, diluted to 10 μg/mL in culture medium. Negative controls received PBS containing 2%
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normal horse serum (NHS, ThermoFisher Scientific) in PBS (PBS/NHS) and all samples were
incubated on ice for 30 minutes. The cells were then washed with PBS/NHS followed by
detection with an Alexa Fluor® 647-conjugated goat anti-rabbit IgG antibody diluted to
7.5 μg/mL in PBS/NHS for 30 minutes on ice. Following labeling, the cells were washed again
in PBS/NHS, fixed in 1.5% formaldehyde in PBS, and analyzed with a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA) using BD CellQuestTM Pro software. 10,000
cells/sample were analyzed with fluorescence intensity displayed on a 4-decade log scale. Four
to five experiments were analyzed per labeling combination.
FR-α and FR-β labeling on blood and tissues
To assess the cellular distribution of FR-α, control mice without tumors and 4T1-tumorbearing mice at the 4-week stage were euthanized. Tumors were harvested and single-cell
suspensions were prepared as follows: tumors were minced with scissors into ~1 mm pieces and
incubated 30-60 minutes at 37°C and 5% CO2 in digestion buffer, containing 562 U/ml
collagenase, 20.6 U/ml deoxyribonuclease I (both from Sigma Aldrich, St. Louis MO), and 5
mg/ml bovine serum albumin (Fisher, Hampton, NH) in PBS. The red blood cells were then
lysed in ACK buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM NA2EDTA, pH 7.4), filtered
through 70 µm mesh and washed three times in PBS. FR-α expression was also analyzed on
normal murine epithelial cells by harvesting the trachea of mice followed by preparation of
single-cell suspension as follows: trachea from 2-3 mice were harvested, placed in a 60 mm
culture dish containing the same digestion buffer described above, and incubated for 30-60
minutes at 37°C in 5% CO2. The cells were then filtered through 70 µm mesh and washed three
times in PBS.
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For assessing the distribution of FR-β in peripheral blood mononuclear cells (PBMCs), 5 ml
blood was drawn from healthy human donors and collected into heparinized tubes. Blood was
diluted in a 1:1 ratio with RPMI media and gently overlayered onto 4 ml of Ficoll (Sigma
Aldrich, St. Louis, MO) in a 15 ml centrifuge tube followed by centrifugation at 550 x g for 30
minutes at room temperature. The PBMC layer was collected and washed two times with PBS.
Human monocytes were identified with an Alexa Fluor® 647-conjugated mouse anti-human
CD14 antibody as described above.
Cell counts and viability were determined using a hemacytometer following appropriate
dilution in trypan blue exclusion dye. Cell concentrations were adjusted to 10 x 106 cells/ml and
0.5x 106 cells were immunolabeled for FR-α and FR-β receptors and analyzed by flow cytometry
as described above.
Immunofluorescence labeling to determine localization of FR-α and FR-β receptors
4T1 cells were seeded at a density of 0.2 × 106 cells/ml on 10 mm round no. 1.5 glass
coverslips (Ted Pella, Redding, CA) and cultured in supplemented RPMI 1640 medium for 18
hours. Cells were incubated as above with the primary antibodies to FR-α or FR-β for 30 minutes
on ice followed by detection with an Alexa Fluor® 647-conjugated goat anti-rabbit IgG antibody
for 30 minutes on ice. Cells were washed with PBS/NHS and fixed in 1.5% formaldehyde in
PBS. Coverslips with the adherent 4T1 cells were then mounted inverted on glass microscope
slides in ProLong Gold® (Life Technologies). The U937 cells were cultured in suspension and
were suspended in RPMI 1640 medium at a concentration of 0.5× 106 cells/50 μl in 5 ml roundbottomed tubes. The cells were labeled with antibodies as described above and then cytospun for
10 minutes. Both 4T1 and U937 cells were then analyzed on a Nikon Eclipse TE2000-U inverted
epifluorescence microscope (Nikon Instruments Inc., Melville, NY) and digital images were
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acquired at a constant exposure setting through a Nikon Plan Apo 60x oil immersion objective
using a Cool SNAP ES digital monochromatic camera (Photometrics, Tucson, AZ). Images were
analyzed using MetaVue™ software (Universal Imaging Corporation, Downingtown, PA),
pseudocolored and imported into Microsoft Powerpoint software. Confocal analyses were
performed using a Leica Microsystems™ TCS SP2 laser-scanning microscope (Richmond, IL).
Images were acquired using a 40x objective and pseudocolored using Leica confocal software.
Images are representative of a minimum of 3-5 independent experiments.
Labeling of tumor cryosections for fluorescence microscopy
4T1 tumors (4-weeks) were harvested from BALB/c mice and then snap-frozen in tissue
freezing medium (Triangle Biomedical Sciences, Inc, Durham, NC) in liquid nitrogen or on dry
ice. Tissue sections with a thickness of 7 μm were cut on a cryostat and adhered onto poly-Llysine-coated microscopic slides. The sections were fixed in -20°C acetone for 5 minutes and
stored at -20°C until labeling. The sections were thawed for 5 minutes and rehydrated in PBS for
10 minutes. The sections were then incubated in 5% normal goat serum in PBS to block nonspecific antibody binding. The sections were labeled for both FR-α and FR-β as described above.
Negative controls received PBS/NHS in place of the primary antibody. To visualize tumorinfiltrating leukocytes, the sections were blocked with 5% normal rabbit serum followed by also
labeling with an Alexa Fluor® APC-conjugated mouse anti-CD45 antibody for 30 minutes at
room temperature. Sections were washed with PBS for 5 minutes followed by incubation with
0.3 μM DAPI (Sigma Aldrich, St. Louis, MO) for 10 minutes. The slides were washed again
with PBS for 5 minutes and mounted in ProLong Gold®. The tumor sections were imaged using
epifluorescence microscopy as above using a 20x objective, pseudocolored and overlaid using
MetaVue™ software. Images are representative of of 3-5 independent experiments.
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Analysis of FR-α and FR-β activity in the presence of free folic acid
4T1 and U937 cells were used at a concentration of 0.5× 106 cells/50 μl and pulsed with 2.2
µM folic acid for 5 minutes at 37°C. Cells were washed with warm folate-free RPMI 1640
medium and then chased with folate-free medium for 5, 15, 30 or 120 minutes. Cells were
labeled with anti-FR-α and anti-FR-β antibodies and analyzed by flow cytometry as described
above.
Statistical analysis
Data are presented as mean ± SEM. Significant differences between sample means were
determined using a Student’s t test with p<0.05 being considered significant. Data between
various treatment groups were analyzed using one-way ANOVA with post-hoc comparison using
Bonferroni multiple-comparison tests using Graph Pad Prism Software, Version 3.00 (San
Diego, CA, USA).
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RESULTS
FR-α expression was restricted to cells of epithelial origin
The FR isoform expressed on 4T1 cells was determined by flow cytometry and microscopy
analyses using FR isoform-specific antibodies. 4T1 cells stained with the anti-FR all isotype
antibody showed a significant increase in the mean fluorescence intensity as compared to the
negative control (Fig. 3A, 49±7 vs 12±1; p<0.05). The 4T1 cells were also stained with the antiFR-β antibody to determine FR-β expression. The cells did not show any detectable FR-β
expression (Fig. 3B). These results demonstrate that 4T1 cells expressed only the FR-α isoform.
Tumors harvested from 4T1 tumor-bearing mice retained FR-α expression
Although FR-α expression was found on the 4T1 cells in culture it was necessary to determine
whether 4T1 tumors harvested from animals retained this expression. Therefore, 4T1 tumors
were harvested from BALB/c mice at an advanced stage (~4-week) and labeled for FR-α
expression. Single-cell suspensions from the tumors were also labeled with anti-CD45 antibody
to identify and exclude infiltrating leukocytes and analyzed by flow cytometry. Gating on the
CD45- population (Fig. 4A, left histogram) eliminated all leukocytes and thus enabled
determination of FR-α expression only on the non-leukocyte population that primarily contained
the 4T1 epithelial tumor cells (Fig. 4A, right histogram). The CD45- cell population showed
uniform positive labeling for FR-α (12±2; p<0.05); however, the expression levels were lower
than that of the 4T1 cultured cells. (Fig. 5, p<0.05).
Tumor sections were also labeled with either the anti-FR-all isotype or the FR-β-specific
antibody along with CD45 (Fig. 4B). With the FR all isotype antibody (left panel), large regions
of the tumor sections showed strong staining indicating positive FR expression. However, no
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positive staining was observed in these same regions in the FR-β stained (right panel) tissue
sections clearly indicating the absence of FR-β receptors in the tissue. CD45-labeled cells
indicated leukocyte infiltration in the tumors and some of these cells showed positive FR-β
staining. Taken together, these results demonstrate that the 4T1 epithelial tumor tissues retain
expression of FR-α.
Tracheal epithelial cells from healthy mice did not express FR-α
Based on previous literature, normal epithelial tissues were expected to have negligible to no
FR expression; however, no reports of FR-α expression on normal murine epithelial cells by flow
cytometry could be found. Hence, the trachea of normal mice were harvested for isolating
epithelial cells. FR-α labeling on the normal epithelial cells was quantified by flow cytometry
and was compared to that of cultured 4T1 cells and 4T1 tumor cell suspensions (Fig. 5). Results
showed that the normal tracheal epithelial cells did not show any FR-α expression. Compared to
the control, significantly higher FR-α expression was observed in the cultured 4T1 tumor cells
(p<0.005) as well as in the 4T1 tumors (p<0.05). These results taken together, confirmed the
overexpression of FR-α on the 4T1 epithelial tumor cells (both in vitro and in vivo) but not on
normal epithelial cells.
FR-β expression was restricted to cells of myeloid lineage
FR isotype expression on U937 cells was quantified by flow cytometry and microscopy
analyses, using FR-β-specific antibodies. U937 cells stained strongly with the anti-FR-β antibody
(Fig 6). Specifically, the FR-β labeled cells had a mean fluorescence intensity of 23.5±6.5
compared to the negative control values of 3.6±0.2. Therefore, the U937 cells can be used as a
model myeloid cell line for functional studies of FR-β. It was also of interest to determine if FR-
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β expression was restricted to myeloid leukemias. To address this, the Jurkat T-cell lymphoma
cell line was used. Jurkat cells showed no positive staining with either the anti-FR all isotype or
anti-FR-β antibodies (Fig. 7). Therefore, FR-β expression appears to be restricted to the myeloid
leukemias.
Monocytes isolated from normal human blood did not express FR-β
FR-β receptors are reported to be overexpressed on myeloid malignancies including leukemia
with very low to negligible expression on normal cells of myeloid lineage. After validating its
expression on the U937 cell lines, it was now important to determine the expression of this
receptor on normal myeloid cells. For this purpose, monocytes from normal human blood were
isolated to serve as a relevant model for comparison to that of the U937 cells. Peripheral blood
mononuclear cells (PBMC) isolated from whole blood were analyzed for FR-β expression (Fig.
8A). The CD14+ population, representing the monocytes, was gated (left histogram) and FR-β
staining on the gated cells was quantified by flow cytometry (right histogram). Results showed
that the anti-FR-β antibody stained cells had the same level of mean fluorescence intensity as
that of the negative control, thus confirming that normal human monocytes do not express FR-β
receptors. Summary data are shown in Fig. 8B and demonstrate the overexpression of FR-β on
U937 tumor cells and the level of expression on normal monocytes.
The FR-α and FR-β receptors exhibited distinct patterns of membrane localization
4T1 and U937 cells stained with either anti-FR all isotype or anti-FR-β-specific antibodies
were analyzed by fluorescence microscopy to determine the patterns of receptor localization on
the cell surface (Fig 9). The 4T1 cells showed distinct punctate receptor staining which was
observed as clusters over the entire cell surface (left panel) while the U937 cells exhibited a more
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polarized staining pattern, where the receptors were found localized towards one end of the cell
(right panel). This distinct membrane localization pattern of the isoforms was further confirmed
by confocal microscopy (Fig. 10). These results suggest that FR-α and FR-β are oriented
differently on the cell surface.
FR-α and FR-β receptors exhibit differential activity in cells
The effect of endogenous folate (present in culture media) was analyzed to determine any
effects in regulating FR expression. 4T1 and U937 cells grown in folate-free RPMI
supplemented media when stained with either anti-FR all isotype or anti-FR- antibodies
exhibited similar levels of FR-α or FR- expression compared to cells that were grown in folatesupplemented regular media (Fig. 11). Thus, it was evident that the folate in culture medium did
not affect receptor expression on the cells. Therefore, experiments associated with folic acid and
receptor activity or targeting could be performed using regular folate-supplemented RPMI
media.
To determine the activity of FR-α and FR- receptors, cells were pulsed with free folic acid
(2.2 μM) and chased with folate-free medium for varying time points to determine receptor
activity in response to the high affinity ligand, folic acid. Receptor expression was quantified
using flow cytometry. 4T1 cells showed a significant (1.5-fold, p<0.05) reduction in cell-surface
FR-α expression within 5 minutes following addition of free folic acid when compared to nonpulsed control cells (Fig. 12). In addition, receptor expression did not begin to recover until 1
hour post-pulse, suggesting that there was no receptor recycling or re-expression during this
time. After a 2-hour post-pulse, FR-α receptor expression was restored back to that of the
positive control. To make sure folic acid was not interfering with antibody binding, cells were
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treated with sodium azide to block cellular activity or treated at 4°C to inhibit membrane
movement. In both cases anti-FR labeling remained unchanged (data not shown). These results
demonstrate that FR-α is rapidly internalized by 4T1 cells following binding of folic acid. To
determine if FR-β expression was regulated similar to FR-α, U937 cells were subjected to the
same pulse-chase experiments (Fig. 12). Interestingly, the U937 cells when exposed to folic acid
did not show any change in receptor staining intensity over the 2-hour time period when
compared to the non-pulsed positive control indicating that the FR- isoform was not
internalized in response to folic acid treatment.
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DISCUSSION
The folate receptor is overexpressed in many carcinomas with very low or negligible
expression on normal cells21,22. This restricted expression of the receptors has encouraged several
studies utilizing the FR-α isoform for selective targeting of tumor cells79. FR has two membraneassociated isoforms, α and β, that are reportedly restricted to epithelial and myeloid
malignancies, respectively1,43. However, the β isoform is not well defined. Therefore, we sought
to investigate the role of FR-β as a potential target for the treatment of myeloid leukemias. It is
already known that both isoforms exhibited high affinity for the ligand, folic acid, but most
studies have only examined targeting of FR-α using folic acid-conjugated drug delivery systems
with almost no information available about FR-β-mediated targeting. Therefore, we also
compared FR-α and FR-β isoforms in epithelial and myeloid cells, respectively to determine
differences in terms of cell-surface expression and activities in response to folic acid.
To study the FR-α and FR-β individually, cell lines expressing only one of the isoforms were
needed. Therefore, the 4T1 murine epithelial breast carcinoma and the U937 myelomonocytic
leukemia cell lines were tested. Antibody labeling experiments showed that the FR-α and FR-β
isoforms were strictly restricted to the respective epithelial and myeloid cell lines (Figs. 3 and 6).
Thus, these cell lines could serve as useful models to study FR-α and FR-β activity. Importantly,
FR-α expression was maintained in tumor cells harvested from 4T1 tumor-bearing mice
indicating consistency between in vivo and in vitro conditions (Fig. 4). In addition, FR-α
expression was significantly higher in 4T1 cells in culture or isolated from tumor tissue than in
normal epithelial cells isolated from the trachea of healthy mice (Fig. 5). This was again
consistent with previous reports indicating the selective expression of the FR-α isoform in tumor
cells but not in healthy cells22. The FR-β receptor is reported to be elevated on myeloid
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leukemias; however, its expression on lymphoid leukemias had not been investigated. Hence,
FR-β expression was analyzed on the Jurkat lymphoid T-cell leukemia cell line. Flow cytometry
analyses revealed that the cells did not express FR-β (Fig. 7), thus confirming the myeloidlineage-restricted expression of this isoform. Furthermore, while FR-β was highly expressed in
the U937 leukemia cell line, normal monocytes (CD14+ cells) isolated from PBMCs of healthy
human donors lacked FR-β expression (Fig. 8).
Antibody staining of FR-α and FR-β in the 4T1 and U937 tumor cell lines, respectively
indicated distinct membrane staining patterns of the receptors. The 4T1 cells had FR-α receptors
over the entire cell surface organized in clusters that looked like punctate while the U937 cells
had the FR-β receptors polarized to one end of the cell (Fig. 9). Confocal analyses confirmed
these distinct staining patterns of the FR isoforms (Fig. 10), which could be attributed to possible
differences associated with the orientation of the isoforms on the cell surface. However, at this
time there is no substantial information regarding any mechanism or regulatory factors that could
be associated with the orientation of the GPI-linked folate receptors on the cell membrane.
Based on past literature, both FR isoforms have high binding affinity to folic acid; however,
FR-β is reported to have ~50 times lower binding affinity than that of FR-α37. That FR-α can
easily internalize into cells95 is one of the most important characteristics of this isoform that has
been utilized to deliver folic-acid drug conjugates into tumor cells74. However, internalization
and/or recycling properties of FR-β are not clearly defined. Hence, FR-β activity in response to
folic acid treatment was investigated and compared to that of FR-α. Results showed that FR-α
and FR-β exhibited differential response when exposed to free folic acid. Specifically, FR-α
receptors showed internalization within 5 minutes of pulse-chase treatment with folic acid and
media, respectively. Receptors remained internalized for at least 30 minutes after which there
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was an increase in FR-α levels (Fig. 12). This could be attributed to either receptors recycling to
the cell surface or new receptors being expressed. On the contrary, FR-β showed no evidence of
internalization over the 2-hour period. In addition, there were no signs of increased FR-β levels
even after 2 hours (Fig. 12). This suggests that FR-β receptors are less active than the FR-α
receptors and may not bind folic acid in U937 cells.
Thus, the results of these studies clearly demonstrate that FR-α and FR-β isoforms are
different from each other in terms of expression, localization and activity in the cells. Despite
this, their high expression level on tumor cells, coupled with their lack of expression on normal
cell lineages, supports further investigation of folic acid-dependent therapies targeting both
isoforms in epithelial and myeloid tumors. However, given that FR-β showed no effects of free
folic acid treatment in U937 cells, it is important to directly test the binding ability of this
receptor to folic acid before any folic acid-dependent therapy is attempted. Of equal importance,
the lack of FR-β internalization following folic acid treatment strongly suggests that any
proposed folic acid-dependent therapies be efficacious at the cell surface level.
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FIGURES AND LEGENDS

A

B

Figure 3. FR expression on the 4T1 murine epithelial breast carcinoma cell line.
4T1 cells were labeled with A) rabbit anti-FR all isotype or B) anti-FR-β antibody followed by
detection with Alexa Fluor® 647-conjugated goat anti-rabbit IgG antibody. The primary antibody
was omitted from the negative control cells. Results represent 5-7 independent experiments.
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Figure 4
Figure 4. In vivo FR-α expression on 4T1 tumor cells.
Tumors were harvested from 4T1-tumor bearing mice at an advanced stage (4-week) and singlecell suspensions were prepared. Cell suspensions were labeled with rabbit anti-FR-all isotype
antibody and were detected with Alexa Fluor® 488-conjugated goat anti-rabbit IgG antibody.
The cell suspensions were also labeled with APC-conjugated anti-CD45 mouse antibody to
identify infiltrating leukocytes present in the tumor. A) The CD45- cells from the tumor cell
suspensions were gated (R2) (left histogram) and analyzed for FR-α expression (right histogram)
60

by flow cytometry. Results represent a minimum of three independent experiments. B) Tumors
that were harvested from advanced stage (4-week) 4T1 tumor-bearing mice were frozen and
cryosections were immunolabeled with anti-FR-all isotype (left panel) or anti-FR-β (right panel)
antibodies. Tissues were also labeled with APC-conjugated anti-CD45 antibody to identify
infiltrating leukocytes and analyzed by epifluorescence microscopy. Digital monochromatic
images were acquired at a constant exposure, and pseudocolored and overlaid using MetaVue™
software. Representative images showing FR expression in green. The CD45+ cells were
pseudocolored red. Nuclear staining was performed with DAPI (blue). Scale bar on all images =
100 µm.
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Figure 5. Comparing FR-α expression in normal and tumor epithelial cells.
Normal epithelial cells were isolated from the trachea of healthy mice and were compared to
those of tumors harvested from 4T1 tumor-bearing mice, and cultured 4T1 tumor cells. The
mean fluorescence intensity from flow cytometry experiments was quantified and represented as
mean ± SEM from 3-5 independent experiments. *Differences between FR labeled normal
tracheal cells and 4T1 cells and 4T1 tumors was significant. p<0.05; **p<0.005.
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Figure 6. FR expression on the U937 myeloid leukemia cell line.
U937 cells were labeled with a rabbit anti-FR-β antibody and detected using Alexa Fluor® 647conjugated goat anti-rabbit IgG antibody. The U937 cell population was gated (left) and
analyzed for FR-β expression (right). Results are representative from 5-7 independent
experiments.

63

Figure 7
Figure 7. FR expression on the Jurkat T-cell leukemia cell line.
Jurkat cells were labeled with rabbit anti-FR-all isotype or anti-FR-β antibody and detected using
Alexa Fluor® 647-conjuated goat anti-rabbit IgG antibody. The cell population was gated (left)
and analyzed for FR-α expression and FR-β expression (right). Black line represents negative
control; green dashed line represents labeling with FR-β antibody and blue dashed line represents
labeling with FR-all isotype antibody. Results are representative of three independent
experiments.
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Figure 8. Comparing FR-β expression on normal peripheral blood monocytes to that of the
U937 myelomonocytic leukemia cell line.
Human blood was drawn and collected over Ficoll followed by separation of the peripheral blood
mononuclear cells (PBMCs). Cells were labeled with Alexa Fluor® 647-conjugated anti-CD14
antibody and anti-FR-β specific antibody followed by detection with Alexa Fluor® 488-conjuated
goat anti-rabbit IgG antibody and analyzed by flow cytometry. A) The CD14+ cells (or
monocytes) were gated (R2, left histogram) and FR-β expression quantified (right histogram). B)
The mean fluorescence intensity of the monocytes was compared with that of the U937 cells and
presented as means ± SEM from three independent experiments. *Differences between FR-β
labeled monocytes and U937 cells was significant, p<0.05.
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Figure 9. FR-α and FR-β expression on 4T1 and U937 cells.
4T1 and U937 cell suspensions were labeled with anti-FR-all isotype and anti-FR-β antibody,
respectively, and collected onto Poly-L-lysine-coated slides. Cells were mounted and analyzed
by epifluorescence microscopy. Digital monochromatic images were acquired at a constant
exposure using a 60X objective and MetaVue™ software. Representative images are of 4T1 cells
expressing FR-α (left) and U937 cells expressing FR-β (right). Results are representative of 5-7
independent experiments.
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Figure 10. High-resolution imaging by confocal microscopy comparing FR-α and FR-β
staining patterns.
4T1 and U937 cells were labeled with anti-FR all isotype or anti-FR-β antibodies and analyzed
on a Leica Microsystems™ TCS SP2 confocal laser-scanning microscope. Images were acquired
using the 40x objective and pseudocolored using the Leica confocal software. Representative
images are of 4T1 cells expressing FR-α (left) and U937 cells expressing FR-β (right). Results
are representative of three independent experiments.
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Figure 11. Effect of endogenous folate on FR expression.
4T1 and U937 cells were grown in normal or folate-free media and labeled with rabbit anti-FR
all isotype or anti-FR-β antibody and detected using Alexa Fluor® 647-conjuated goat anti-rabbit
IgG antibody. 4T1 cells were analyzed for FR-α expression (left), and U937 cells were analyzed
for FR-β expression (right). Results are representative of a minimum of three independent
experiments.
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Figure 12. Comparing FR-α and FR-β activity in 4T1 and U937 cells.
4T1 and U937 cells were cultured in suspension and pulsed with 2.2 µM free folic acid for 5
minutes, washed and the cells harvested after 5, 15, 30, 60 or 120 minutes incubation in normal
media. Cells were then labeled with primary rabbit antibodies recognizing FR-α (left) or FR-β
(right) receptors followed by detection with Alexa Fluor® 647-conjugated goat anti-rabbit IgG
antibody. Cells were fixed and analyzed by flow cytometry. The mean fluorescence intensity of
the cells was compared and analyzed over time. Values represent the mean ± SEM results from
6-8 independent experiments. *Differences in sample means were significant, p<0.05.
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CHAPTER 3
FR-α and FR-β ISOFORMS EXHIBIT DIFFERENT INTRACELLULAR FATE
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ABSTRACT
Knowledge of the overexpression of the FR-α isoform on epithelial cancers and its
restricted expression on normal cells have initiated many targeting studies. In addition, its high
binding affinity has led to the use of folic acid-mediated strategies for effective cancer therapy.
In contrast, the FR-β isoform that is elevated on myeloid leukemias remains undefined, hence its
potential use as a therapeutic target has not been evaluated. In many cancer patients, the antitumor immune response is often inhibited by a population of suppressor cells known as myeloidderived suppressor cells (MDSCs), which have been reported to express FR-β. Therefore, FR-β
targeting could potentially be used to eliminate MDSCs in addition to myeloid leukemias. The
goal of this study was to determine the potential of FR-β in targeting myeloid cells. FR-β studies
were performed using the myelomonocytic leukemia cell line (U937) and MDSCs that were
harvested from 4T1 tumor-bearing mice. FR-α studies were also performed using the 4T1 breast
epithelial tumor cell line. Our previous findings suggested that the FR-β isoform was
comparatively less active than the FR-α and also did not internalize into U937 cells. Therefore,
to further investigate the details of the intracellular fate of FR-α and FR-β, studies were
conducted using the physiologic ligand, folic acid. Folic acid (FA)-fluorochrome conjugates
were synthesized using the fluorescent dyes fluorescein isothiocyanate (FITC) and
tetramethylrhodamine isothiocyanate (TRITC) to track the receptors. Bovine serum albumin
(BSA) was used as a linker to stabilize the conjugate. The resulting probes, FA-BSA-FITC and
FA-BSA-TRITC, were used to examine FR-α and FR-β binding activity and the fate of the
bound receptors in tumor cells (4T1 and U937) and in MDSCs. Flow cytometry and light
microscopy analyses demonstrated that the FA-BSA-FITC and FA-BSA-TRITC probes showed
strong and specific binding to both tumor cell lines and MDSCs. However, one dramatic
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difference was that while probe bound to FR-α was readily internalized, the FR-β receptors did
not internalize the bound probe.
To examine the differences more closely, mechanisms associated with FR trafficking were
investigated. Comparisons with clathrin-mediated endocytosis using transferrin receptor as a
model, and with pinocytosis using fluorescent dextran revealed that FR-α internalization was not
associated with these pathways. The role of lipid rafts in FR trafficking was also investigated by
determining the sensitivity of FR-α and FR-β to membrane cholesterol depletion. Results showed
that removal of membrane cholesterol dramatically reduced FR-α binding and internalization
while uptake of transferrin and dextran remained mostly unaffected.
The above results suggested that the FR-β isoform could be targeted using folic aciddependent methods; however, only at the cell surface. Hence, we sought to determine the
potential of a folic acid-based technique that could be potentially used to target both FR isoforms
at the cell surface. Therefore, a folic acid-nanoparticle conjugate was synthesized using 18 nm
gold nanoparticles (FA-BSA-Au18) to which both 4T1 and U937 cells showed specific
nanoparticle binding compared to the control (BSA-Au18). This provided direct evidence that
future nanoparticle-mediated targeting of FR-α and FR-β at the cell surface could take advantage
of magnetic nanoparticle technology to destroy target cells through localized hyperthermia. All
these findings suggest: 1) both FR-α and FR-β can be targeted using folic acid-dependent
techniques; 2) FR-α binding and internalization was regulated by membrane cholesterol content,
thus indicating possible association of FR-α with lipid rafts; and 3) colloidal nanoparticles can be
specifically targeted to FR-α and FR-β-expressing cells thereby increasing the number of
potential therapeutic strategies.
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INTRODUCTION
Selective overexpression of FR isoforms on tumor cells identifies them as potential targets for
effective cancer therapy. A variety of ligand- and antibody-conjugated cancer targeting strategies
have gained prominence for their potential use as therapeutics2. The high binding affinity for
folic acid (FA) exhibited by both the FR-α and FR-β isoforms makes them ideal candidates for
FA-dependent therapies. The importance of FA in such ligand-based therapies is further
enhanced due to its low immunogenicity, small size, compatibility with a variety of organic and
aqueous solvents, stability and low cost. In addition, conjugation of potential targeting molecules
to FA generally does not affect their binding affinity for the receptor making it highly desirable
for such a purpose106. There have been many studies that have shown successful delivery of FAconjugated therapeutic agents to epithelial tumors in vitro and in vivo3,77; however, the prospects
of using FA-dependent therapeutics to target FR-β remains unknown. FR-β is reportedly
overexpressed on some myeloid leukemias45 and some myeloid suppressor populations, namely
myeloid-derived suppressor cells (MDSCs)399. MDSCs are of special interest because they are
expanded significantly during pathological conditions such as inflammation and cancer and
function to suppress T cell immune responses. In cancer patients, this results in inhibition of the
anti-tumor immune response. Thus, characterizing the FR-β isoform could provide insights into
the role these receptors play in myeloid cell function and assess their potential as a therapeutic
target.
Previous studies have indicated that folate-conjugates directed to target FR-α were internalized
via receptor-mediated endocytosis136. However, later studies contradicted this idea and suggested
that they were not associated with clathrin-coated pathways74,106. Instead, they proposed that FRs
were arranged as clusters in association with flask-shaped structures called “caveolae” or into
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cholesterol-rich domains, also known as lipid-rafts87,93. Thus, the actual mechanism(s) associated
with FR internalization is yet to be elucidated. Interestingly, the FR-β isoform has long been
considered to be inactive despite being detected on cells of the myelomonocytic lineage50,51.
However, its strong binding affinity for FA still makes it a potential candidate for targeting
myeloid cells. Therefore, in the present studies, the function of FR-β in myeloid cells and the
potential of FA-conjugated therapeutics to target this isoform were investigated. The intracellular
fates of both the FR-α and FR-β isoforms were compared and potential approaches for targeting
them are proposed.
In this study, we synthesized FA-fluorochrome conjugates, showed that they bound
specifically to tumor cells and MDSCs, and determined that the FR-α isoform was internalized
following binding while the FR-β isoform was not. To further characterize the FR isoforms,
potential pathways that could be associated with FR trafficking were investigated. Results
demonstrated that the FA-conjugated probe was internalized into the 4T1 cells; however, there
was no co-localization with either clathrin-mediated endocytosis or pinocytosis. Our findings
also indicated that upon membrane cholesterol depletion, FR-α binding and internalization was
significantly inhibited while clathrin-mediated endocytosis and pinocytosis remained mostly
unaffected. This result, indicating sensitivity of FR-α to membrane cholesterol content, suggests
their possible association with lipid rafts.
A common FA-based system that could target both FR isoforms and be used for cell depletion
was prepared and tested. Specifically, a FA-colloidal gold conjugate (FA-BSA-Au18) was
produced and tested for binding efficiency to the 4T1 and U937 cells. Compared to the BSAAu18 control, the FA-BSA-Au18 exhibited strong binding to both cell lines indicating the
conjugate could bind to both the FR-α and FR-β isoforms. This result was important in validating
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that future nanoparticle-mediated therapy using magnetic nanoparticles and hyperthermia to
target receptors at the cell surface would be applicable to both FR isoforms.
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MATERIALS AND METHODS
Animals and tumor induction
BALB/c (wild type) mice were originally purchased from the Jackson Laboratories (Bar
Harbor, ME) and further housed and bred in a specific pathogen-free facility at the University of
Wisconsin-Milwaukee and screened regularly for pathogens. All procedures were approved by
the Animal Care and Use Committee of the University of Wisconsin-Milwaukee. For tumor
induction, 1x104 4T1 cells in 50 µl of supplement-free RPMI 1640 medium were injected
subcutaneously into the mammary fat pad of 8-12 week old wild type BALB/c female mice.
Tumors were monitored by caliper measurements of the major (L, length; mm) and minor (W,
width; mm) axes and tumor volume (V, volume; mm3) was calculated by the formula: V= (L x
W2) / 2.
Cell lines and reagents
The 4T1 murine mammary carcinoma epithelial cell line (ATCC CRL-2539) and the U937
human myelomonocytic leukemia (myeloid) cell line (ATCC CRL-1593.2) were both purchased
from ATCC (Manassas, VA) and maintained as described in Chapter 2, “Materials and
Methods”. Cell counts and viability were determined using a hemacytometer following
appropriate dilution in trypan blue exclusion dye.
Antibodies used in the flow cytometry and fluorescence microscopy experiments included:
polyclonal rabbit anti-FR-β antibody (Cat #PA5-24963, ThermoFisher Scientific, Waltham,
MA); and polyclonal rabbit anti-mouse/rat/human FR-all isotypes antibody (FL-257, Santa Cruz
Biotechnology, Santa Cruz, CA). The primary rabbit antibodies were detected with a secondary
Alexa Fluor® 647- or Alexa Fluor® 488-conjugated goat anti-rabbit IgG antibody (Jackson
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Immunoresearch, West Grove, PA). Other antibodies included fluorescein FITC-conjugated,
allophycocyanin (APC)-conjugated, or biotinylated anti-CD11b (Clone M1/70 BD Biosciences,
San Jose, CA); phycoerythrin (PE)-conjugated or FITC-conjugated anti-Ly-6G (Clone 1A8, BD
Biosciences); and peridinin-chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)-conjugated anti-Ly6C (Clone RM4-5, BD Biosciences). Biotinylated antibodies were detected with Alexa Fluor®
488-conjugated neutralite avidin (Life Technologies, Grand Island, NY).
For the synthesis of FA-conjugates, folic acid powder was purchased commercially
(ThermoFisher). 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC, Pierce) was used as an
activator of the carboxyl group on FA. Bovine serum albumin (BSA, ThermoFisher) was used as
a linker, and the fluorescent dyes FITC and TRITC (ThermoFisher) were used for tracking
receptors on the cell surface as well as intracellularly. Gold (Au) nanoparticles (18nm) were
synthesized by standard methods and provided by Dr. Julie Oliver, Department of Biological
Sciences, University of Wisconsin-Milwaukee. The colloidal Au18 nanoparticles were conjugated
to FA-BSA and BSA and analyzed by scanning electron microscopy (SEM) for determining
receptor activity. Dimethylsulfoxide (DMSO) was used as a universal solvent to dissolve FA
and EDC during synthesis of the conjugates.
Transferrin (Tfn)-FITC (Invitrogen, Carlsbad, CA) was used to track internalization of
transferrin receptors and served as a marker for clathrin-mediated endocytosis. Dextran (Dxt)FITC (Sigma Aldrich), which is a fluid-phase marker, was used to study macropinocytosis in
cells. DAPI (4’,6-diamidino-2-phenylindole, Sigma Aldrich) was used as a nuclear stain.
Methyl-β-cyclodextrin (MβCD, Sigma Aldrich) was used to deplete plasma membrane
cholesterol for the analysis of receptor activity.
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MDSC isolation and labeling
For labeling MDSCs, spleens were harvested from 4T1 tumor-bearing mice at an advanced
stage (4-weeks) and a single-cell suspension of the spleen was performed as follows: the spleen
was harvested and then teased apart in a 60 mm culture dish filled with PBS as previously
described401. Briefly, the suspensions were filtered through 70 µm mesh and centrifuged; red
blood cells were lysed in ACK buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 Na2EDTA, pH 7.4),
and the cells were filtered again and then washed three times with PBS. Cell counts and viability
were determined using a hemacytometer following appropriate dilution in trypan blue exclusion
dye. A 2X optimal dilution of anti-CD11b, anti-Ly-6G, and anti-Ly-6C antibodies in PBS
containing 2% normal horse serum (PBS/NHS), was added at a 1:1 ratio of 1x106 per 50 µl of
spleen cells and incubated for 30 minutes on ice. Following labeling, the cells were washed in
PBS/NHS, fixed in 1.5% paraformaldehyde in PBS and analyzed with a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA) using BD CellQuest TM Pro software. 10,000
cells/sample were analyzed with the fluorescence intensity displayed on a 4-decade log scale.
Synthesis of FA-linked fluorescent probes (FA-BSA-FITC or FA-BSA-TRITC)
Folic acid was conjugated to BSA and FITC as previously described402–404. Briefly, FA was
dissolved in anhydrous DMSO and incubated with a 5-fold molar excess of EDC and stirred for
1 hour at 23°C in the dark to activate the carboxyl group of FA. BSA solution (4 mg/ml) was
prepared by dissolving BSA in 0.1 M KH2PO4 and 0.1 M H3B03 at pH 8.5, and then dialyzing
(M.W. cut-off 12,000) against the same buffer overnight. Then the “activated” vitamin, FAEDC, was added at a 10-fold molar excess to the BSA solution and stirred for 16 hours at 23°C
in the dark followed by overnight dialysis against 0.1 M KH2PO4 and 0.1 M H3B03 at pH 8.5.
FITC (3 mg/ml in DMSO) or TRITC (3 mg/ml in DMSO) was then added to the FA-EDC-BSA
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mixture at a ratio of 50 μl per 1 mg BSA, incubated for 4 hours with stirring at 23°C in the dark
and then dialyzed extensively against PBS. The control or untargeted probes (BSA-FITC or
BSA-TRITC) were made by directly adding 50 μl FITC or TRITC per 1 mg of BSA solution as
described above. The mixture was incubated on a shaker for 4 hours in the dark at 23°C,
followed by dialysis against three changes of PBS. The final concentration of the probe was
determined using the absorbance of BSA (OD280), folic acid (OD368), FITC (OD494) and TRITC
(OD545) using a Nanodrop® ND-1000 Spectrophotometer (ThermoFisher Scientific, Waltham,
MA). The Beer-Lambert formula, A280= €cl was used to determine the final protein
concentration (A = absorbance, € = molar extinction co-efficient, c = concentration, l = path
length of the nanodrop). A FITC or TRITC correction factor (CF) was also included before
calculating the final protein concentration using the formula, Amax = A280 x CFdye). Degree of
labeling of folate-BSA was calculated as follows: Moles of folate per moles of BSA = Number
of moles of folate / Number of moles of BSA.
Analysis of FR-α and FR-β receptor binding to FA-BSA-FITC probe
4T1 and U937 cells were lifted and treated in suspension as described in Chapter 2, “Materials
and Methods”. MDSCs were isolated from single-cell suspension of spleen that was harvested
from 4T1 tumor-bearing mice as described above. Cell counts and viability were determined
using a hemacytometer following appropriate dilution in trypan blue exclusion dye. Cell
concentrations were adjusted to 20x106 cells/ml. All cells were incubated for 30 or 120 minutes
at 37°C and 5% CO2 with either medium alone, BSA-FITC, or FA-BSA-FITC at concentrations
of 10 and 100 μg/ml. Probe binding by MDSCs was also determined by treating the cells with
either the FA-BSA-FITC probe or the BSA-FITC control followed by labeling with antibodies
for 30 minutes on ice, which would identify the granulocytic and monocytic subsets of MDSCs
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as previously described. All cells were washed with cold PBS to prevent further membrane
mobility and immediately fixed in 1.5% formaldehyde in PBS and analyzed by flow cytometry
using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) using BD CellQuest TM
Pro software. 10,000 cells/sample were analyzed with fluorescence intensity displayed on a 4decade log scale.
Visualization of FR-α and FR-β binding and/or internalization
Flow cytometry does not discriminate between FA-BSA-FITC on the cell surface or
internalized conjugate. Therefore, to directly visualize internalized FA-BSA-FITC, analysis was
performed using fluorescence microscopy. 4T1 cells were cultured on 10 mm round no. 1.5 glass
coverslips (Ted Pella) for 18 hours and U937 cells were handled in suspension in 5 ml conical
tubes (BD Biosciences) as described above. MDSCs were harvested from the spleen of 4-week
tumor-bearing mice followed by preparation of single-cell suspensions as described above. 4T1
cells were labeled with 1 μg/ml BSA-FITC or FA-BSA-FITC probe while U937 cells and
MDSCs were labeled with 100 μg/ml probe. All samples were incubated for 30 or 120 minutes at
37°C. Cells were washed with PBS, fixed in 1.5% formaldehyde and stained with 0.3 μM DAPI
(Sigma Aldrich). Following DAPI staining, 4T1 cells were mounted on glass slides in ProLong
Gold®, anti-fade media. The U937 cells and MDSCs were cytospun at 16,000 x g for 10 minutes
using a cytocentrifuge (Beckman Coulter, Inc., Brea, CA) followed by mounting under glass
coverslips in ProLong Gold®. All samples were then analyzed on a Nikon Eclipse TE2000-U
inverted epifluorescence microscope (Nikon Instruments Inc., Melville, NY) equipped with a
CoolSNAP ES digital monochromatic camera (Photometrics, Tucson, AZ). Images were
acquired using 40 and 60x Plan Apo objectives at a constant exposure setting, pseudocolored and
overlaid using MetaVue™ software (Universal Imaging Corporation, Downington, PA).
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Internalization of folate receptors was determined with a Leica Microsystems™ confocal laserscanning upright microscope (Richmond, IL) using a 40x objective. Images were pseudocolored
using the Leica confocal software. All experiments were performed a minimum of 5 times.
Immunohistochemistry of 4T1 tumors
4T1 tumors (4-week) were harvested from BALB/c mice and then snap-frozen in tissue
freezing medium (Triangle Biomedical Sciences, Inc., Durham, NC) in liquid nitrogen or on dry
ice. Tissue sections with a thickness of 7 μm were cut on a cryostat and placed on poly-L-lysinecoated microscopic slides. The tumor sections were fixed in cold acetone for 5 minutes and
stored at -20°C until labeling. The sections were thawed for 5 minutes and rehydrated in PBS for
10 minutes. The sections were then incubated in 5% normal goat serum in PBS to block nonspecific antibody binding. To visualize the location of the myeloid population, the sections were
incubated with a fluorochrome-conjugated antibody against CD11b for 30 minutes at room
temperature. Sections were washed with PBS for 5 minutes followed by incubation with the FABSA-TRITC or the BSA-TRITC probe (100 µg/ml) for 1 hour at room temperature. Sections
were again washed and incubated with 0.3 μM DAPI for 10 minutes. The slides were washed
again with PBS for 5 minutes and mounted in ProLong Gold® anti-fade mounting medium. The
tumor sections were imaged as described above. Images are representative of a minimum of 3
independent experiments.
Determining effect of free folic acid on FR binding activity
4T1 cells and U937 cells were cultured in folate-free RPMI 1640 medium as described above.
The cells were pre-incubated with 2.2 μM FA acid for 30 minutes at 37°C followed by 30
minutes incubation with either BSA-FITC or FA-BSA-FITC at 100 μg/ml. The cells were
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washed with cold PBS to prevent further membrane mobility, immediately fixed in 1.5%
formaldehyde in PBS and analyzed by flow cytometry.
Comparing FR internalization with receptor-mediated endocytosis and pinocytosis
4T1 cells were cultured on coverslips as described above. Cells were treated with BSA-TRITC
or FA-BSA-TRITC at 1 μg/ml, FITC-conjugated transferrin (Tfn-FITC) at 20 μg/ml, or FITCconjugated dextran (Dxt-FITC) at 50 μg/ml for 30 or 120 minutes at 37°C. Following treatment,
cells were washed with PBS and fixed with 1.5% paraformaldehyde in PBS. 0.3 μM DAPI was
added to the cells for 15 minutes to stain the nucleus, followed by mounting in ProLong Gold®
and analysis by epifluorescence microscopy as described above. Images were acquired at a
constant exposure using an oil immersion 60X objective as described above.
Analyzing the role of membrane cholesterol in regulating FR activity
For cholesterol removal, cell monolayers were washed with PBS and incubated for 1 hour at
37°C in the absence (control cells) or presence (treated cells) of 5 mM MβCD). After 1 hour, the
medium was removed and the cells were washed with PBS. Following cholesterol depletion, the
cells were treated with the FA-BSA-FITC or BSA-FITC probes (100 μg/ml) and Tfn-FITC (20
μg/ml) or Dxt-FITC (50 μg/ml) conjugates for 30 or 120 minutes at 37°C. Cells were washed
with PBS, fixed in 1.5% paraformaldehyde in PBS and analyzed by flow cytometry as described
above.
For microscopy, the cells were treated with MβCD as described above followed by treatment
with the BSA-TRITC or the FA-BSA-TRITC probe at 1 μg/ml (for 4T1 cells) and 100 μg/ml (for
U937 cells). Cells were also simultaneously labeled with either Tfn-FITC (20 μg/ml) or Dxt-
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FITC (50 μg/ml) to determine and compare receptor internalization and/or co-localization with
that of FR-α and FR-β.
Synthesis of FA-BSA-Au18 nanoparticle conjugates
FA-BSA (or BSA as control) was conjugated to Au18-nanoparticles that were provided by
Dr. Julie Oliver178. Briefly, the optimal concentration of protein to stabilize the Au18
nanoparticles was determined empirically through concentration isotherms and 200 µg of FABSA was found to stabilize 1 ml of Au18. Once determined, the protein was conjugated to the
Au18 nanoparticles at pH 5.1 and the conjugates were stabilized by addition of polyethylene
glycol (average MW 20,000, Sigma Aldrich). Free protein was removed by pelleting the Au18
nanoparticles at 16,000 x g for 5 minutes. The nanoparticles were resuspended in 250 µl of
RPMI 1640 medium and used immediately.
Analyzing FA-BSA-Au18 binding using scanning electron microscopy (SEM)
4T1 cells were grown on coverslips and U937 cells were cultured in RPMI 1640 medium
until they reached 70% confluency as described above. All cells were washed in PBS and
labeled with FA-targeted (FA-BSA-Au18) or control nanoparticles (BSA-Au18) in Hank’s
balanced salt solution (HBSS) for 1 hour at 37°C. After labeling, the cells were washed three
times in HBSS. The cells were then fixed for 30 minutes in 1% glutaraldehyde and 0.4% osmium
tetroxide (OsO4) in 0.1 M HEPES, (pH 7.3), followed by 3 washes in 0.1 M HEPES. The U937
cells were allowed to adhere to poly-L-lysine-coated Thermanox™ coverslips (Ted Pella)
overnight at 37°C, while the 4T1 cells were kept in 0.1 M HEPES overnight. Both 4T1 and U937
cells were then dehydrated in a graded ethanol series, and dried by the critical-point method. The
coverslips were mounted onto stubs, sputter-coated with 4 nm iridium, and visualized with a
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Hitachi S-4800 scanning electron microscope using secondary and backscattered electron
detection.
Statistical analysis
Data are presented as mean ± SEM. Significant differences between sample means were
determined using a Student’s t test with *p<0.05 considered significant. Data between various
treatment groups were analyzed using one-way ANOVA and then compared by Bonferroni
multiple comparison tests using GraphPad Prism Software, Version 3.00 (San Diego, CA, USA).
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RESULTS
Folic acid-conjugated fluorescent probes were successfully synthesized
To specifically target folate receptors, FA-conjugated fluorescent probes were designed using
BSA as a linker protein and FITC or TRITC as the fluorochrome to track receptor binding and/or
internalization (Fig. 13). UV-Vis analysis confirmed the presence of FA in the FA-BSA-FITC
and FA-BSA-TRITC probes (Fig. 14). On the contrary, the untargeted probes, BSA-FITC or
BSA-TRITC showed no absorbance at OD368 that corresponded to the wavelength of folic acid.
The presence of FITC and TRITC in the probes was also confirmed at OD494 and OD545,
respectively. There were approximately 2-3 molecules of folic acid per molecule of BSA.
FR-α receptors showed strong binding to the FA-BSA-FITC probe
The probe binding efficiency of the FR-α expressed on 4T1 cells was assessed by treating the
cells with varying concentrations of the FA-BSA-FITC probe or control (BSA-FITC) for 30 and
120 minutes followed by analysis of their fluorescence intensity using flow cytometry. Results at
the 30-minute time-point showed that the 4T1 cells bound the FA-BSA-FITC probe weakly at
the 10 µg/ml concentration but had higher binding at the 100 µg/ml concentration (Fig. 15A). At
the 120-minute time-point, both concentrations of FA-BSA-FITC probe showed increased
binding over that of the 30-minute time-point, with the 100 µg/ml concentration showing the
highest level of binding overall. In all cases, the control BSA-FITC conjugate showed little-to-no
binding to 4T1 cells. Summary data for the 100 µg/ml concentration of FA-BSA-FITC showed
that there was a significant 5-fold increase in binding over that of the BSA-FITC at 30 minutes
that increased to 8-fold by 120 minutes (Fig. 15B). Comparison between FA-BSA-FITC binding
at 30 minutes vs 120 minutes showed a significant ~2-fold increase. Therefore, FA-BSA-FITC
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probe binding to FR-α on 4T1 cells demonstrated both concentration- and time-dependent
effects.

As a result of these experiments, 100 µg/ml was considered to be an optimal

concentration for studying FA-BSA-FITC probe binding in the 4T1 cells.
Immunofluorescence microscopy analysis confirmed the specific binding of FA-BSA-FITC
probe to the 4T1 cells but not the BSA-FITC control. Interestingly, the probe concentrations of
10 and 100 µg/ml (used for flow cytometry) were too high and gave poor resolution results with
fluorescence microscopy. Therefore, lower concentrations were tested and 1 µg/ml was found to
be optimal for microscopy. Analysis showed that the 4T1 cells had significant binding of the FABSA-FITC probe at the 30 minute time point that was localized primarily to the cell surface (Fig.
15C). At this time point, the FA-BSA-FITC probe was mostly localized in larger aggregates or
clusters which was different from the distinct punctate staining observed following anti-FR
antibody labeling (Chapter 2, Figs. 9 & 10). After 120 minutes, the staining intensity was not
only higher compared to the 30 minute time point, but a large amount of what appeared to be
internalized probe had accumulated within the cell (as indicated by arrows). In contrast, the cells
showed only minimal binding of the BSA-FITC control at either 30 or 120 minutes. Therefore,
these results demonstrate that the FR-α receptors on the 4T1 cells not only showed specific doseand time-dependent binding to the FA-BSA-FITC probe but also showed internalization.
FR-β receptors showed strong binding to the FA-BSA-FITC probe
The binding activity of FR-β on U937 cells was assessed by treating the cells with varying
concentrations of the FA-BSA-FITC probe or control BSA-FITC conjugates for 30 and 120
minutes followed by flow cytometric analysis. Initial labeling experiments showed that binding
activity of FR-β on the U937 cells was much lower than that of the FR-α on 4T1 cells.
Specifically, at a concentration of 10 µg/ml of the FA-BSA-FITC probe, the U937 cells did not
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show any positive staining above the control BSA-FITC staining (data not shown). Subsequent
experiments were next performed using concentrations of 100 and 200 µg/ml. At the 100 µg/ml
concentration, the cells showed specific binding of the FA-BSA-FITC probe at 30 minutes that
increased by 2-fold at 120 minutes (Fig. 16A). At 200 µg/ml, the FA-BSA-FITC probe showed
increased binding over that of the 100 µg/ml concentration at the 120-minute time-point;
however, this was not observed at the 30-minute time-point. Thus the probe binding efficiency of
the U937 cells was lower compared to the 4T1 cells and therefore the 200 µg/ml concentration
was considered optimal for all U937 cell analysis.
The mean fluorescence intensity of probe (200 µg/ml) binding across experiments was
analyzed and results showed a 3-fold difference between the BSA-FITC and the FA-BSA-FITC
treated samples at both 30 and 120 minutes (Fig. 16B, p<0.05). Although there was no
significant difference in probe binding at 30 and 120 minutes unlike what was observed in the
4T1 cells, increased binding approached significance at 120 minutes (p<0.07). Thus, overall the
data demonstrate that the FR-β receptors exhibited a lower binding activity than FR-α receptors.
In contrast to the 4T1 cells, initial experiments showed that a FA-BSA-FITC probe
concentration of 100 µg/ml gave optimal labeling for FR-β for microscopic analysis. The U937
cells demonstrated markedly higher staining with the FA-BSA-FITC probe compared to the
BSA-FITC control (Fig. 16C). However, there was no change in the staining intensity over time,
unlike that observed in 4T1 cells. The FA-BSA-FITC probe staining on the U937 cells was
found somewhat polarized on the surface of the cell membrane at 30 minutes (as indicated by
arrows) while at 120 minutes the probe was located diffusely on the cell surface. Importantly,
there was no evidence of internalization over the 120-minute time-period unlike that observed
for 4T1 cells. Taken together, the flow cytometric data and microscopic analyses demonstrated
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that the FR-β isoform has strong specific binding to the FA-BSA-FITC probe, but is not
internalized following binding.
Overall, in comparison to the FR-β receptors on U937 cells, the FR-α receptors expressed on
the 4T1 cells showed significantly higher binding of the FA-BSA-FITC probe at the 100 µg/ml
concentration at both 30 and 120 minutes (Fig. 16D; p<0.05). Thus, these results suggest that the
FR-α receptors are more active relative to FR-β.
Internalization of FR-α following binding
Fluorescence microscopic analysis strongly suggested that the FA-BSA-FITC probe was
internalized into 4T1 cells while it was not internalized following binding to U937 cells. To
confirm internalization, confocal microscopy was performed on 4T1 and U937 cells that were
treated with FA-BSA-FITC probe for 120 minutes as described above. Image analysis indicated
that the FA-BSA-FITC probe was internalized in the 4T1 cells at this time. The axes on the
images showed that the probe was localized directly beneath the membrane in the form of
clusters (Fig. 17A). On the contrary, the FA-BSA-FITC probe bound on the U937 cells was
found diffusely located over the cell surface, and did not demonstrate internalization even after
120 minutes (Fig. 17B).
4T1 tumors showed strong and specific binding to the FA-BSA-TRITC probe
Previous studies showed that advanced stage (4-week) 4T1 tumor cells exhibited FR-α
expression (Chap 2, Fig. 4). Therefore, the binding activity of the FA-BSA-TRITC probe to 4T1
tumor sections was analyzed. The tumor sections showed strong binding to the FA-BSA-TRITC
probe but not to the BSA-TRITC control (Fig. 18, red). Specifically, the FA-BSA-TRITC probe
bound throughout the tumor, with the tumor epithelial cells (CD11b-) staining the most intensely,
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consistent with their expression of FR-α (Fig. 18 b, d) The myeloid cell population in the tumor
sections was identified using an antibody against CD11b (green), and these cells demonstrated
lower binding of the FA-BSA-TRITC probe. Therefore, these results indicate that FR-α present
on the epithelial tumor tissue, and also to a lesser degree FR-β on tumor myeloid cells, were able
to specifically bind to the folic acid conjugate.
Free folic acid did not competitively inhibit FA-BSA-FITC binding to FR-α
In order to determine potential competition between the free FA and the FA-BSA-FITC probe
for binding to the receptors, 4T1 and U937 cells were pre-treated with 2.2 µM FA and then
incubated with probe followed by analysis with flow cytometry. In the 4T1 cells, the mean
fluorescence intensity of the FA-BSA-FITC probe-treated samples remained unchanged when
pre-treated with free FA (Fig. 19). In contrast, the U937 cells that were pre-treated with free FA
prior to FA-BSA-FITC probe treatment exhibited a significant reduction in fluorescence
intensity compared to untreated cells. These results demonstrate that free FA does not block the
binding or uptake of FA-targeted molecules to the high affinity FR-α isoform, but can block
binding to the lower affinity FR-β isoform.
Myeloid-derived suppressor cells (MDSCs) showed strong and specific binding to the FABSA-FITC probe
Bulk MDSCs were harvested from the spleens of advanced stage (4-week) 4T1 tumor-bearing
mice. Cells were treated with 100 µg/ml of BSA-FITC or the FA-BSA-FITC probe for 30 and
120 minutes followed by flow cytometric analysis. Results showed that both the monocytic and
granulocytic MDSC subsets had specific binding to the FA-BSA-FITC probe at both 30 and 120
minutes (Fig. 20A). Notably, the monocytic subset of MDSC had much higher binding to the
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FA-BSA-FITC probe as compared to the granulocytic subset. In addition, while the monocytic
MDSC subset showed increased binding to the FA-BSA-FITC probe with the longer incubation
time, the granulocytic subset remained mostly unchanged.
Summary data for the flow cytometry results are shown in Fig. 20B. The granulocytic MDSC
subset showed an ~7-fold increase (p<0.05) in the mean fluorescence intensity when treated with
the FA-BSA-FITC probe for 30 minutes compared to the BSA-FITC control. After 120 minutes
of treatment, these cells showed an ~2-fold increase in binding to the FA-BSA-FITC probe
compared to the 30-minute time-point but this did not reach statistical significance (p = 0.08).
The monocytic MDSC subset also exhibited specific binding to the FA-BSA-FITC probe.
Specifically, the cells showed a significant 12-fold increase (p<0.005) in binding to the FA-BSAFITC probe at 30 minutes and a 15-fold increase (p<0.005) after 120 minutes compared to the
control. Therefore, the overall FA-BSA-FITC probe binding intensity exhibited by the
monocytic MDSC subset was significantly higher than that of the granulocytic MDSC subset at
both 30 and 120 minutes.
For microscopic analysis, MDSCs were treated with 100 µg/ml of the BSA-FITC or FA-BSAFITC probe along with antibodies to identify the granulocytic and monocytic MDSCs as
described above. Compared to the BSA-FITC control (Fig. 20, upper panel), both subsets of
MDSCs showed significantly higher binding with the FA-BSA-FITC probe (Fig. 20, lower
panels). MDSCs isolated from the spleen of advanced stage tumor mice were mostly of the
granulocytic subset (~90%) or CD11b+Ly-6Clow (red) and showed moderate binding to the FABSA-FITC probe (green). The monocytic subset or CD11b+Ly-6Chigh (blue) exhibited strong
binding to the FA-BSA-FITC probe and could be identified by a pink hue on the cell membrane.
In particular, the FA-BSA-FITC probe binding by the monocytic MDSCs was quite evident from
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the high intensity of probe staining (green) that was visible on these cells. Therefore, consistent
with the flow cytometric data, fluorescence microscopic analysis of bulk MDSCs not only
showed specific binding to the FA-BSA-FITC probe but also confirmed higher probe binding
activity in the monocytic MDSC subset.
To determine if MDSCs internalized the FA-BSA-TRITC probe following binding, confocal
laser-scanning microscopy was used. MDSCs harvested from 4T1 tumor-bearing mice were
isolated and treated with the FA-BSA-TRITC probe as described above. Interestingly, the probe
was found localized at the surface of the cells after 30 minutes (left panel) while after 120
minutes (right panel), the probe was internalized (Fig. 20D). Thus, these results suggest that a
more active version of FR-β is expressed on MDSCs that behave differently from that found on
the U937 tumor cells.
The FA-BSA-Au18 conjugates exhibited specific binding to the 4T1 and U937 cells
The previous studies showed that the FR-β isoform expressed on U937 myeloid tumor cells
did not internalize. Therefore, a successful targeting strategy using FR-β to eliminate these cells
could not depend on delivery of a drug or toxin into the cell. A previous study done in
collaboration with Dr. Oliver’s lab was able to successfully target the 4T1 cells using an anti-FR
antibody-magnetite nanoparticle conjugate and then kill the cells by generating localized heating
at the cell surface178. This technique utilizes an optimized oscillating magnetic field (OMF) that
can generate localized heating around the Au-coated magnetite nanoparticles strong enough to
kill the target cells without affecting the neighboring healthy cells. In the present study, we
demonstrated the potential of FA-targeted nanoparticle conjugates to specifically bind to the 4T1
and U937 cells. Specifically, 4T1 cells were treated with either FA-BSA-Au18 or BSA-Au18
nanoparticle conjugates and then analyzed by SEM (Fig. 21). Results showed that the FA-BSA91

Au18 conjugates showed significantly higher numbers of nanoparticles bound to the cell surface
as compared to the BSA-Au18 control. In addition, the FA-BSA-Au18 nanoparticles were located
in clusters bound to flattened regions of the membranes as well as on membrane protrusions and
ruffles.
Similarly, U937 cells were treated with either FA-BSA-Au18 or BSA-Au18 nanoparticle
conjugates and analyzed by SEM (Fig. 22). The U937 cells treated with the FA-BSA-Au18
conjugates showed significantly higher numbers of nanoparticles bound to the cell surface as
compared to the BSA-Au18 control. In addition, the FA-BSA-Au18 nanoparticles were found
mostly as individual labels or in small clusters, but confined to a specific area of the cell
membrane. This finding was similar to the polarized anti-FR-β antibody-staining pattern
observed on the U937 cells previously (Chapter 2, Figs. 9 & 10).
FR-α receptors did not internalize via clathrin-mediated endocytosis in the 4T1 cells
Previous reports have also demonstrated internalization of the FR-α into epithelial cells;
however, the mechanisms associated with this process have not been completely elucidated.
Therefore, we sought to investigate the FR-α internalization pathway in the 4T1 cells.
Specifically, 4T1 cells were treated with the FA-BSA-TRITC probe to track the receptors
intracellularly. The cells were also treated with a transferrin (Tfn)-FITC conjugate as a marker
for clathrin-mediated endocytosis so direct comparisons could be made with that of FR-α
internalization.
Analysis of 4T1 cells treated with the FA-BSA-TRITC probe along with Tfn-FITC for 30
minutes showed two distinct staining patterns. Specifically, the FA-BSA-TRITC probe was
mostly localized to the cell surface (Fig. 23, red staining) while the transferrin receptors were
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internalized in the form of clusters (green staining). After 120 minutes, the FA-BSA-TRITC
probe showed internalization but there was no co-localization with the internalized transferrin
receptors. These results clearly indicated that FR-α internalization was not associated with the
clathrin-mediated endocytic pathway.
FR-α internalization in the 4T1 cells was not associated with pinocytosis
A second major pathway of uptake by cells is pinocytosis which is also commonly known as
“cell-drinking”97. Therefore, we sought to determine if there was any co-localization of the FR-α
internalization pathway with that of pinocytosis. Dextran is a standard marker for studying
pinocytosis in cells and hence was used to compare FA-BSA-TRITC probe internalization in the
4T1 cells.
Pinocytosis in tumor cells is reported to occur as early as 5 minutes thus we analyzed the cells
treated with the FA-BSA-TRITC probe and dextran-FITC conjugate from 5-120 minutes. At the
early time points of 5 and 15 minutes, both the dextran-FITC conjugate (Fig. 24, green staining)
and the FA-BSA-TRITC probe (red staining) were found on the cell membrane. Interestingly,
both the FA-BSA-TRITC and dextran-FITC conjugates exhibited punctate staining and some colocalization on the cell membrane (yellow color) at this time. After 30 minutes of treatment, the
intensity of dextran-FITC staining as well as the FA-BSA-TRITC staining appeared much
stronger and indicated some internalization had occurred in both cases. However, the internalized
FA-BSA-TRITC probe at this time did not exhibit any co-localization with that of the dextranFITC conjugate. After 120 minutes, the amount of internalized FA-BSA-TRITC probe and
dextran-FITC were further enhanced, indicating increased uptake by the cells and both exhibited
internalized clusters. However, the dextran-FITC uptake by the cells remained distinct from that
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of the FA-BSA-TRITC probe, thus indicating that FR-α internalization is not mediated through
pinocytosis.
FR-mediated binding activity was sensitive to cell membrane cholesterol depletion
Previous reports have suggested a possible role of lipid rafts in FR binding activity. Specifically,
it is proposed that the cholesterol deposits present within the lipid rafts on the cell membrane are
responsible for mediating FR binding to ligands and facilitating FR internalization; however, this
process remains obscure60. Therefore, the role of cholesterol in FR-α and FR-β binding and
internalization was investigated in 4T1 and U937 cells, respectively. For these studies, a
cholesterol inhibitor, methyl-β-cyclodextrin (MβCD) was used to deplete free cholesterol from
the cell surface membrane. 4T1 and U937 cells were pre-treated with MβCD and then incubated
with the FA-BSA-FITC probe or BSA-FITC for 30 and 120 minutes, and binding ability was
quantified by flow cytometry. Initial analysis showed that FA-BSA-FITC probe binding to 4T1
cells was reduced in the presence of MβCD (Fig. 25A). A similar albeit lesser effect was also
observed in the MβCD-treated U937 cells. Summary data showed that the 4T1 cells showed
significant reduction (p<0.05) in FA-BSA-FITC probe binding after treatment with MβCD at
both 30 and 120 minutes (Fig. 25B). Specifically, pre-treatment of 4T1 cells with MβCD
followed by FA-BSA-FITC probe staining for 30 minutes resulted in a 2-fold reduction in the
fluorescence intensity compared to untreated cells. After 120 minutes, this difference in mean
fluorescence intensity was increased to ~2.5 –fold indicating that this inhibition of FR-α binding
activity remained consistent over time. In fact, at both the 30 and 120 minute time points, the
fluorescence intensity of the MβCD-treated FA-BSA-FITC stained cells was equal to or lower
than the equivalent BSA-FITC stained cells. Therefore, these results showed that the FR-α

94

binding activity was completely inhibited by cholesterol depletion, thus suggesting a possible
association of lipid rafts with FR-α binding activity.
The U937 cells pre-treated with MβCD also showed a reduction (~1.5-fold) in FA-BSA-FITC
staining; however, this change did not reach statistical significance (p = 0.08) and was only
observed after 120 minutes (Fig. 25B). To determine if the above observed inhibition in FR
binding activity was due to receptor sensitivity to cholesterol depletion or due to cellular stress
resulting from cell-surface cholesterol depletion, the effects of cholesterol depletion on clathrinmediated endocytosis and pinocytosis were determined. In general, MβCD-treated 4T1 cells
showed a reduction in Tfn-FITC binding at later time points (Fig. 26A). Specifically, Tfn-FITC
binding to MβCD-treated 4T1 cells was reduced by 50% (p<0.05) compared to untreated cells at
the 120-minute time-point (Fig. 26B). By contrast, the U937 cells did not exhibit any statistically
significant change in transferrin binding activity with the MβCD treatment, although labeling
tended to be reduced. Similarly, the effect of cholesterol depletion on pinocytosis was also
determined using flow cytometric analysis. After treatment with MβCD, neither the 4T1 cells nor
U937 cells exhibited a significant reduction in dextran-FITC binding (Fig. 27). While a reduction
in dextran-FITC fluorescence was observed at the 120-minute time-point in both cell lines, this
did not reach statistical significance (p = 0.08). Fluorescence microscopy analysis showed that
FA-BSA-TRITC probe binding in the 4T1 cells was significantly inhibited at both 30 and 120
minutes while the transferrin receptor activity and dextran-mediated pinocytosis remained
unaffected in the cells (Fig. 28). Although the FA-BSA-TRITC probe binding in the U937 cells
was not significantly affected by cholesterol depletion unlike the 4T1 cells (Fig. 25B),
fluorescence microscopic analysis showed markedly reduced probe binding in the cells at the
120 minute time point while transferrin internalization and pinocytosis remained unaffected in
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the U937 cells (Figs. 28 and 29). Importantly, cholesterol depletion did not affect FR-α and FR-β
expression in the 4T1 and U937 cells, respectively, as assessed by antibody labeling (data not
shown). Thus, taken together, these studies revealed that cholesterol, possibly in the form of lipid
rafts, may be a key factor in regulating FR binding activity in tumor cells without affecting
receptor expression levels.
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DISCUSSION
FR-α and FR-β isoforms are reported to not only be differentially expressed, but are also
suggested to function differently in cells36. However, the differences associated with their
intracellular trafficking are not completely understood. We have already shown their lineagespecific expression and their differential activity in response to folic acid (Chapter 2). Therefore,
in these studies, FR-α and FR-β isoforms were tracked to determine their intracellular fate
following ligand binding. The goal of the study was to provide new information that would aid in
designing folic acid-based methods to target these isoforms.
For tracking the receptors, FA-fluorochrome conjugates (FA-BSA-FITC or FA-BSA-TRITC)
were synthesized (Fig. 13 and 14). BSA-FITC and BSA-TRITC were also synthesized as
equivalent controls. The FA-BSA-FITC probe exhibited strong and significantly higher binding
to the 4T1 cells than did the BSA-FITC control (Fig. 15A & B). In addition, there was a dosedependent as well as time-dependent increase in FA-BSA-FITC probe binding in the cells. The
specific binding ability of the FA-BSA-FITC probe alone to the 4T1 cells demonstrated the high
affinity of the FR-α receptors for FA and confirmed the utility of FA for targeting. The FA-BSAFITC probe was found localized to the 4T1 cell membrane surface 30 minutes after addition but
began to internalize thereafter (Fig. 15C) which was consistent with previous reports75. However,
the time taken by the receptors to internalize the probe (~120 minutes) was longer than that
observed with addition of free folic acid (5-30 minutes), which could be attributed to the size of
the probe molecule being internalized (Fig. 12, Chapter 2). The probe (FA-BSA-FITC) being a
much larger molecule may require a longer time to be internalized as compared to the free folic
acid. Alternatively, the FA-BSA-FITC probe may engage multiple FRs at once given that there
are ~2 molecules of FA in each conjugate, and this could alter the internalization rate.
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As in the 4T1 cells, the FA-BSA-FITC probe showed significantly higher binding to the U937
cells than the BSA-FITC control (Fig. 16). However, demonstration of specific binding to the
FA-BSA-FITC probe required a higher concentration of probe (200 µg/ml) than for the 4T1
cells, thus indicating a lower binding affinity of the FR-β isoform to the FA-BSA-FITC probe. In
addition, the FA-BSA-FITC probe binding remained constant at both 30 and 120 minutes in
U937 cells, suggesting saturation of the FR-β receptor activity in these cells. Fluorescence
microscopy studies also revealed that the FA-BSA-FITC probe was not internalized by the U937
cells. Instead, the probe remained localized on the cell surface up to 120 minutes (Fig. 17C).
Taken together, these studies revealed that the FR-α isoform has a high binding activity for FA
conjugates and has the ability to internalize into cells. On the contrary, the FR-β isoform has
lower binding activity than FR-α and lacks the ability to internalize into cells.
Previous studies showed that tumor sections harvested from 4T1 tumor-bearing mice exhibited
high FR-α expression (Chapter 2, Fig. 4). The present studies determined whether the receptors
exhibited correspondingly high FA binding activity in the tumors. For this, tumors from 4T1
tumor-bearing mice were harvested and tissue sections were treated with the FA-BSA-TRITC
probe. Results showed that the FA-BSA-TRITC probe exhibited strong staining on the tumor
sections (Fig. 18). Therefore, FR-α expressed in the tumors maintained its ability to specifically
bind to the FA-conjugated probe. Interestingly, pretreatment of 4T1 cells with free FA had no
effect on the subsequent binding of the FA-BSA-FITC probe (Fig. 19). In contrast, similar
treatment in U937 cells reduced FA-BSA-FITC binding. This suggests that the affinity of the
FA-BSA-FITC probe for the FR-α receptor is higher than that of free folate, while this is not the
case for binding the lower affinity FR-β isoform. This may also reflect the fact that FR-α is
internalized and recycled following binding while FR-β remains on the cell surface.
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It has previously been reported that FR-β is restricted to cells of the myeloid lineage. Apart
from the in vitro model cell line, U937, it was also of interest to investigate the role of FR-β in
non-tumor cells isolated from in vivo conditions, which would add relevance in interpreting the
functions of this isoform. For this, MDSCs were chosen to examine the expression and
functional characteristics of FR-β. These cells increase during chronic inflammatory responses
and during cancer where they inhibit the immune response of the host229. Previously in our
laboratory, MDSCs were shown to express the FR-β receptor; hence, this was a relevant cell type
to further study the functions of this isoform399. Understanding the role of FR-β in this
population of suppressor cells can provide valuable insights in determining its potential as a
target to eliminate MDSCs. The FA-BSA-FITC probe showed significantly stronger binding to
both the granulocytic and monocytic subsets of MDSCs than the BSA-FITC control (Fig. 20A
and B). However, the monocytic subset demonstrated significantly higher binding activity than
the granulocytic subset, which could be attributed to higher expression of FR-β on their
surface399. In addition, the FA-BSA-FITC probe showed increased binding over time to the
monocytic subset while binding to the granulocytic subset remained unchanged. This also
suggests that the monocytic MDSCs are the more active subset in the population, and in fact
have been shown to be more immunosuppressive than the granulocytic subset405. Fluorescence
microscopy analysis further confirmed the specific binding of the FA-BSA-TRITC probe to both
subsets of MDSCs (Fig. 20C). Unexpectedly, confocal microscopy showed that the FA-BSATRITC probe was internalized by MDSCs at 120 minutes (Fig.20D), unlike in the U937 cells.
However, cells isolated from in vivo inflammatory conditions or the tumor environment exhibit
higher uptake rates or pinocytosis than cultured cell lines75. Hence, this ability of MDSCs to
internalize the probe may be attributed to the more active nature of the cells being isolated from
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4T1 tumor-bearing mice. Regardless, this difference in FR-β function in MDSCs vs tumor cells
following FA-conjugate binding should be considered when designing future targeting strategies.
The current studies demonstrate that both FR-α and FR-β exhibit strong specific binding to FA
conjugates, thus supporting the idea that FA-based targeting methods can be applied to target
both isoforms of the receptor. However, it is important to note that the FR-β isoform was not
internalized into tumor cells unlike FR-α. Therefore, FA-targeted delivery strategies that could
target the receptors at the cell surface and still result in killing were investigated. Through
collaboration with Dr. Julie Oliver, who specializes in the synthesis and use of nanoparticles, we
sought to conjugate FA-BSA to gold nanoparticles (FA-BSA-Au18 and BSA-Au18) to use as a
potential targeting system. Importantly, the FA-BSA-Au18 conjugates bound to FR-α on 4T1
cells while the BSA-Au18 control conjugates did not (Fig. 21). The FA-BSA-Au18 nanoparticles
were found in clusters over the entire cell surface which was consistent with the previous data
showing a distinct punctate FR-α staining pattern on 4T1 cells obtained through antibody
labeling (Chapter 2, Figs. 9 and 10) and FA-BSA-FITC probe binding (Fig. 15). The FA-BSAAu18 conjugates also showed specific binding to the U937 cells (Fig. 22). However, in this case
the nanoparticles were mostly bound to flattened areas of the membrane that were localized to
discrete areas of the cell. This finding is consistent with the polarized staining pattern observed
when using antibody labeling of FR-β (Chapter 2, Figs. 9 and 10).
Overall, these data support the targeting of both FR-α and FR-β receptors using FAnanoparticle conjugates. Previous collaborative studies with Dr. Oliver demonstrated specific
targeting of FR-α using an indirect antibody-nanoparticle-based system in 4T1 cells.
Furthermore, using this strategy with gold-coated magnetite nanoparticles successfully killed
4T1 tumor cells by induction of hyperthermia at the cell-surface level178. Therefore, the aim of
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the current studies was to develop a FA-nanoparticle conjugate that could deliver this
hyperthermia-mediated therapy to both isoforms of the folate receptor in a single step. These
current findings using FA-BSA-Au18 nanoparticles as a model validated our premise that
hyperthermia-mediated targeting through magnetic FA-nanoparticle conjugates (e.g., FA-BSA
gold coated-magnetite) could be a potential targeting therapy to eliminate both FR-α- and FR-βexpressing cells.
FR-α has been widely used as a targeting system to deliver drugs to epithelial tumor cells;
however, concerns such as drug toxicity and non-specific tissue damage has resulted in only
partial success of this therapeutic strategy. One contributing issue to the lack of success is that a
detailed endocytic mechanism associated with this receptor isoform has not been described. A
better understanding of FR-α function could provide valuable insights for devising alternative
therapies to target this receptor. Therefore, we sought to better characterize the FR-α
internalization pathway by comparing it to other standard endocytic receptor pathways in 4T1
tumor cells. Comparisons with the clathrin-receptor pathway marker transferrin indicated that
FR-α is not associated with clathrin-mediated endocytosis as there was no co-localization
between the FA-BSA-TRITC probe and the Tfn-FITC conjugate at any time points (Fig. 23). In
addition, the FA-BSA-TRITC probe did not co-localize with the dextran-FITC conjugate (Fig.
24), thus demonstrating that the FR-α internalization pathway is also distinct from pinocytosis.
These data taken together strongly indicate that FR-α-mediated internalization of bound ligand
occurs through a non-typical mechanism or an endocytic pathway that needs further
investigation.
One possible alternative internalization mechanism that has been suggested for FR is lipid
rafts, although this has not been substantiated87. Hence, the association of FR to membrane lipid
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rafts was investigated by determining their sensitivity to depletion of cholesterol, a major
constituent of lipid rafts. Results showed that depleting cell membrane cholesterol with MβCD
treatment eliminated FA-BSA-TRITC probe binding in the 4T1 cells at both early and later time
points (Fig. 25). In the case of the U937 cells, there was a tendency towards reduced probe
binding, but these data did not reach statistical significance. Thus, overall, these results
demonstrated that both FR-α, and to some degree FR-β activity, was strongly affected by the
absence of membrane cholesterol, thus indicating their dependence on lipid rafts. However, to
confirm that these effects were induced due to cholesterol depletion and not from other indirect
effects of MβCD, the effects of cholesterol depletion on clathrin-mediated endocytosis and
pinocytosis were examined (Fig. 26 and 27). Our results showed that transferrin endocytosis and
pinocytosis of dextran were largely unaffected by cholesterol depletion. While there was a
decrease in transferrin endocytosis at 120 minutes, this could be attributed to cellular stress or
membrane damage from long-term cholesterol-deficient conditions. Collectively, the data show a
dependency of both FR isoforms on membrane cholesterol compared to that of the other typical
internalization pathways. Since cholesterol is a major component of lipid rafts it is most likely
that lipid rafts play an important role in regulating FR ligand binding and trafficking in cells.
Thus, these studies provide novel insights into trafficking mechanisms associated with FR
endocytosis, which could be manipulated for potential receptor targeting.
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FIGURES AND LEGENDS

Figure 13. Synthesis of folic acid-conjugated fluorescent probes.
To specifically target folate receptors, folic acid (FA) was activated by the protein linker, EDC,
to generate FA-EDC (a). FA-EDC was next coupled to bovine serum albumin (BSA), a protein
carrier, to generate FA-BSA (b). Any unconjugated molecules were removed by dialyzing the
product against sodium bicarbonate buffer overnight (c). Fluorescein isothiocyanate (FITC) or
tetramethyl rhodamine (TRITC) was then attached to FA-BSA to generate FA-BSA-FITC and
FA-BSA-TRITC, respectively (d), allowing visualization of the probe following dialysis of the
product against PBS (e).
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Figure 14. UV-Vis analysis of the BSA-FITC, BSA-TRITC, FA-BSA-FITC and FA-BSATRITC probes
The BSA-TRITC (left) and FA-BSA-TRITC (right) probes represented in the upper panel were
quantified by measuring the absorbances of BSA, FA and TRITC using UV-Vis spectroscopy.
The BSA-FITC (left) and FA-BSA-FITC (right) probes represented in the lower panel were
quantified similarly. The concentrations of the probes were calculated using Beer-Lambert Law
after using a correction factor for the TRITC or FITC dyes.
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Figure 15. FA-BSA-FITC probe showed specific binding to FR-α in 4T1 cells.
4T1 cells were treated with the FA-BSA-FITC probe or BSA-FITC control for 30 or 120
minutes. A) Cells were treated with 10 or 100 µg/ml of the conjugates and analyzed by flow
cytometry. Histogram plots are representative of a minimum of 5 independent experiments. B)
Summary data of the flow cytometry experiments represent the means ± SEM of results.
*Difference in means between groups were significant, p<0.05, **p<0.05. C) 4T1 cells were
grown on coverslips and treated with 1 µg/ml of the FA-BSA-FITC or BSA-FITC probe and
analyzed with fluorescence microscopy. Digital images were acquired at a constant exposure and
pseudocolored using the MetaVue™ software. Scale bars are 2.5 μm. Images are representative
of 4 independent experiments.
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Figure 16. FA-BSA-FITC probe showed specific binding to FR-β in U937 cells.
U937 cells were treated with the FA-BSA-FITC probe or BSA-FITC control for 30 or 120
minutes. A) Cells were treated with 100 or 200 µg/ml of the conjugates and analyzed by flow
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cytometry. Histogram plots are representative of a minimum of 5 independent experiments. B)
Summary data of the flow cytometric experiments represent the Means ± SEM of results.
*Difference in means between groups were significant, p<0.05. C) U937 cells were treated with
100 µg/ml of the FA-BSA-FITC probe or BSA-FITC control and analyzed with fluorescence
microscopy. Digital images were acquired at a constant exposure and pseudocolored using
MetaVue™ software. Scale bars = 0.5 μm. Images are representative of 4 independent
experiments. D) The mean fluorescence intensity of the FA-BSA-FITC probe (100 µg/ml)
binding ability by the 4T1 cells was compared with that of the U937 cells and presented as
means ± SEM from 3-5 independent experiments. *Differences in sample means were significant
p<0.05.

109

Figure 17. Comparing FR-α and FR-β internalization by high-resolution confocal
microscopy
4T1 and U937 cells were treated with FA-BSA-TRITC probe for 120 minutes and analyzed on a
Leica Microsystems™ TCS SP2 confocal laser-scanning microscope. Images were acquired
using a 40x objective and pseudocolored using the Leica confocal software. Images are
representative of 3 independent experiments.
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Figure 18. The FA-BSA-TRITC probe showed strong staining on tumor sections harvested
from 4-week 4T1 tumor-bearing mice.
Tumors were harvested from advanced stage (4-week) 4T1 tumor-bearing BALB/c mice.
Cryosections were immunolabeled against the myeloid cell marker CD11b. Sections were also
treated with either the FA-BSA-TRITC probe or BSA-TRITC control (100 μg/ml) for 1 hour at
room temperature. Sections were counterstained with DAPI to label cell nuclei (blue). The
sections were mounted and analyzed with fluorescence microscopy. Digital monochromatic
images were acquired at a constant exposure, and pseudocolored and overlaid using MetaVue™
software. Representative images show the difference in staining when treated with the BSATRITC or FA-BSA-TRITC probe (red). CD11b+ cells (green) are predominantly myeloidderived suppressor cells (MDSCs) present in clusters and as individual cells found in some areas
of the tumor. Images are representative of 3 independent experiments. Scale bar = 100 μm.
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Figure 19. Free folic acid did not compete with the FA-BSA-FITC probe for binding to the
FR-α isoform.
4T1 and U937 cells were treated with 2.2 μM free FA for 10 minutes at 37°C followed by
treatment with the FA-BSA-FITC probe or the BSA-FITC control at a concentration of 100
μg/ml for 30 minutes at 37°C. Cells were then washed in PBS and fixed in 1.5% formaldehyde.
Cells that were incubated with the probe in the absence of free FA were used as controls. The
fluorescence intensity of the cells was quantified using flow cytometry. Data represent the mean
± SEM results from 5 independent experiments. *Differences in means between groups were
significant, p<0.05. n.s = non-significant.
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Figure 20
Figure 20. The FA-BSA-FITC probe showed specific binding to FR-β receptors on myeloidderived suppressor cells (MDSCs).
Bulk MDSCs were harvested from the spleens of advanced stage 4T1 tumor-bearing mice and
were treated with the FA-BSA-FITC probe or BSA-FITC control for 30 or 120 minutes. A)
Spleen cells were labeled with fluorochrome-conjugated antibodies against CD11b, Ly-6C and
Ly-6G and treated with 100 µg/ml of the probe and analyzed by flow cytometry. Individual
subsets of MDSCs were gated and the mean fluorescence intensity of probe staining was
quantified. Histogram plots are representative of a minimum of 5 independent experiments. B)
Summary data of the flow cytometry experiments represent mean ± SEM of a minimum of 5
independent experiments. *Difference in means between groups were significant, p<0.05;
**p<0.005. C) Spleen cells were treated with 100 µg/ml of the BSA-FITC (upper panel) or the
FA-BSA-FITC probe (lower panels) for 30 minutes and immunolabeled with fluorochromeconjugated antibodies against a granulocyte marker (CD11b), and MDSC markers (Ly-6G and
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Ly-6C), and then analyzed by fluorescence microscopy. Images compare the binding specificity
between the FA-targeted vs the untargeted probe. The circled cells on the FA-BSA-TRITC
treated sample indicates the monocytic MDSCs binding the probe. D) Internalization of the FABSA-TRITC probe was also determined using confocal laser-scanning microscopy. Spleen cells
were treated with 200 µg/ml of the FA-BSA-TRITC probe for 30 (left) and 120 minutes (right)
followed by labeling with CD11b, Ly-6G and Ly-6C to identify MDSCs. All digital images were
acquired at a constant exposure using a 40x objective and pseudocolored using the MetaVue™
or Leica™ confocal software. Scale bars = 50 μm (c) or 5 μm (d). Images are representative of 34 independent experiments.
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Figure 21. The FA-BSA-Au18 conjugates showed specific binding to FR-α receptors on the
4T1 cells.
4T1 cells were grow on coverslips and treated with either BSA-Au18 (a) or FA-BSA-Au18 (b-d)
conjugates for 1 hour at 37°C. Cells were fixed in 1.5% glutaraldehyde, post-fixed in OsO4, and
prepared for SEM analysis. High-magnification back scattered electron images were acquired at
a constant voltage and current setting. Images are representative of 3 independent experiments.
The arrows point to nanoparticles that are bound on the cell surface.
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Figure 22. The FA-BSA-Au18 conjugates were localized to spread areas of the membrane of
U937 cells.
U937 cells were grown in suspension cultures and treated with either BSA-Au18 or FA-BSAAu18 conjugates for 1 hour at 37°C. Cells were fixed in 1.5% glutaraldehyde and post-fixed in
OsO4. Cells were washed and a drop of the cell suspension was then allowed to adhere to poly-Llysine coated coverslips. Samples were prepared for electron microscopy and imaged on a
scanning electron microscope. High-magnification back scattered electron images were acquired
at a constant voltage and current setting. Images show comparison between BSA-Au18 (a) and
FA-BSA-Au18 (b) conjugates. (c-d) Examples of membrane areas of the cell where most FABSA-Au18 nanoparticles were bound. Images are representative of 3 independent experiments.
The arrows point to the nanoparticles that were bound on the cell surface.
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Figure 23. Comparing FR-α and transferrin receptor internalization pathways
4T1 cells were incubated with a transferrin-FITC conjugate (20 μg/ml) and the FA-BSA-TRITC
probe or BSA-TRITC control at a concentration of 1 μg/ml for 30 and 120 minutes at 37°C.
Cells were washed with PBS, fixed in 1.5% formaldehyde and labeled with DAPI for nuclear
staining. Cells were washed again, mounted with ProLong® Gold and analyzed by fluorescence
microscopy. Digital monochromatic images were acquired at a constant exposure and
pseudocolored and overlaid using MetaVue™ software. Overlays include BSA-TRITC or FABSA-TRITC probe (red), transferrin-FITC (green) and DAPI (blue). Scale bars = 2.5 μm. Images
are representative of 3-5 independent experiments.
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Figure 24. Comparing FR-α internalization with dextran pinocytosis.
4T1 cells were incubated with dextran-FITC conjugate (50 μg/ml) and the BSA-TRITC or FABSA-TRITC probe at a concentration of 1 μg/ml for 5, 15, 30 and 120 minutes at 37°C. Cells
were washed with PBS, fixed in 1.5% formaldehyde, and mounted with ProLong® Gold. Cells
were analyzed by fluorescence microscopy. Digital monochromatic images were acquired at a
constant exposure and pseudocolored and overlaid using MetaVue™ software. Overlays include
FA-BSA-TRITC (red) and dextran-FITC (green) across various time points ranging from 5, 15,
30 and 120 minutes. Scale bars = 2.5 μm. Images are representative of 3 independent
experiments.
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Figure 25. FR-α activity was inhibited by cholesterol depletion.
4T1 and U937 cells were incubated with MβCD at a concentration of 5mM for 1 h at 37°C. All
cells were washed with PBS and incubated with the BSA-FITC or FA-BSA-FITC probe at a
concentration of 100 μg/ml for 30 or 120 minutes at 37°C. Cells were washed with PBS, fixed in
1.5% formaldehyde and analyzed by flow cytometry. A) Histogram plots are representative of a
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minimum of 3 independent experiments and indicate the difference in FR-α binding activity in
4T1 cells (left) and FR-β binding activity in the U937 cells (right) after treatment with the probe
under intact or cholesterol-depleted conditions. B) The summary data of the flow cytometric
experiments of FR-α (left) and FR-β (right) receptor activity in 4T1 cells and U937 cells,
respectively, is graphed. Data represent the mean ± SEM from 3 independent experiments.
*Difference in means between groups were significant, p<0.05.
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Figure 26. Transferrin-mediated endocytosis was largely unaffected by cholesterol
depletion in both 4T1 and U937 cells.
4T1 and U937 cells were incubated MβCD at a concentration of 5mM for 1 h at 37°C. Cells
were washed with PBS and incubated with transferrin-FITC conjugate at 20 μg/ml for 15, 30 or
120 minutes at 37°C. Cells were washed with PBS, fixed in 1.5% formaldehyde and analyzed by
flow cytometry. A) Histogram plots are representative of a minimum of 3 independent
experiments and indicate the difference in transferrin binding activity in 4T1 cells (left) and
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U937 cells (right) after treatment with the transferrin-FITC conjugate under intact or cholesteroldepleted conditions. B) The summary data of the flow cytometry experiments of transferrin
binding in 4T1 (left) and U937 (right) cells is graphed. Data represent the mean ± SEM from 3
independent experiments. *Difference in means between groups were significant, p<0.05.
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Figure 27. Pinocytosis in 4T1 and U937 cells was unaffected by cholesterol depletion.
4T1 and U937 cells were incubated with MβCD at a concentration of 5mM for 1 h at 37°C. Cells
were washed with PBS and incubated with dextran-FITC conjugate at 50 μg/ml for 30 or 120
minutes at 37°C. Cells were washed with PBS, fixed in 1.5% formaldehyde and analyzed by
flow cytometry. A) Histogram plots are representative of a minimum of 3 independent
experiments and indicate the difference in dextran binding activity or pinocytosis in 4T1 cells
(left) and U937 cells (right) after treatment with the dextran-FITC conjugate under intact or
cholesterol-depleted conditions. B) Summary data of the flow cytometry experiments of dextran
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binding in 4T1 (left) and U937 (right) cells. Data represent the mean ± SEM from 3 independent
experiments.
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Figure 28. Cholesterol depletion inhibited FA-BSA-TRITC probe binding and
internalization without affecting transferrin receptor activity in 4T1 and U937 cells.
4T1 and U937 cells were incubated with MβCD at a concentration of 5mM for 1 h at 37°C
followed by treatment with transferrin-FITC (20 μg/ml) and the FA-BSA-TRITC probe at a
concentration of 1 μg/ml (4T1 cells) and 100 μg/ml (U937 cells) for 30 or 120 minutes at 37°C.
Cells were washed with PBS, fixed in 1.5% formaldehyde, mounted with ProLong® Gold and
analyzed with fluorescence microscopy. Digital monochromatic images were acquired at a
constant exposure and pseudocolored and overlaid using MetaVue™ software. Overlays include
BSA-TRITC or FA-BSA-TRITC (red) and transferrin-FITC (green). Scale bars for 4T1 and
U937 cells are 2.5 μm and 0.5 μm, respectively. Images are representative of a minimum of 3
independent experiments.
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Figure 29. Cholesterol depletion inhibited FA-BSA-TRITC probe binding and
internalization but pinocytosis activity remained unaffected in 4T1 and U937 cells.
4T1 and U937 cells were incubated with MβCD at a concentration of 5mM for 1 h at 37°C
followed by treatment with dextran-FITC (50 μg/ml) and the FA-BSA-TRITC probe at a
concentration of 1 μg/ml (4T1 cells) and 100 μg/ml (U937 cells) for 30 or 120 minutes at 37°C.
Cells were washed with PBS, fixed in 1.5% formaldehyde, mounted with ProLong ® Gold and
analyzed with fluorescence microscopy. Digital monochromatic images were acquired at a
constant exposure and pseudocolored and overlaid using MetaVue™ software. Overlays include
BSA-TRITC or FA-BSA-TRITC (red) and dextran-FITC (green). Scale bars for 4T1 and U937
cells are 2.5 μm and 0.5 μm, respectively. Images are representative of a minimum of 3
independent experiments.
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CHAPTER 4
DETERMINING THE POTENTIAL OF A NOVEL HISTONE DEACETYLASE INHIBITOR
(HDACi) AS AN ANTI-CANCER AGENT

130

ABSTRACT
An evolving field of cancer therapy is the use of drugs and small molecules that can mediate
anti-tumor effects by altering gene expression in cells. Histone deacetylase (HDAC) inhibitors
are one such category of small molecule inhibitors that exhibit abilities to regulate transcription
in cancer cells, thus making them potential therapeutic molecules in cancer therapy. Tumor cells
have been shown to have elevated HDAC levels, which skews the balance between histone
acetyl transferase (HAT) and HDAC activities, thus inducing abnormal gene regulation in the
cell. Treatment with HDAC inhibitors block HDAC functions by chelating the zinc ion in the
HDAC enzyme, which reverses the repression of key tumor suppressor genes in cancer cells and
restores the balance between the histone enzymes, enabling the normal cellular processes to
occur. Some HDAC inhibitors such as Vorinostat and Romidepsin are approved by the FDA and
are currently in use for the treatment of T cell lymphomas. However, major concerns associated
with HDAC inhibitors are their lack of HDAC class specificity and acute toxicity to normal cells.
Hence, there is a large demand for identification of novel inhibitors that would show improved
selectivity to HDAC classes and be able to mediate anti-tumor activity with minimal damage to
normal cells. Recently, Dr. Mahmun Hossain developed a panel of novel HDAC inhibitors based
on the scaffolds of FK228 (Romidepsin) and SAHA (Vorinostat), which were designed to
increase their solubility in aqueous solution and decrease systemic toxicity while maintaining
their anti-tumor activity. As part of a collaboration, one of these novel synthesized compounds,
that showed high HDAC class I specificity, compound 5 (Cpd5), was subjected to biologic
testing to determine its intracellular inhibitory activity of HDAC in vitro and its in vivo
pharmacokinetics.
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In vitro studies showed that Cpd5 had strong anti-proliferative activity (IC50300 nM) against
a panel of human tumor cell lines. Results were comparable, albeit less effective, to the parent
compound, FK228 (IC501 nM). Cpd5 also exhibited much lower levels of systemic toxicity
(MTD > 200 mg/kg body weight) compared to FK228 (MTD = 3.25 mg/kg body weight) when
tested in mice. In addition, 4T1 tumor-bearing mice treated with Cpd5 showed significant
inhibition in the rate of tumor growth compared to DMSO-treated mice. Quantification of
histone acetylation showed that Cpd 5-treated tumor cells exhibited dose-dependent increases in
levels of acetylated H3 histones compared to control-treated cells. Liver microsomal assays and
mass spectrometry analyses revealed that Cpd5 was metabolically stable and possessed desirable
pharmacologic characteristics, including a relatively long half-life in tumor tissue. Therefore,
Cpd5 exhibits characteristics supporting its continued development into a new anti-cancer
therapeutic agent.
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INTRODUCTION
Acetylation regulates many cellular functions such as protein-protein interactions, DNA
recognition and protein stability, and might act as a signaling mechanism that is similar to
phosphorylation303. Histone acetylation and deacetylation in eukaryotic cells are maintained by
histone acetyltransferases (HATs) and histone deacetylases (HDACs). These enzymes are
responsible for modifications of chromatin structure and regulation of transcription303,306. HATs
mediate their activity by adding acetyl groups to histone proteins, which leads to an increased
negative charge and thus reduced binding to the DNA backbone, resulting in an open chromatin
structure that induces activation of transcription factors. In contrast, HDACs catalyze the
removal of the acetyl groups on lysine residues located on the NH2 terminal tails of core
histones, which leads to gene repression by chromatin condensation. As a result, inhibition of
HDAC activity can result in a general hyperacetylation of histones, followed by the
transcriptional activation of certain genes through relaxation of the DNA conformation. These
post-translational modifications are essential for the regulation of many cellular processes307,327,
and this balance between the HATs and the HDACs maintains homeostasis in the cell306.
There are 18 known human histone deacetylases, which are grouped into four classes based on
their size, number of catalytic sites, subcellular localization, and sequence identity to yeast
counterparts. Class I (HDACs 1-3 and 8), II (HDACs 4-7, 9, and 10), and IV (HDAC 11)
enzymes are the 11 Zn2+-dependent histone deacetylase enzymes406. Class III proteins called
sirtuins (SIRT 1-7) are defined by their dependency on the coenzyme and electron transporter
NAD+327. The class I HDACs are predominantly located in the nucleus, while the class II
HDACs are located in the nucleus and cytoplasm. It has been found that Zn2+-dependent
isozymes, especially class I and class II HDACs, are closely related to tumorigenesis309,310,344.
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Therefore, in the past 10 years, over 490 clinical trials of more than 20 HDAC inhibitor
candidates have been initiated as single agents or in combination with other chemotherapy drugs,
culminating in the approval of two antitumor drugs, Vorinostat (SAHA) and Romidepsin
(FK228) for the treatment of cutaneous T-cell lymphoma. Vorinostat is a pan-inhibitor that
interacts with all HDAC classes while Romidepsin preferentially inhibits Class I407,408. FK228 is
a particularly potent inhibitor that mediates its inhibitory activity through a reduced disulfide
bond in its structure that directly interacts with the enzyme’s active zinc, thus making it inactive.
HDACs are not only regulators of mitosis, cell differentiation, apoptosis, and chromatin
organization but are also involved in the regulation of metabolism, learning, memory, and
immune response409. Modification of epigenetics by selectively inhibiting specific isoforms of
histones has emerged as a promising avenue toward disease therapy291,293,310. In particular,
selective inhibition of HDACs by small molecules often leads to a cascade of chromatin
remodeling, tumor suppressor gene reactivation, apoptosis, and regression of cancer290,382.
HDAC1 and HDAC2 are 95% similar in terms of binding pocket and size of the protein.
Therefore, HDAC1 and HDAC2-selective inhibitors are of great interest as potential anticancer
agents expected to exhibit few side effects382,387,410.
In collaboration with Dr. Mahmun Hossain (Department of Chemistry, University of
Wisconsin-Milwaukee), a novel compound was synthesized based on the scaffold of the FDAapproved HDAC inhibitor FK228. The compound, also known as Cpd5, was subjected to both in
vitro and in vivo analysis to assess its potential as an anti-cancer agent. Anti-proliferative activity
of

Cpd5

was

determined

by

performing

MTT

[3-(4,5-dimethylthiazol-2-yl)-2,5-

Diphenyltetrazolium Bromide] assays against a panel of human prostate, breast, renal and
ovarian tumor cell lines. Cpd 5 exhibited potent dose-dependent anti-proliferative activity in the
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sub-micromolar range. Specifically, the IC50 of Cpd5 was ~200-fold higher compared to FK228
but it was ~5-fold lower than SAHA. Analysis of the effects of Cpd5 on the histone acetylation
levels in tumor cells revealed that Cpd5 induced a dose-dependent increase in the expression of
acetylated H3 histones. Cpd5 was also injected into healthy BALB/c mice at escalating doses to
determine the maximum tolerated dose (MTD) by the animals. Mice treated with Cpd5 exhibited
a MTD >200 mg/kg body weight while the MTD of FK228 was only 3.25 mg/kg, thus indicating
a dramatically lower systemic toxicity to Cpd5 in vivo. 4T1 tumor-bearing BALB/c mice were
also injected with Cpd5 (25 mg/kg, i.p) to determine effects on tumor growth. Cpd5 was found to
significantly inhibit the rate of tumor growth compared to SAHA or DMSO (vehicle)-treated
mice. Metabolic studies performed with human and mouse liver microsomes demonstrated that
Cpd5 was stable (~2 hours) in the samples. Pharmacokinetic studies were performed on healthy
mice by injecting them with Cpd5 (10 mg/kg, i.p) followed by harvesting of blood, brain and
tumors at various time points to determine drug availability in the samples over time. Mass
spectrometric analysis indicated that Cpd5 was available in the system for as long as 2 hours,
demonstrating a low clearance rate, desirable for a potential drug.
These preliminary data provide important evidence regarding the potential of Cpd5 as a novel
anti-cancer agent. These results are promising because the compound exhibited strong inhibitory
properties against several tumor cell lines but had minimal side effects in vivo. Based on these
findings, histone acetylation levels induced in the cells correlated with the biologic activity of
Cpd5 (i.e., modulation of histone activity) and not from random side effects. In addition, the low
clearance rate and long half-life makes it even more attractive as a potential drug or therapeutic
agent. Collectively, these studies help to identify the in vitro and in vivo activity profile of Cpd5,
and thus highlight its potential use as a cancer therapeutic.
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MATERIALS AND METHODS
Cell lines and reagents
A panel of human cell lines that included a prostate cancer line (DU145), cervical cancer line
(HeLa), renal cancer line (RXF 393) and colon cancer line (HCT-116) were all purchased from
ATCC (Manassas, VA). A 4T1 murine mammary carcinoma epithelial cell line was also
purchased from ATCC. All human cell lines were cultured in DMEM medium (Life
Technologies, Grand Island, NY), supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Flowery Branch, GA), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM Lglutamine (all from ThermoFisher Scientific). Cell counts and viability were determined using a
hemacytometer following appropriate dilution in trypan blue exclusion dye. The 4T1 cells were
grown in RPMI 1640 media that was supplemented as above along with addition of 55 μM 2mercaptoethanol (Life Technologies, Grand Island, NY) and maintained as described in Chapter
2, “Materials & Methods”.
Cpd5 was synthesized and purified by high-performance liquid chromatography (HPLC) in
Dr. Hossain’s Lab (Department of Chemistry, University of Wisconsin-Milwaukee), as
described411. The FDA-approved drugs, vorinostat (SAHA) and romidepsin (FK228), were
purchased commercially (Selleckchem, Houston, TX) and used as positive controls for
comparison purposes. Dimethylsulfoxide (DMSO, ThermoFisher) was used to dissolve the drugs
and served as vehicle controls for all experiments.
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] or MTT (Sigma Aldrich) was
used as a colorimetric reagent to determine cell proliferation. Live cells actively convert MTT
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into a purple insoluble formazan product, while dead cells do not, and this change can be
measured spectrophotometrically after being dissolved in DMSO.
Animals
Wild type BALB/c mice and C57BL/6J (B6) mice were originally purchased from the Jackson
Laboratories (Bar Harbor, ME) housed and bred in a specific pathogen-free facility at the
University of Wisconsin-Milwaukee, and screened regularly for pathogens. All procedures were
approved by the Animal Care and Use Committee of the University of Wisconsin-Milwaukee.
For tumor induction, 1x104 4T1 cells in 50 µl supplement-free RPMI 1640 medium were injected
subcutaneously into the mammary fat pad of 8-12-week-old wild-type BALB/c female mice.
Determining anti-proliferative activity of Cpd5 by MTT
The anti-proliferative effect of Cpd5 was tested on the DU145, HeLa, HCT-116 and RXF-393
cells using the MTT colorimetric assay. Briefly, 200 μl of cell suspension (7×104 cells/ml) was
dispensed into 96-well, flat-bottomed microplates (Nunc, Denmark) and incubated for 24 hours
at 37°C and 5% CO2. After 24 hours, Cpd5 was added at various concentrations (1 µM, 100 nM,
10 nM and 1 nM) and incubated for another 48 hours. Cells were then washed twice with PBS
followed by incubation with 200 μl of MTT solution (250 µg/mL) for 4 hours. The formazan
crystals were solubilized by the addition of 200 μl of DMSO and by rotating the plate on a
shaker for 10 minutes. Absorbance was determined at 570 nm with a reference wavelength of
690 nm using a microtiter plate reader (Infinite M200 Pro TECAN). All treatments were done in
triplicate and control cells received fresh medium or 0.01% DMSO concentration equivalent to
that in the treatment groups. The anti-proliferative effect of Cpd5 was expressed as the relative
viability (% control). Relative viability = (experimental absorbance - background absorbance) /
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(absorbance of DMSO-treated controls-background absorbance) × 100. Results were used to
calculate the inhibitory concentration of the compound that led to 50% of control values (IC50).
Histone acetylation
DU145 cells were seeded at a density of 7 x 104 cells/ml into 24-well flat-bottomed multiwell
plates and incubated for 24 hours at 37°C and 5% CO2. Cpd5 or FK228 was added at varying
concentrations (1 μM, 100 nM and 10 nM) to the wells and incubated for 24 hours. DMSO
(0.01% ) was also included as a vehicle control while wells with untreated cells were included as
negative controls. After 24 hours, cells were treated with 4% paraformaldehyde for 10 minutes
followed by treatment with Tris-buffered saline, 0.1% Tween 20 (TBS-T), and 1% BSA for 1
hour at 4°C. Cells were next treated with a rabbit polyclonal anti-acetyl histone H3 (Lys
K9/K14) antibody (Cell Signaling Technology) at a 1:2000 dilution and incubated overnight at
4°C. The primary antibody was washed off with TBS-T and 1% BSA solution followed by
incubation with an Alexa Fluor® 488-conjugated goat anti-rabbit IgG antibody (Jackson
Immunoresearch, West Grove, PA) at a 1:500 dilution in TBS-T and 1% BSA for 1 hour at 4°C.
The cell membranes were stained with Cell tracker™ Red CMTPX (Molecular Probes) at a final
concentration of 1 µM for 30 minutes followed by the addition of Hoechst 33342 Nuclear Stain
(Enzo Life Sciences) for 15 minutes. Cells were washed again, mounted with Prolong® Gold,
and visualized using a Nikon inverted epifluorescence microscope. Images were acquired at a
constant exposure setting, pseudocolored and overlaid using Metavue® software (Universal
Imaging Corporation, Downingtown, PA).
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Determining a maximum tolerated dose (MTD)
To determine the MTD in vivo, each animal was initially weighed using a digital scale and
injected with Cpd5, SAHA, FK228 or DMSO intraperitoneally (i.p), and mortality was
monitored over two weeks. One mouse was given a single i.p injection of 200 mg/kg body
weight, a second mouse received a dose of 100 mg/kg and a third mouse received a single dose
of 50 mg/kg. The mice were observed and weighed every other day for a period of 2 weeks.
They were euthanized if they lost more than 20% of their body weight or if there were other
signs of overt toxicity. If none of the mice survived with the first three doses, the next three dose
levels (25 mg/kg, 12.5 mg/kg and 6.25 mg/kg) were tested in a similar manner. This process was
repeated until a tolerated dose was found, and the MTD value was determined. Each treatment
was performed with three animals/group receiving the same dose of drug or vehicle (DMSO).
Tumor growth inhibition studies
To determine the effects of Cpd5 on tumor growth, BALB/c mice were first injected with 4T1
cells (1x104 cells in 50 μl) in supplement-free RPMI medium subcutaneously into the mammary
fat pad. After 7 days, the animals were injected i.p. with 25 mg/kg body weight of Cpd5, SAHA
or DMSO (vehicle) every other day. Injections were continued for 30 days and tumor growth
was monitored by caliper measurements of the major (L, length; mm) and minor (W, width; mm)
axes and tumor volume (V, volume; mm3) was calculated by the formula: V = (L x W2) / 2.
Human and murine liver microsomal assay
To determine the metabolic stability of Cpd5, microsomal assays were performed in
collaboration with Dr. Arnold, Department of Chemistry, University of Wisconsin-Milwaukee.
Microsomes (0.5 mg/ml) were pre-incubated with a 2 μM test compound for 5 minutes at 37°C
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in 0.1 M phosphate buffer, pH 7.4. Specifically, Cpd5 was dissolved in DMSO to achieve a
concentration of 1 mM. Verapamil at a concentration of 5 μM in acetonitrile was used as an
internal standard for the assay. The microsomal assay mixture (MAM) was prepared by
combining 0.5 M potassium phosphate buffer (pH 7.4) with the co-factors NADPH A and
NADPH B (Corning Incorporated, Corning, NY), and with Cpd5. The MAM was sonicated for 5
minutes on ice followed by incubation with human or murine liver microsomes at a
concentration of 20 mg/ml (BD Gentest, San Jose, CA) for 10, 20, 30, 40, 50 and 60 minutes at
37°C. Samples incubated with only the MAM and no microsomes served as the control. The
reactions were stopped by adding an equal volume of acetonitrile containing 5 μM verapamil
(internal standard). Samples were centrifuged at 5,000 x g for 5 minutes and 100 µl of
supernatant was transferred to Spin-X® HPLC filter tubes (Corning Incorporated). Samples were
again centrifuged at 6,500 x g for 5 minutes and 5 µL of the supernatant was then diluted in 500
µl of LCMS grade methanol (ThermoFisher Scientific, Waltham, MA) and analyzed using a
LCMS-8040 Triple Quadrupole Liquid Chromatograph Mass Spectrometer (LC-MS/MS,
Shimadzu) to determine the intrinsic clearance of Cpd5 in vitro. The peak area ratio was
calculated using the formula: peak area ratio = peak area of test compound (Cpd5) / peak area
ratio of internal standard (verapamil). The percentage of compound remaining after time (T) was
calculated using the formula: (peak area ratio at particular time T / peak area ratio at zero time
point) x 100. All metabolic parameters are represented as mean ± SD obtained through three
assays that were run simultaneously in two independent experiments.
Pharmacokinetic Assay
In order to determine the in vivo biodistribution of Cpd5, blood, brains and tumors were
harvested from healthy B6 mice following a single i.p. injection of the Cpd5 (10 mg/kg) in
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DMSO. Blood (200 µl) was collected from animals at 5, 15, 30, 60, 90 and 120 minutes
following injection. The blood was collected in 1.5 ml heparinized tubes and kept at -20°C until
analysis. Animals were euthanized at the 60- and 120-minute time-points and the brains were
harvested from two of the mice. In addition, 4T1 tumor-bearing BALB/c mice at an advanced (4weeks) stage were also injected with Cpd5 as described above. Animals were euthanized at 30
and 120 minutes and tumors were harvested. The brains and the tumors were transferred to 1.5
ml tubes followed by addition of 300 μl acetonitrile and then homogenized using a mechanical
homogenizer. The tissues were then centrifuged at 6,500 x g for 3 minutes. The supernatant was
transferred to Spin-X® Centrifuge filter tubes and centrifuged at 6,500 x g for 5 minutes. Blood
(200 µl) was collected in 1.5 ml heparinized tubes and mixed with 200 µl methanol and 100 µl
acetonitrile. Samples were centrifuged at 6,500 x g for 6 minutes. The supernatants from all
samples were collected and analyzed on a LCMS-8040 Triple Quadrupole Liquid
Chromatograph Mass Spectrometer (LC-MS/MS). Each time point represented three animals.
Statistical Analyses
Data are presented as mean ± SEM unless stated otherwise. Significant differences between
sample means were determined using a Student’s t test with p<0.05 being considered significant.
Data between various treatment groups were analyzed using one-way ANOVA and then
compared by Bonferroni multiple comparison tests using GraphPad Prism software, Version 3.00
(San Diego, CA, USA). Microsomal stability of Cpd5 was calculated by linear regression plots
using GraphPad Prism software. Pharmacokinetic studies depicting availability of Cpd5 was
determined by linear regression plots using Microsoft Excel. The in vivo tumor growth data was
first analyzed by 2-way ANOVA and when significance was detected, the data were analyzed by
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one-way ANOVA and compared by Bonferroni multiple comparison tests using GraphPad Prism
software
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RESULTS
Cpd5 showed strong anti-proliferative activities against human tumor cell lines
The in vitro anti-proliferative activity of Cpd5 was evaluated at different concentrations
against a panel of human tumor cell lines that included a prostate tumor (DU-145), cervical
tumor (HeLa), renal tumor (RXF 393) and colon tumor (HCT-116). SAHA and FK228 were
used as positive controls to compare to the anti-proliferative activities of the novel Cpd5, while
DMSO was used as the vehicle control. After 48 hours of drug treatment, cell proliferation was
measured using an MTT assay and the percent cell survival was determined relative to that of the
vehicle control. In comparison to the vehicle, Cpd5 induced a significant (p<0.05) inhibition in
cell proliferation of all cell lines tested at 10 and 1 µM (Fig. 30). Treatment of cell lines with
SAHA resulted in nearly identical results. By contrast, FK228 exhibited detectable antiproliferative activity even at 0.01 µM and thus demonstrated the most potent anti-tumor effects
of the HDACis. From the above data, IC50 values were calculated (Table I). The average IC50
value for Cpd5 was 0.475 µM across all cell lines, which was ~190-fold higher than that of
FK228 (IC50 = 0.0025 µM). However, Cpd5 was ~5-fold more potent than SAHA (IC50 = 2.5
µM). Thus, overall Cpd5 exhibited very potent in vitro anti-proliferative properties against a
range of tumors.
Cpd5 treatment led to an increase in histone acetylation levels in DU-145 cells
The above results showed that Cpd5 retained strong anti-proliferative activity in vitro.
However, since HDAC inhibitors can affect a number of non-histone targets356, it was possible
that the anti-proliferative effects were not due to changes in histone acetylation. Therefore, it was
important to determine whether Cpd5 was able to induce changes in the acetylation levels of
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histones in the treated cells. To examine this, the DU-145 cells were treated with Cpd5 and the
acetylation levels of H3 histone proteins were determined by epifluorescence microscopy.
Control-treated cells showed a low basal level of H3 acetylation that was detectable in a small
percentage of the population (Fig. 31A). In contrast, Cpd5-treated cells exhibited intense staining
of acetylated H3 that increased with increasing concentration (Fig. 31B). As expected, FK228
treatment resulted in very high levels of histone acetylation in virtually all cells (Fig. 31C). With
increasing concentrations of FK228, the staining approached saturation and thus looked similar
at both the 100 nM and the 1 µM concentrations. Therefore, the acetylation levels of H3 in
Cpd5-treated cells was comparatively lower than that for the FK228-treated cells, which was
consistent with the anti-proliferative activity of the two compounds in vitro.
Cpd5 was metabolically stable
The liver contains several drug-metabolizing enzymes and thus liver microsomes are useful in
in vitro models for determining hepatic clearance. An indication of the potential in vivo activity
of a compound or drug can be estimated by determining its rate of metabolism in the body.
Hence, the microsomal assay analysis was chosen to determine the intrinsic clearance of Cpd5.
Both human and murine microsomes were used for determining the metabolism of Cpd5. The
percent peak area ratio when plotted over time generated a linear slope that remained mostly
constant over time, thus indicating that Cpd5 remained in its original state after 60 minutes (Fig.
32). The graphs represent linear regression plots obtained from two independent experiments
labeled as Experiment 1 (left) and Experiment 2 (right) following incubation with A) human or
B) murine microsomes.
All metabolic parameters associated with Cpd5 were determined through these linear
regression plots and are summarized in Table II. The half-life of Cpd5 was found to be 391 ±
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114 minutes when assayed with human microsomes in the first experiment and this was
consistent in the second experiment (471 ± 162 minutes).

In murine microsomes, Cpd5

exhibited a half-life of 1,514 ± 2,057 min and 666 ± 500 min in experiments 1 and 2,
respectively. The intrinsic clearance obtained from the two experiments from the human
microsomal assay was 0.147 and 0.177 µl/min/mg, respectively. On the other hand, the murine
microsomal assay yielded a clearance of 0.04577 µl/min/mg and 0.103 µl/min/mg in experiments
1 and 2, respectively. Both sets of data from the human and murine microsomal assays seemed to
fit well into the “low clearance” category of drug standardization, thus indicating that Cpd5 was
not readily eliminated by liver enzymes. The percentage of compound remaining after 60
minutes of treatment with human microsomes was 88 ± 0.36 % and 90.3 ± 0.36% from
experiments 1 and 2, respectively. The murine microsomes also showed similar values of 94.1 ±
0.47% and 89 ± 0.51%. Overall, it was evident that about 88-95% of Cpd5 was still found to be
available in the samples after 60 minutes, thus indicating the stable nature of the compound.
Cpd5 was detectable in vivo for at least 2 hours
To determine the pharmacokinetic parameters of Cpd5, mice were injected i.p. with 10 mg/kg
Cpd5 and blood was sampled over a 2-hour time-period. Results demonstrated that Cpd5
remained detectable in the blood for at least 2 hours after the injection (Fig. 33). In addition,
Cpd5 was also found in the brain and tumor after 2 hours (data not shown). These in vivo data,
together with the previous in vitro microsomal assay data, showed that Cpd5 was metabolically
stable and available in vivo for an extended period of time.
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Cpd5 exhibited a high maximum tolerated dose (MTD) in mice
The MTD for the HDAC inhibitors was determined by injecting wild type BALB/c mice with
increasing doses of Cpd5, SAHA, and FK228, and monitoring morbidity and mortality over a
two-week period (Table III). Results indicated that the mice remained healthy even at a dose of
200 mg Cpd5/kg body weight. SAHA also showed a MTD of >200 mg/kg while FK228 showed
a MTD of only 3.25 mg/kg, which was at least 50 times lower than that for Cpd5. These results
demonstrate that Cpd5 had much lower levels of systemic toxicity than the FDA-approved
FK228 parent compound.
Cpd5 inhibited tumor growth in animals
To determine effects of Cpd5 on tumor growth in mice, 4T1 cells were injected into BALB/c
mice and tumors were allowed to grow for 7 days. The mice were randomized into three groups
and received i.p. injections of Cpd5 (25 mg/kg), SAHA (25 mg/kg) or an equivalent volume of
DMSO every other day for 30 days. Preliminary results showed that mice treated with Cpd5
exerted significant (by ~40-45%, p<0.05) inhibition in the rate of tumor growth from day 24 to
30 compared to the SAHA- and DMSO-treated animals (Fig. 34). This reduction in tumor
growth was detectable after 2 weeks of treatment and was maintained until the end of the
experiment. Therefore, Cpd5 was able to slow the rate of tumor growth in mice.
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DISCUSSION
Chromatin modulation via modification of histone enzymes is crucial in regulating major
cellular process such as gene transcription and DNA repair299. However, recent studies have
implicated epigenetic aberrations in the initiation and progression of human cancer291,309,333.
Epigenetics is responsible for mediating gene regulation via post-translational modifications of
several protein complexes associated with the DNA. One such modification is the acetylation
and deacetylation of histones, regulated by HATs and HDACs that work in coordination to
maintain a proper balance in the cell. However, during cancer this balance is altered and this
results in overexpression of deacetylated histones296. HDAC inhibitors are small molecules that
can inhibit deacetylase activity, thus restoring the balance of histone acetylation in the cells and
mediating several effects such as cellular differentiation, expression of tumor suppressor genes,
apoptosis and anti-angiogenic activity352,369. Hence, there has been an expanding interest in
developing these molecules as potential anti-cancer agents.
In order to qualify as a potential anti-cancer agent it is necessary that the naturally occurring or
synthesized compound exhibit strong anti-proliferative activities but with minimal non-tumor
toxicity. In addition, based on reports that suggest HDAC inhibitor-mediated effects varied with
the type of tumor cell line290, it was first important to determine the in vitro effects of Cpd5
against a panel of major human tumor cell lines (Fig. 30). For this purpose, we chose several
types of tumor lines (prostate, renal, cervical and colon cancer) and compared the activity of
Cpd5 to that of SAHA and FK228, the two drugs currently approved by the FDA. Cpd5 showed
consistent growth inhibitory concentrations (IC50) against all tested tumor lines with a stronger
anti-proliferative activity than SAHA (Table I). Although Cpd5 demonstrated 190-fold lower
anti-proliferative activity than that of the parent compound FK228, its IC50 concentrations were
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still in the nM range. Therefore, overall Cpd5 was found to be more potent that SAHA but less
potent than FK228.
A HDAC inhibitor is anticipated to mediate anti-cancer effects in vitro and in vivo via
modifying the histone acetylation levels. Specifically, the inhibitor is responsible for blocking
the functions of the overexpressed HDACs in tumor cells to restore the balance between the
HATs and HDACs306. Therefore, experiments were performed to determine if Cpd5-mediated,
anti-proliferative effects in tumor cells correlated with the acetylation levels of histones. The
results clearly showed that Cpd5-treated DU-145 cells showed increased acetylated levels of H3
histone compared to control cells (Fig. 31). In addition, the intensity of histone acetylation in the
cells increased with increases in Cpd5 concentrations. Thus, the in vitro and in vivo effects
induced by Cpd5 can most likely be attributed to changes in the histone acetylation levels.
For a compound to qualify as a potential therapeutic agent, it must demonstrate favorable
pharmacokinetic characteristics that include low metabolism, long half-life and appropriate
biodistribution. Our results demonstrate that Cpd5 was metabolically stable for at least two hours
in microsomal preparations, with 80-90% of the compound remaining in the samples (Fig. 32,
Table II). Cpd5 had a low intrinsic clearance rate and thus fit into the “low clearance” category
of drug standardization. In addition, Cpd5 was also found to be available in the blood, tumor and
brain even after 2 hours (Fig. 33, and data not shown), which further supports its low clearance
rate and stable nature. Overall, Cpd5, due to its potent anti-proliferative effects, stable nature and
low clearance demonstrates a good potential to qualify as an anti-cancer drug.

148

Before analyzing the anti-tumor activity of the drug in vivo, it was first necessary to
determine if Cpd5 led to any overt toxicity in the animals. FK228 turned out be very toxic for
the animals and exhibited a MTD of only 3.25 mg/kg body weight. In contrast, both SAHA and
Cpd5 had MTDs of > 200 mg/kg (Table III). Thus, it was evident that Cpd5 exhibited much
lower levels of systemic toxicity than the parent compound FK228. This high level of systemic
toxicity of FK228 correlates with its potent anti-proliferative activity in vitro but severely limits
the dose than can be safely given to patients. Importantly, while both SAHA and Cpd5 were
equally tolerated in vivo, Cpd5 was significantly more potent than SAHA in inhibiting cellular
proliferation. Consistent with this finding, Cpd5 treatment in 4T1 tumor-bearing mice resulted in
a significant reduction in the tumor growth rate compared to SAHA-treated animals (Fig. 34).
Unfortunately, no regression of the tumor was observed with this Cpd5 treatment, and thus other
doses or treatment regimens need to be tested. As with the majority of cancer treatments, it is
unlikely that a single treatment with any HDAC inhibitor will be successful but rather these
agents will be used as adjuncts to other established treatments. Taken together, these data
identify the potential of Cpd5 as a promising and novel HDAC inhibitor for the treatment of
cancer.
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FIGURES AND LEGENDS

Figure 30. In vitro anti-proliferative effects of Cpd5, SAHA and FK228 against a panel of
human tumor cell lines.
Four different human tumor cell lines (RXF 393, HeLa, HCT-116 and DU-145) were treated
with Cpd5, FK228 or SAHA at varying concentrations for 48 hours. Cell proliferation was
analyzed using an MTT assay. DMSO-treated wells served as vehicle controls and were used to
calculate percent survival of the cells post drug treatment. Treatments were done in triplicate and
presented as the mean ± SEM. Statistical significance was determined using two-way ANOVA.
*Differences between drug-treated and DMSO-treated cells were significant, p<0.05.
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Table I. Growth inhibitory concentration (IC50) of Cpd5, SAHA and FK228 against
human tumor cell lines.
Cells from human tumor cell lines (HeLa, RXF 393, DU-145 and HCT-116) were treated with
Cpd5, FK228 or SAHA for 48 hours and proliferation was determined using an MTT assay as
shown in Fig. 30. Values represent IC50 of the test compounds that were calculated from the
average of triplicate wells using GraphPad Prism software.
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Figure 31. Immunofluorescence staining of acetylated histones in DU-145 cells.
DU-145 cells were grown overnight on coverslips and then incubated with DMSO (control) or
the indicated concentrations of Cpd5 or FK228 for 24 hours at 37°C. Cells were then fixed with
4% paraformaldehyde, permeabilized and labeled with a purified rabbit polyclonal anti-acetyl
histone H3 (Lys K9/K14) antibody which was detected using an Alexa Fluor® 488-conjugated
goat-anti rabbit IgG antibody (Green). The cell membranes were stained with Cell Tracker™
Red CMTPX (Red) followed by the addition of Hoechst 33342 Nuclear Stain (Blue). Cells were
mounted with Prolong® Gold and visualized with an epifluorescence microscope. Images were
acquired at a constant exposure setting, and pseudocolored and overlaid using MetaVue™
software. Representative images are of cells showing the varying intensities of histone
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acetylation after treatment with A) DMSO (control), B) Cpd5 and C) FK228. Data are
representative of a minimum of 3 independent experiments. Scale bars = 2.5 µm.

Human microsomes
Metabolic
parameters

Murine microsomes

Experiment
1

Experiment
2

Experiment
1

Experiment
2

Half-life
(min)

391 ± 114

471 ± 162

1514 ± 2057

666 ± 500

Intrinsic
clearance
(µl/min/mg)

0.177

0.147

0.04577

0.103

remaining
at 60 min
(%)

88 ± 0.36

90.3 ± 0.36

94.1 ± 0.47

89 ± 0.51

Table II. Metabolic activity of Cpd5 determined by human and murine microsomal assays.
Human and murine liver microsomes were used to determine parameters associated with Cpd5
metabolism in the liver. Data were obtained from two independent experiments. Linear
regression plots were constructed using GraphPad Prism and were used to calculate metabolic
parameters (half-life, intrinsic clearance and percent availability) of Cpd5 over time. The data
represents the mean ± SD from three assays that were run simultaneously for both experiment 1
and experiment 2.
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Figure 32. Human and murine microsomal analysis depicting Cpd5 stability over time.
The microsomal assay mixture (MAM) was prepared by mixing Cpd5 (1 mM) with the cofactors, NADPH A and B. The mixture was then incubated with the microsomes (20 mg/ml) at
37°C for 10, 20, 30, 40, 50 and 60 min. Verapamil (5 µM) was included in the assay to serve as
an internal standard. At the end of every time point, the samples were analyzed using a LCMS8040 Triple Quadrupole Liquid Chromatograph Mass Spectrophotometer (LC-MS/MS). The
disappearance of Cpd5 was monitored over a period of 60 minutes. Data are representative of 3
independent assays showing the stability of Cpd5 in form of linear regression plots after
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treatment with A) human and B) murine microsomes. The peak area ratio was calculated using
Microsoft Excel using the formula: Peak area ratio = Peak area of test compound (Cpd5) / peak
area ratio of internal standard (Verapamil). These values were then used to generate linear
regression plots using GraphPad Prism.

Figure 33. Pharmacokinetic study depicting availability of Cpd5 in normal mouse blood.
Normal mice were injected with Cpd5 (i.p.) and followed by collection of heparinized blood at
various time points (5, 15, 30, 60, 90 and 120 minutes). Samples were centrifuged and the
supernatants collected and analyzed on a LC-MS/MS. Concentration of Cpd5 in blood over time
was determined by linear regression analysis using Microsoft Excel.
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Table III. Comparing systemic toxicity levels of Cpd5, FK228 and SAHA in vivo.
Female BALB/c mice were injected with varying doses (200, 100, 50, 25, 12.5, 6.25 and 3.25
mg/kg) of Cpd 5, FK228, SAHA or DMSO (vehicle, not shown) intraperitoneally. The mice
were observed and weighed every other day for a period of 2 weeks. This process was repeated
until a tolerated dose was found, and the MTD value was determined. Each treatment was done
with three animals/group receiving the same dose of drug or vehicle.
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Figure 34. Cpd5-mediated tumor growth inhibition in 4T1 tumor-bearing mice.
Female BALB/c mice were injected with 4T1 cells subcutaneously into the mammary fat pad.
After 7 days, mice were treated i.p. with Cpd5 (25 mg/kg), SAHA (25 mg/kg) or DMSO every
other day for 30 days. Tumors were measured on treatment days and their volumes were
determined as described in “Materials and Methods”. Data represents average tumor volume ±
SD of two independent experiments with one mouse per treatment. *Significance between the
various treatment groups was determined by two-way ANOVA and Bonferroni multiple
comparison tests, p<0.05.
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CHAPTER 5
CONCLUSIONS
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CONCLUSIONS
Folate receptors are overexpressed on epithelial and myeloid carcinomas with most normal
cells having negligible expression. In normal cells that do express FR, it is limited to the apical
surface. These features have encouraged many studies utilizing FR to target tumor cells. To date,
most of these studies involved drug delivery using FR-targeted nanocarriers and liposomes to the
cells of interest. However, drug toxicity and non-specific targeting have been major issues that
have resulted in only limited success of such anti-tumor therapies. There are multiple isoforms of
FR among which the α and β are membrane-associated and detectable in cells and tissues,
thereby facilitating their study. However, most of the previous studies have focused solely on
FR-α while ignoring FR-β. Importantly, FR-β is reported to be overexpressed on myeloid
leukemias and thus is a potential target to treat these malignancies, which can be more
challenging to treat than epithelial tumors. Herein, the role of FR-β as a potential target was
investigated and functional characteristics of both the FR-α and FR-β isoforms were
characterized.
One important observation from this study was that the FR-α and FR-β exhibited differential
functional characteristics. First, lineage-specific expression of FR-α and FR-β was confirmed in
the model 4T1 epithelial tumor cell line and the U937 myelomonocytic leukemia cell line,
respectively. FR-α was overexpressed on the 4T1 cells and FR-β on the U937 cells; however, as
expected, the normal epithelial and myeloid cells did not exhibit FR-α and FR-β expression,
respectively. In addition, overexpression of the FR-α isoform was maintained in vivo, which is of
relevance for designing targeting therapies utilizing this receptor.
Interestingly, antibody labeling studies showed that FR-α and FR-β exhibited differential
membrane staining patterns on the 4T1 and U937 cells, respectively. The FR-α appeared very
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distinct and mostly in clusters on the 4T1 cells, while the FR-β was localized to one end of the
U937 cells. At this time it is not known what functional effect(s) this has on the receptors.
While it is well established that both FR isoforms exhibit relatively high affinity for folic acid,
functional differences between these receptors are yet to be elucidated36.The findings from the
present studies show that the activity profiles of the isoforms were very different from each
other. The FR-α isoform was internalized into 4T1 cells within 5 minutes in response to folic
acid, which was consistent with previous studies using other cell lines75. However, the FR-β
isoform was not internalized into the U937 cells following ligand binding. Further
characterization of the isoform activities utilizing folic acid-fluorochrome conjugates such as
FA-BSA-FITC and FA-BSA-TRITC was then performed. Specifically, the receptors were
tracked intracellularly in response to folic acid conjugates vs unconjugated controls (BSA-FITC
or BSA-TRITC). Results showed that the FA-BSA-FITC or FA-BSA-TRITC probes had strong
binding to the tumor cells while the controls did not. This clearly indicated that both FR-α and
FR-β expressed on the 4T1 and U937 tumor cells exhibited specific binding ability for the folic
acid conjugated probes. However, the FR-β on the U937 cells did not internalize the folic acidconjugated probes, unlike the internalization of FR-α observed in the 4T1 cells. Therefore, the
results of the probe-mediated studies demonstrated that both FR isoforms could still be targeted
utilizing folic acid-based strategies despite exhibiting differences in internalization.
These studies were expanded to determine the role of FR-β in an in vivo cell model, thereby
adding more relevance to the current research. For these studies, MDSCs were chosen due to
their relevance to cancer. Specifically, MDSCs increase during inflammatory conditions such as
cancer and suppress the immune system of the host. Our laboratory has previously demonstrated
that MDSCs express FR-β; therefore, determining whether FR-β could be used as a potential
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target to eliminate MDSCs was logical. Although MDSCs can be identified with specific
markers, similarities in expression of these with other normal cell populations such as
neutrophils187 and monocytes are a primary concern. Hence, our studies not only provide novel
insights into using FR-β as an additional MDSC marker but also as a potential target to eliminate
MDSCs. Demonstration of specific binding of the folic acid-conjugated probes to both subsets of
MDSCs showed that FR-β expressed on MDSCs was functional for mediating folic acid binding.
Importantly, the monocytic subset showed higher binding efficiency of the folic acid conjugates
than the granulocytic subset, which could be beneficial, as the monocytic subset is reportedly
more active and has higher suppressive activities. These findings support the idea that folic aciddependent FR-β targeting could be extended to eliminate MDSCs, thereby making this qualify as
a potentially novel immunotherapeutic.
Based on the findings that the FR-β isoform cannot internalize, a potential FR targeting
mechanism that could lyse cells while remaining on the cell surface was investigated. Previous
collaborative studies demonstrated that 4T1 tumor cells could be eliminated via antibodyconjugated gold-coated magnetite nanoparticles, through a technique known as hyperthermia178.
Hence, the potential of this technique in using folic acid-nanoparticle conjugates was tested.
However, before these studies could be attempted, the technique was first modeled using
colloidal gold nanoparticles. FA-BSA-Au18 and BSA-Au18 (control) conjugates were generated
and the FA-targeted conjugates were shown to bind specifically to both FR-α and FR-β. These
studies provide the foundation for future studies using FR-targeted magnetite nanoparticle
conjugates for hyperthermia-mediated cell killing. Importantly, this technique could have an
advantage over drug-dependent cell targeting, as the former does not suffer from systemic drug
toxicity, non-specific tissue damage, or development of drug resistance.
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The FR-α isoform internalizes into cells but the details associated with receptor trafficking
mechanisms remain largely unknown. Interestingly, FR-α did not internalize via a clathrinmediated endocytic pathway or by pinocytosis. Of interest is a report suggesting the possible role
of lipid rafts in mediating FR endocytosis in cells88. Lipid rafts are lipid microdomains on the
cell membrane that have high deposits of cholesterol and sphingolipids and could be involved in
regulating the localization of the folate receptors on the cell surface. In addition, it is suggested
that cholesterol anchors receptors and is considered to be a key player in triggering endocytosis.
However, details of any such mechanism(s) are unknown. Therefore, the role of cholesterol in
mediating FR-α and FR-β activities was examined in the cells. Results of cholesterol depletion
showed that probe binding through both FR-α and FR-β was inhibited. However, it was the FR-α
isoform that showed higher sensitivity to membrane cholesterol depletion than FR-β.
Furthermore, the internalization of FR-α was significantly inhibited in the absence of membrane
cholesterol, thus indicating a possible crucial role for cholesterol in FR endocytosis (Fig. 35).
Interestingly, the overall degree of cholesterol sensitivity of FR-mediated binding and
endocytosis was much higher compared to the relative insensitivity of other trafficking
pathways. These studies increase the overall understanding of FR trafficking in tumor cells,
which could then be exploited for therapeutic studies. Other than drug delivery and
hyperthermia-mediated receptor targeting, proteins associated with the FR-trafficking pathways
could also serve as potential targets.
So far in this study, the folate receptor isoforms have been characterized and their potential
use for targeting epithelial and myeloid malignancies demonstrated. In addition to this, the latter
studies sought to determine the potential of therapeutics in exploiting tumor cell activity at the
nuclear level. In collaboration with Dr. Hossain (Department of Chemistry, UW-Milwaukee), the
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effectiveness of novel HDAC inhibitors in modifying histone activity in cells with potential for
anti-tumor effects were studied. Many investigators have attempted to define a role for HDACs
and HDAC inhibitors in cancer therapy. Previous reports have indicated that aberrant recruitment
and overexpression of HDACs can lead to the suppression of tumor-suppressor genes, which
may promote tumor onset and progression. Therefore, this has made HDACs attractive candidate
targets for anti-cancer therapies. To date, many natural and synthetic compounds have been
identified that are able to inhibit Class I and II HDACs. However, major concerns involve nonspecific class activity and broad toxicity of HDAC inhibitors. Overt toxicity is not surprising
given that HDACs not only modulate histone proteins but also several non-histone substrates.
Although the mechanism(s) of their action is still not completely elucidated, much effort is being
put into discovering novel compounds that exhibit higher HDAC class specificity and lower
toxicity. Despite a tremendous amount of work and a large number of clinical trials, there are
presently only two HDAC inhibitors, FK228 (romidepsin) and SAHA (vorinostat) that are FDAapproved for the treatment of cancer. Based on the scaffolds of these two compounds, the
Hossain lab synthesized a panel of novel compounds that are being tested for their potential as
novel HDAC inhibitors. One of the most effective compounds (Cpd5) was selected for detailed
analyses in this thesis. Compared to FK228 (the parent compound), Cpd5 exhibited lower antiproliferative activity against a panel of human tumor cell lines, and had markedly lower toxic
effects in animals. In addition, Cpd5 showed increased acetylation of histones, had desirable
pharmacokinetic properties, and was able to slow tumor growth in animals. These findings
validated the further pursuit of developing Cpd5 into a therapeutic drug for cancer treatment.
In conclusion, these studies provide a better understanding of the folate receptor isoforms to
be used to target epithelial and myeloid malignancies. We have characterized FR-α and FR-β,
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and identified their differential activity, which would be relevant in devising therapeutic
strategies. In addition, investigation of FR-trafficking pathways has highlighted receptor
mechanisms that could be further studied to identify more molecular targets. The role of
epigenetics in cancer therapy was also studied utilizing a novel HDAC inhibitor, and its
prospects as a potential anticancer agent were investigated. Based on these findings, it is
proposed that future development of Cpd5 as a therapeutic could involve FR targeting (Fig. 36).
In this way, HDAC inhibitor-mediated effects would be targeted to the cells of interest, thus
leaving healthy cells unharmed. These studies therefore, address a major concern of non-specific
targeting in cancer therapy and provide new insights into future therapeutic strategies with
improved selectivity.
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Figure 35. FR-α (and to a lesser extent FR-β) exhibited sensitivity to membrane cholesterol
depletion and is internalized via non-clathrin coated pathways.
Model shown depicts two potential pathways through which FR internalization may occur. FR
can internalize via a caveolae-mediated pathway through the formation of endosomal vesicles
also known caveosomes, which is reported to be regulated by the protein, caveolin. It is also
likely that FR can internalize via lipid-rafts that are made up of high deposits of cholesterol and
sphingolipids with the cholesterol playing a potential role in mediating FR binding and
endocytosis. However, the molecular mechanisms of the two pathways are not completely
elucidated and hence interactions between lipid-raft-mediated endosomes and caveosomes need
to be investigated.
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Figure 36. Cpd5 conjugation to folic acid to induce selective targeting in tumor cells.
HDAC inhibitors have been used as chemotherapeutic agents but their non-specific nature leads
to adverse effects on non-target cells. Therefore, targeting HDAC inhibitors directly to tumors
could help improve their therapeutic efficiency. One possible targeting mechanism would
involve conjugating Cpd5 to the carboxyl terminus of folic acid. Importantly, a linker (e.g.,
EDC) that allows the amino terminus of folic acid to bind to FRs expressed on tumor cells is
required. In this way, the HDAC inhibitor would only enter FR+ cells (tumor cells), thereby
preventing non-specific effects of HDAC inhibitors on normal cells.
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